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ABSTRACT 
Background:  
 
Gastro-oesophageal reflux and aspiration may be associated with airway disease. Bile acid 
aspiration has been shown to be prevalent among patients with advanced airway disease, 
which raises the concern that recurrent microaspiration of bile acids may cause airway 
epithelial injury which may lead to inflammatory airway disease. 
Objectives: 
To investigate the possible links between bile acids and lung injury which may cause pro-
inflammatory cytokine release using  BEAS- 2B, NCI-H292, 16HBE14o- and Calu-3 cell 
lines. Moreover, this study aimed at exploring whether primary bronchial epithelial cell 
cultures taken from lung transplant patients (PHBECs), tracheal epithelial cells (upper airway 
cells) from the subglottic area cells, BEAS-2B and 16HBE14o- cell lines undergo EMT like 
processes after stimulation with primary and secondary bile acid. Finally, the role of duodeno-
gastro-oesophageal refluxate in mucus production from NCI-H292 and Calu-3 cell lines was 
investigated.  
Methods:  
BEAS-2, 16HBE14o-, NCI-H292 and Calu-3 cell lines were cultured and stimulated with Bile 
acid (BAs). Pro-inflammatory markers including IL-8, IL-6 and GMCSF were measured. 
Primary bronchial epithelial cell cultures taken from lung transplant patients and tracheal 
epithelial cells from the subglottic area cells were cultured. The effect of individual primary 
and secondary bile acids were evaluated by 48 hour challenge. Post-challenge TGFβ1, MMP9 
and pro-collagen concentrations were measured using commercial ELISAs. RNA was isolated 
to determine the changes in expression of an epithelial marker E-cadherin and the 
mesenchymal marker fibronectin at a molecular level using a quantitative real-time PCR. The 
NCI-H292 and Calu-3 cell lines were also used as an in vitro model system to study MUC 
gene regulation. Cells were stimulated with bile acids and mucin content of the culture 
medium measured using an indirect ELISA and quantitative real-time PCR was used to 
evaluate MUC5AC and MUC5B expression in NCI-H292 and Calu-3 cell lines. 
  
ii 
Results:  
The cells used in this study elevated levels of IL-8, IL-6 and GMCSF released after treatment 
by primary and secondary bile acids. IL-8, IL-6 and GM-CSF are common finding in airways 
and lung disease where reflux and aspiration have been implicated as a possible injury. 
Significantly greater concentration of TGFβ1, MMP9 and pro-collagen were measured in 
cultures of PHBEs, tracheal epithelial cells, BEAS-2B and 16HBE14o- cell lines treated with 
BAs. E-cadherin expression significantly decreased while fibronectin was significantly 
increased. MUC5AC and MUC5B levels were induced in response to stimulation of Calu-3 
and NCI H292 cells with BAs. 
Conclusion: 
The NCI-H292, Calu-3, BEAS-2B and 16HBE14-o cell lines are sensitive and useful models 
to study human respiratory processes and diseases related to BAs aspiration-induced lung 
injury. Aspiration of bile acids may cause cell injury, inflammation and cell death relevant to 
the pathophysiology of chronic airways disease. Furthermore, Bile acids stimulated EMT 
related processed in PHBEC, tracheal epithelial cells, BEAS-2B and 16HBE14O-cell lines. 
The Calu-3 and NCI H292 cells can be used as an in vitro model system to study MUC5AC 
and MUC5B gene regulation.  
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CHAPTER 1:  GENERAL INTRODUCTION 
1.1 The respiratory system and airway epithelium 
The human respiratory tract Figure 1-1 (Tu et al., 2013) comprises the upper airways, which 
include the nose, sinuses, mouth and throat; and the lower airways: the trachea, bronchi and 
lungs. Within the lungs, the bronchi divide into increasingly smaller tubes called bronchioles 
and ultimately into alveoli, which are the air sacs where gas exchange occurs. This study will 
focus on the epithelial cells – of which there are various types – which line the system. 
 
Figure 1-1: The anatomy of the respiratory tract (Tu et al., 2013). 
1.2 Anatomy of the airway epithelium 
The airway epithelium includes a range of specialised cell types, each with a specific function 
that contributes to lung homeostasis. At least eight different types of epithelial cell are found 
in the system and, according to their location these fall into one of three categories: basal, 
ciliated columnar and non-ciliated secretory columnar cells (Knight and Holgate, 2003). 
Epithelial function is also assisted by immune and inflammatory cells, which migrate to the 
airway epithelium via the basement membrane. An example of these different cell types is 
seen in Figure 1-2 below, which shows a cross-section through the airway wall including the 
underlying mesenchyme. 
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Figure 1-2: Schematic cross-section of the airway wall. The airway is lined with an epithelium, anchored 
together with several different junctions. The underlying mesenchyme is also shown consisting of 
myofibroblasts, smooth muscle cell bundles, blood vessels, and afferent nerve endings positioned deep into the 
airway. Drawing is not to scale (West, 2012). 
The airway epithelium is particularly susceptible to damage by external factors, such as 
chemical toxins and other pollutants, bacteria, viruses, dust and smoke particles. However, the 
cells in this layer are arranged in an adhesive mechanism to ensure three dimensional 
structure and normal function is maintained. Hemidesmosomes are extra-cellular matrix 
(ECM) junctions, which connect basal cells to the basement membrane, conferring the tissue 
with increased mechanical integrity (Green and Jones, 1996). Interactions between basal and 
columnar cells are assisted by desmosomes, which are intercellular adhesion molecules of the 
cadherin family. These also function to create trans-cellular networks within the tissue, further 
increasing its mechanical integrity (Green and Jones, 1996). Interactions between columnar 
cells are aided by belt-like tight junctions (zona occludens), which regulate cellular transport. 
E-cadherin adherens junctions also help maintain cell adherence (Roche et al., 1993). It is 
thought that the airway epithelium is pseudostratified in large airways, becoming columnar 
and cuboidal as it progresses through the airways to the lower airways (Crystal et al., 2008).   
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1.2.1 Basal cells 
Despite relative abundance, the density of basal cells varies according to the other cell types 
in different regions of the airway (Wang et al., 1992). Basal cells are pyramidal in shape, with 
a large nucleus (Evans et al., 2001) and use hemidesmosomes to attach other epithelial cells to 
the basement membrane. It is believed that epithelial stem cells originate from the basal cells, 
before differentiating into ciliated and secretory columnar cells in the upper part of the tract 
(Boers et al., 1998). Basal cells have been discovered to secrete various active molecules 
including cytokines, chemokines, and growth factors. 
1.2.2 Columnar secretory cells 
Found within the epithelial layer’s apical surface, the predominant secretory cells in the upper 
airways are mucus-secreting goblet cells, which are the system’s primary mucus source. The 
primary role of mucus is to protect the airway epithelium by trapping toxins or small particles. 
Moreover, mucus stops airway epithelium drying out. These cells are characterized by 
membrane-bound electron-lucent acidic mucin granules (Jeffery and Li, 1997) and are 
involved in mucociliary clearance. Diseases such as asthma and COPD cause the number of 
these cells to increase, resulting in the characteristic productive cough (Lumsden et al., 1984). 
In smaller airways (terminal bronchioles), Clara cells are predominant and also contain 
electron dense granules (Jeffery and Li, 1997). Xenobiotic compounds are metabolised via 
p450 monooxygenases in Clara cells, which also produce bronchiolar surfactant (Knight and 
Holgate, 2003) and can absorb and secrete ions (Van Scott et al., 1987). Stem cells for the 
lower airway epithelium are found in areas of high Clara cell population and low mucous and 
basal cell population (Hong et al., 2001). The serous cell is a different type of secretory cell 
similar to the mucus cell, but with a more electron dense granule content. Normally only 
found in rodent airways, these rare cells have occasionally been observed in the smaller 
airways of the human lung (Rogers et al., 1993). 
1.2.3 Columnar ciliated cells 
More than half of all airway epithelial cells are ciliated (Knight and Holgate, 2003). These 
cells are involved in the transport of mucus and foreign objects in a directional capacity from 
the lower to the higher airway. Until recently, it was believed that these cells could not 
differentiate any further and were derived from secretory or basal cells. However, studies into 
the effects of naphthalene injury on mouse epithelia showed that these cells can trans-
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differentiate, signalling a potential role in epithelial repair (Lawson et al., 2002; Park et al., 
2006). 
1.2.4 Alveolar type I cells 
Of the two types of epithelial cells found in the alveoli, type I cells are squamous thin cells, 
covering 90-95% of the alveolar surface (Crapo et al., 1982). They are particularly vulnerable 
to injury and do not divide. They are vital in maintaining alveolar cellular composition and 
the thin blood-gas barrier they form is vital to gas exchange (Williams, 2003). They also play 
an important role in alveolar epithelial homeostasis (Berthiaume et al., 2006). Type I cells do 
not exhibit specific molecular markers and are difficult to isolate in vitro. Consequently, type 
II cells have received more scientific attention. 
1.2.5 Alveolar type II cells 
The remaining 5% of the alveolar epithelium is made up of the cuboidal type II cells. These 
are progenitors for type I cells, which cannot reproduce on their own. Type II cells are 
therefore vital in maintaining alveolar health following injury (Sugahara et al., 2006).  
1.2.6 Other cell types surrounding the airway epithelium 
There are a range of other cell types and tissues proximal to the airway epithelium. These 
include: fibroblasts, blood vessels, smooth muscle, afferent nerve ending and immune cells. 
The latter include mast cells, lymphocytes, dendritic cells, and macrophages. When an 
external threat is present, these immune cells migrate to the epithelium to play a defensive 
role (Rennard et al., 1994). Intra-epithelial nerves are populous in the bronchial epithelium. 
They have been found to penetrate the basement membrane to form a network between the 
epithelial cells and the basal lamina, as revealed by immunoreactivity for the pan-neuronal 
marker protein gene product (PGP) 9.5 (Adriaensen and Scheuermann, 1993). Below the 
basement membrane, fibroblasts secrete growth and attachment factors, which are involved in 
tissue repair and airway remodelling (Pollak and Lefebvre, 1992). They also stimulate 
bronchial epithelial cell migration via the production of chemotactic cytokines, which further 
contributes to the airway repair (Shoji et al., 1989). Airway Smooth Muscle Cells (ASMCs), 
present between the trachea and the alveoli, control airway wall contraction and relaxation. 
These are governed by intracellular signalling (Hall, 2000), through which phospholipase C, 
adenylyl cyclase, and ion channel pathways control a series of homeostatic mechanisms. 
ASMCs play a critical role in asthma pathology, which involves increased bronchial SMC 
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mass and airway inflammation. It is therefore suggested that the airway hyper-responsiveness 
exhibited by asthma patients may be caused by ASMC abnormality (Borger et al., 2006). 
ASMC responses are affected by cytokines in both directions (constrictor or relaxant) and 
therefore demonstrate a degree of immune function (Hakonarson et al., 2001). 
1.2.7 Basement membrane 
The basement membrane is structurally composed of the extracellular matrix (ECM) proteins, 
anchoring filaments of laminin 5, collagen IV, and proteoglycans, and is found under the 
airway epithelium. In healthy bronchi, this layer is about 10nm (Jones, 2012). Further down 
(away from the epithelial cells), the composition is mainly made up of collagen III. 
1.3 Functions of the airway epithelium 
1.3.1 Epithelial barrier function and adhesion mechanisms 
As was described in the previous section, the airway epithelium serves primarily to protect the 
airways from external threats, including toxic gases, pathogens, viruses, bacteria and 
allergens, including pollen and dust mite antigens (Knight and Holgate, 2003). 
1.3.2 Mucociliary clearance and protective factors secretions 
Further to the airway epithelium’s protective role, secretory epithelial cells produce mucus, 
which traps foreign objects. Coordinated cilial beating then assists in transporting these out of 
the tract (Bals et al., 2004). Anti-oxidants and anti-bacterial agents, such as lactoferrin, 
lysozyme, and opsonins as well as anti-proteases and α1-Anti-trypsin such as tissue inhibitors 
of metalloproteinases are produced by epithelial cells (Velden and Versnel, 1998). 
1.3.3 Epithelial inflammatory potential 
Injury to the airway epithelium triggers a pro-inflammatory response. This causes the 
production of such mediators as TGF-β, cytokines, arachidonic acid products and including 
IL-8 and IL-6. 
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1.4 Gastro-oesophageal reflux 
1.4.1 Definition 
Gastro-oesophageal reflux (GOR) is, most of the time, a normal response caused when the 
lower oesophageal sphincter becomes relaxed and gastric contents travel up into the 
oesophagus. Generally, this is harmless and there are no symptoms (Herbella and Patti, 2010). 
Under a specific set of conditions however, GOR may become pathological, leading to gastro-
oesophageal reflux disease (GORD) (Morehead, 2009; Herbella and Patti, 2010). Vakil et al. 
define GORD as “a condition which develops when the reflux of gastric contents causes 
troublesome symptoms and/or complications” (Vakil et al., 2006). However, it is discussed 
that this definition does not have any quantitative that  can be used to measure the incidence 
and prevalence of the GORD (McCarthy, 2013). Heartburn and regurgitation are the primary 
symptoms of GORD, although since these are also associated with over eating and 
indigestion, this makes distinguishing chronic GORD more difficult. The following definition 
has therefore been proposed: “GORD is the incidence of heartburn or regurgitation once or 
more daily” (McCarthy, 2013). Classifications of GORD exist which are tighter still, 
including: heartburn or regurgitation without erosions on endoscopic examination (Non-
erosive Reflux Disease, NERD), or with erosions present (Erosive Reflux Disease, ERD). A 
range of risk factors have been identified in the development of GORD, including alcohol, 
tobacco, obesity, diabetes asthma, hiatus hernia, old age and pregnancy. Furthermore, even in 
non-obese patients, obstructive sleep apnoea is also identified as a risk factor (Morehead, 
2009).  
1.4.2 Diagnosis of GOR 
1.4.2.1 Endoscopy 
In addition to mucosal biopsies, visual investigation can indicate the severity of GORD 
(McCarthy, 2013). This method is also important in ongoing assessment of the disease, 
including checking for oesophagitis (by tracking morphologic changes in the squamous 
epithelium) and columnar lined oesophagus (CLO), caused by columnar metaplasia. CLO in 
particular can indicate the onset of oesophageal adenocarcinoma (aka Barrett’s Carcinoma). 
Endoscopy is therefore a vital investigative tool in identifying potential GORD-related 
oncologic complications (Lenglinger et al., 2006). 
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1.4.2.2 Ambulatory pH testing 
Ambulatory pH testing is an established standard method for monitoring GORD (Hirano, 
2006). This involves placing a probe 5cm above the lower oesophageal sphincter and 
measuring the length of time the pH is less than 4 (Lenglinger et al., 2006). For accuracy, 
some monitors use two probes, one proximal and one distal. Of course, non-acidic reflux is 
not detected using this method (Hirano, 2006). 
1.4.2.3 Impedance-pH monitoring  
When the reflux is non-acidic (or of low acidity), more sensitive methods are used. A 
technique involving combined multichannel intraluminal impedance and pH monitoring is 
able to measure all types of reflux as well as bolus transport (Figure 1-3) (Hong and Vaezi, 
2009). This is considered more accurate than the previously dominant method of 24h pH 
monitoring. 
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Figure 1-3: Impedance-pH catheter. The pH electrode is located 5 cm above the lower oesophageal sphincter 
(LES) and the distal electrode in the stomach, allowing impedance measurements at 3, 5, 7, 9, 15 and 17 cm 
overhead the LES (Tutuian and Castell, 2006). 
Ambulatory impendence monitoring has been in use since 1991 and is agreed as a reliable 
method for measuring GOR. An impendence probe is used, with electrode rings placed at 
various intervals to measure the refluxate electrical conductivity. This data, in addition to pH 
data yields information on exposure of the oesophagus to gastroduodenal contents and its 
acidity levels (Hong and Vaezi, 2009).  
Patients who presented with symptoms of reflux (heartburn and regurgitation), but for whom 
endoscopy revealed nothing, previously underwent oesophageal pH testing. However, since 
proton pump inhibitors became the dominant empirical method in diagnostic testing, more 
objective methods are now used for patients who are unresponsive to acid suppressants, prior 
to considering fundoplication (Hirano and Richter, 2007; Kahrilas et al., 2008). 
Where oesophagitis is observed visually, ambulatory 24-hour pH monitoring is considered 
acceptably sensitive (77%-100%) and specific (85%-100%). In cases where GORD cannot be 
verified by endoscope, the results are less easy to interpret (0-71% sensitive and 85-100% 
specific) (Kahrilas and Quigley, 1996). Impedance monitoring is more than 90% sensitive and 
specific, compared to both manometry and pH monitoring. This has led to consensus that 
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impedance monitoring is the best available method for testing the implications of reflux 
symptoms. Ambulatory pH testing may be considered an accurate test of oesophageal reflux, 
but is far less sensitive in cases of endoscopy negative GORD, which may indicate an acid-
sensitive oesophagus. Both devices are considered far less efficacious in patients who do not 
respond to proton pump inhibitor therapy (Sifrim et al., 2004). 
1.4.2.4 Bilitec monitoring 
When pH levels seem normal, Bilitec monitoring can be used in place of ambulatory pH 
testing (Lenglinger et al., 2006), to identify bile refluxate in the oesophagus and measure its 
concentration. This method is not without its disadvantages; refluxate can become trapped in 
the sensor and a special diet is required. Biomarkers in bronchioalveolar lavage fluid may be 
used to get around these factors (Hirano, 2006), but the method is generally unpopular among 
patients and is rarely taken up.  
1.4.2.5 Bravo capsule 
A more tolerable option is the Bravo Capsule (Medtronic, MN, USA) (Hirano, 2006). The 
capsule is applied to the lower oesophageal mucosa via either a catheter or endoscope and 
measures pH levels over about 24h, transmitting data to a wireless receiver. 
1.4.3 Composition of gastric juice 
Gastric juice is secreted by cells which have a structural arrangement referred to as ‘gastric 
pits’. These comprise several gastric glands and can be found all along the gastric mucosa. 
The juice itself is usually transparent and is made up of a mixture of: hydrochloric acid (HCl), 
mucin, lipase, pepsin, intrinsic factor, peptides, nucleic acids and electrolytes. Parietal cells 
secrete HCl, which maintains gastric conditions at between pH2-3. This is necessary for 
pepsin activation, which plays a defensive role against pathogens in the stomach and intestine. 
Gastric pH (hypochlorhydria) can be elevated by disease, bile reflux, or pharmaceuticals, 
which may causes bacterial overgrowth in the stomach. These bacteria can produce nitrite and 
nitroso-compounds, one of the causes in the atrophy-metaplasia-dysplasia carcinoma pathway 
(Lu et al., 2010). 
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1.4.4 Treatment 
Treatment options are intended to: provide symptom relief, oesophageal healing, prevent and 
manage other complications associated with GORD, and maintain oesophageal and mucosal 
remission (Fock and Poh, 2010) 
1.4.4.1 Lifestyle modifications 
All medications have side effects to a varying degree. Less severe cases of GORD can and 
should therefore be managed through lifestyle changes, including diet and weight-loss 
measures, bed-head elevation, smoking cessation and avoiding postprandial recumbency for 
at least 3h. It has been suggested, however, that in spite of the fact that smoking, citric acid, or 
fatty foods can raise oesophageal pH, GORD outcomes show no significant improvement 
when these factors are removed (Fock and Poh, 2010).  
1.4.4.2 Antacids 
Instantaneous, albeit temporary relief can be provided by antacids, which are widely 
accessible, but require frequent ingestion. However, they only treat the discomfort and not the 
causes of GORD (Herbella and Patti, 2010). Furthermore, some antacids, such as 
metoclopramide, can cause side effects, such as depression, drowsiness and involuntary 
spasms (Ganzini et al., 1993), as well as diarrhoea, constipation and interference with the 
absorption of other drugs (McCarthy, 2013).  
1.4.4.3 Acid suppression therapy 
Histamine-2 receptor antagonists (H2RAs) and proton pump inhibitors are two classes of 
medications which can result in acid suppression. 
1.4.4.3.1 Histamine-2 receptor antagonists 
H2RAs (e.g. cimetidine, ranitidine, famotidine and nizatidine) can heal mucosal damage and 
relieve symptoms, and so have significantly improved the control of GORD-related 
symptoms. Furthermore, the same efficacy as antacid treatment can be achieved with only a 
twice-daily treatment. However, they are less suitable for long-term treatments, due to the 
potential for tolerance (Hatlebakk and Berstad, 1996) and are also less effective in controlling 
acid secretion than PPIs (Katz and Tutuian, 2001). 
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1.4.4.3.2  Proton pump inhibitors (PPIs) 
PPIs have become established as the dominant therapy for gastric acid-related diseases 
(McCarthy, 2013). Patients who were on proton pump inhibitor (PPI) therapy had 
significantly reduced oesophageal acid exposure and a reduced number of reflux events; and, 
as antisecretory compounds, are more effective – and last longer - than Histamine-2 receptor 
antagonists (H2RAs) (Fock and Poh, 2010). Five PPIs are currently on the market: 
omeprazole, lansoprazole, rebeprazole, pantoprazole and esomeprazole. The risks associated 
with PPI are very low. However, levels of pepsin and bile were comparable in both patients 
who were on PPls and those that were not. This suggests that while PPI treatment can reduce 
gastric acid secretion, it cannot prevent gastric aspiration (Blondeau et al., 2008b) so, acid 
suppression alone may not be totally effective (Patel and Hurst, 2013). Acid suppression also 
has side effects, including: increased potential for: fractures; risk of infection; greater 
susceptibility to atrophic gastritis; hypomagnesaemia; Clostridium difficile-associated 
diarrhoea; as well as vitamin B12 and iron deficiencies (Bredenoord et al., 2013). 
1.4.4.4 Anti-reflux surgery 
Some GORD patients are appropriate candidates for anti-reflux surgery. This has been shown 
by longitudinal studies to enable better symptom control than medical therapeutic 
interventions (Fock and Poh, 2010). The Nissen fundoplication procedure is commonly 
performed on children with GOR (Georgeson, 2009), in which a 1.5-2cm fundus is wrapped 
around the oesophagus, using a bougie to control the tightness of the wrap. As a result, 
pressure at the lower oesophagus is increased, limiting the change of reflux occurring 
(Dallemagne et al., 1991). Patients may experience complications after surgery, such as 
dysphagia, post-vagotomy symptoms and gas-bloat syndrome. The Society of American 
Gastro-Enterological Surgeons (SAGES) has recommended, based on the high reoccurrence 
of GORD symptoms, that surgery should only be performed as a last resort; after other 
medical management options have been exhausted, in complicated circumstances (e.g. 
Barrett’s Syndrome), with atypical symptoms (e.g. asthma), or when age or medication 
expenses make management difficult (Dumonceau et al., 2013). 
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1.4.5  Extra-oesophageal reflux disease 
At a conference in 2006, the Montreal Consensus Group distinguished two types of GORD 
syndrome: oesophageal and extra-oesophageal. The latter is subdivided into either 
‘established’ or ‘proposed’ (Figure 1-4) (Vakil et al., 2006). When describing GOR that has 
breached the upper sphincter of the oesophagus to interfere with the laryngeal or pharyngeal 
mucosa (Figure 1-5), ENT specialists use the terms: extra-oesophageal reflux disease (EORD) 
or laryngopharyngeal reflux (LPR). LPR can result in a wide range of symptoms, which may 
cause concomitant symptoms to be overlooked (e.g. heartburn), which increases the 
complexity of diagnosis. In cases such as this, 24h pH monitoring and laryngoscopy are 
usually used (Kavitt and Vaezi, 2013). 
 
Figure 1-4: Classifications of extra-oesophageal syndromes linked to GORD in agreement with Montreal 
Consensus Conference (Vakil et al., 2006). 
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Figure 1-5: Extra-oesophageal pass from stomach to oesophageal. Laryngopharyngeal reflux results when 
refluxate reaches the vulnerable mucosa of the pharynx, larynx, oral cavity and nasal cavity (Patel and Hurst, 
2013). 
1.4.6 Aspiration 
When material, such as food, liquids, particles, blood, secretions of bacteria enter the airways, 
this is called aspiration (Raghavendran et al., 2011). Sometimes, small volumes of refluxate 
are inhaled into the lungs (microaspiration), which can lead to pulmonary parenchymal 
lesions. These cases are rarely associated with the more traditional respiratory symptoms and 
so are harder to diagnose. Consequently, microaspiration has been deemed a ‘silent’ 
phenomenon (Lee et al., 2010). 
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1.4.7  Duodenogastro-oesophageal reflux (DGOR) 
Refluxate may contain bile salts, pancreatic enzymes, stomach enzymes and duodenal 
contents, as well as HCl. The severity of oesophageal mucosal damage is heavily affected by 
these compounds, which are regurgitated through the pylorus into the stomach, then refluxed 
into the oesophagus. Bile acids have toxic effects on the colonic mucosa (Turjman and Nair, 
1981; Owen et al., 1984), hepatocytes (SchÖLmerich et al., 1984) and gastric mucosa 
(Gadacz and Zuidema, 1978; Gillen et al., 1988). However, their toxicity to the oesophageal 
mucosa is less well-researched (Nasr et al., 2013). A strong evidence base exists linking 
oesophageal acid exposure (OAE) to both mucosal damage and Barrett’s oesophagus and its 
associated complications (Legrand et al., 1990; Iftikhar et al., 1993; Takahashi et al., 2011). 
However, It has been suggested that excessive DGOR may also have a damaging effect on the 
gastric mucosa (Stern et al., 1984). Indeed, patients with a range of airway diseases were 
found to have increased bile acid concentrations in their BAL fluid. In comparison to 
aspiration of gastric contents, aspiration of bile acid may lead to non-cardiac pulmonary 
oedema, derived from the increased severity of pneumonitis. These findings are critical to the 
understanding of GORD, as they challenge the established idea that oesophagitis and other 
GORD symptoms were caused only by reflux of HCl. As a result of this misconception, the 
majority of therapies were aimed at gastric parietal cells, which produce gastric acid. A study 
of acid reflux (via pH monitoring) and reflux of duodenal juice (via bilirubin monitoring) 
among 53 GORD patients, found that two-thirds of the patients had a mixture of both types of 
reflux (Kauer et al., 1995). Furthermore, higher bilirubin levels were found in patients with 
Barrett’s metaplasia. These results provide a potential explanation for why PPI therapy is only 
partially successful in symptom control in some patients and why, despite PPI therapy, some 
patients have increased risk of developing Barrett’s oesophagus. 
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1.4.8 Relationship between lung disease and GOR 
Patients with advanced stages of lung diseases often exhibit GOR, suggesting that recurrent 
microaspiration – and consequently further lung injury may be partially caused by reflux 
(Allaix et al., 2013). No reliable diagnostic tool has yet been identified to measure the impact 
of aspiration on clinical outcomes (Meyer and Ganesh Raghu, 2013). Lung diseases can be 
caused by GOR either by a) neural reflex mechanism, in which reflux is limited to the lower 
oesophagus, or b) proximal GOR, in which refluxate breaches the upper sphincter of the 
oesophagus, causing injury to the upper airway. Furthermore, if aspiration occurs, this 
increases the risk of lung disease (Morehead, 2009). 
GOR has been implicated in the lung damage in Idiopathic Pulmonary Fibrosis (IPF) in 
patients with GOR and also hiatus hernia. GOR has also been implicated in a range of other 
chronic lung diseases included COPD, CF and asthma.  In these cases, aspiration may be a 
contributing  factor, rather than viral or autoimmune causes, as initially believed (Mays et al., 
1976). 
A number of key factors of GORD-related complications beyond the oesophagus have been 
suggested: In a study of 100 pathological reflux patients, a correlation was established 
between weak oesophageal peristalsis and slow clearance of the oesophagus, and symptoms in 
the respiratory system following reflux. The study concluded that inadequate oesophageal 
motility may indicate increased respiratory symptoms following reflux events. pH testing also 
indicates a sequential link between reflux and cough. Where the cough preceded a reflux 
event, this is assumed to cause an increase in abdominal pressures. When reflux precedes a 
cough, it is believed that this causes the cough. Reflux symptoms including heartburn, 
regurgitation and dysphagia have limited correlation with reflux measured via pH (Pellegrini 
et al., 1979). 
Decreased oesophageal motility was found in 16 out of 24 systemic sclerosis patients (67%) 
and this was associated with impaired lung compliance (Denis et al., 1981). Another study of 
patients with systemic sclerosis found that 13 were affected by reflux, which was implicated 
in their associated pulmonary problems. Patients underwent endoscopy, mucosal biopsies at 
both ends of the oesophagus, pulmonary function tests, oesophageal manometry and pH 
monitoring probes. Peristalsis was not detected in 77% of patients. Of these, some patients 
exhibited the presence of acid in their upper oesophagus. Based on these findings, it was 
suggested that the pulmonary complications associated with systemic sclerosis may be due to 
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chronic aspiration of gastric juices. However, it is worth acknowledging that many of these 
patients exhibit end-stage oesophageal disease symptoms with zero peristalsis – so this study 
does not necessarily apply to the average GORD patient (Johnson et al., 1989). 
A study of 70 GORD patients aimed to find a correlation between coughing and oesophageal 
reflux, using a dual-sensor pH probe. The study’s hypothesis proposed that when cough and 
distal reflux were concomitant, then a vagal reflux arc due to oesophageal irritation was 
responsible for the accompanying symptoms. However, when reflux went further, reaching 
the upper oesophagus, then the cough was more likely to be caused by microaspiration, and 
this was more prevalent in patients with low oesophageal motility (Patti et al., 1993). 
Previously, this data had been limited to individual case studies. However, the association 
between respiratory complications and reflux in population settings was confirmed by El-
Serag and Sonnenberg. Using a case control study of 200,000 US veterans, it was found that 
where erosive oesophagitis was present, indicating severe GORD, there was a 1.36 odds ratio 
(OR) of pulmonary fibrosis, a 1.28 OR of chronic bronchitis and a 1.22 OR of chronic 
obstructive pulmonary disease (COPD). This data, despite not proving a certain causal effect, 
nevertheless makes a connection between GORD and advanced lung disease (ALD) (el-Serag 
and Sonnenberg, 1997; Sweet et al., 2009). Another study on the association between reflux 
and O2 desaturation used pulse oximetry monitoring and a 24h pH impedance. The study 
found a positive correlation between reflux episodes at both ends of the oesophagus and with 
O2 desaturation. These findings could enable more accurate ways to predict reflux episodes. 
These events were found to decrease following anti-reflux surgery (Wilshire et al., 2013). 
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1.5  Bile Acids 
Hepatocytes in the liver synthesise bile acids, which serve digestive and secretory functions, 
are water-soluble and aid lipid absorption in the small intestine. Using cholesterol as a starting 
point, a number of pathways are responsible for the production of bile acids (Monte et al., 
2009). Primary bile acids are first synthesised by the catabolism of cholesterol into cholic acid 
(CA) and chenodeoxycholic acid (CDCA). Bacterial enzyme action in the colon aids primary 
BA deconjugation into free bile acids and further enzymatic action converts CA into 
deoxycholic acid (DCA) and CDCA into lithocholic acid (LCA). More specifically, the 
hydroxyl (OH) group is detached from the 7th carbon atom by the enzyme 7 alpha-
dehydroxylase. DCA and LCA are moved to the canaliculi of the liver through the portal vein 
to join the new primary BAs and re-conjugate with glycine or taurine. This is a closed-system 
recycling process, involving the bile flow from the liver, via the biliary tract to the intestine 
then back to the liver. This process of ‘enterohepatic circulation’ enables recycled bile to be 
stored in the gall bladder for release after meals. This usually happens in two bursts, resulting 
in up to eight bursts per day (Jenkins and Hardie, 2008). 
 
Figure 1-6: The classical pathway for bile acid (BA) formation. In human hepatocytes, the two primary BAs, 
cholic acid (CA) and chenodeoxycholic acid (CDCA), are synthesised as a result of cholesterol metabolism. CA 
and CDCA differ in their hydroxylation at C-12~. These primary BAs are usually conjugated to glycine or 
taurine before they enter biliary flow. Once they reach the digestive tract, microbes in the gut can remove the 
conjugated glycine or taurine, transforming primary BAs into secondary BAs via dehydroxylation at C-7. CA is 
transformed into deoxycholic acid (DCA) and CDCA is transformed into lithocholic acid (LCA). Most BAs then 
re-enter enterohepatic circulation returning to the liver where they are re-conjugated to taurine or glycine. Image 
from: [https://upload.wikimedia.org/wikipedia/commons/thumb/c/c4/Bile_acid_differentiation.svg/ 655px-
Bile_acid_differentiation.svg.png [accessed on 11 September, 2016]. 
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Most circulating bile acid is conjugated to glycine or taurine. Unconjugated BAs tend to 
remain in the colon, where the glycine or taurine subunits are removed via microbial 
modification (Monte et al., 2009). Gastro-oesophageal reflux disease (GORD) patients 
undergoing therapy which targets acid suppression can exhibit overgrowth of bacteria in the 
intestine. In turn, this causes BAs to deconjugate, resulting in a greater number of 
unconjugated BAs in circulation (Figure 1-6) (Solaas et al., 2000).  
1.5.1 Evidence for the presence of Bile Acid in the airway  
Reports of BA presence within the airway have increased over the last decade and this has 
similarly been associated with lung function decline. BAs may reach the lung in one of two 
ways; they may be aspirated during reflux episodes, or via increased circulatory BAs in blood. 
In a porcine lung model, BA aspiration caused severe chemical pneumonitis, and rabbit 
models, injected BAs caused pulmonary damage (Kaneko et al., 1990; Porembka et al., 1993; 
Perez and Briz, 2009).  
Gastroesophageal reflux (GOR) and subsequent BA aspiration causes lung injury in adults. In 
transplant patients, immunosuppressive drugs and iatrogenic vagal nerve injury may induce 
GOR, or it may already be present prior to lung transplant (D’Ovidio and Keshavjee, 2006). 
Following lung transplantation, BA aspiration may be increased and has been implicated in 
the onset of bronchiolitis obliterans syndrome (BOS). BOS, defined by a loss of lung function 
can be associated with inflammatory cells in and around the airway and also fibrosis 
(D’Ovidio et al., 2005). BOS patients who have also received a lung transplant have been 
reported to exhibit greatly increased BA levels in BAL fluid, up to 32 µmol/L compared to 
normal level which is from 0 to 16 µmol/L (D’Ovidio et al., 2005).  
BA aspiration is injurious to the pulmonary system (el-Serag and Sonnenberg, 1997; Wilshire 
et al., 2013). Cell membranes are particularly susceptible to bile. In vitro studies on Type II 
pneumocytes have demonstrated this (D’Ovidio et al., 2005; D'Ovidio and Keshavjee, 2006). 
BAs also have a detergent effect. In the lungs however, damage to the mucus barrier may 
result in disruption to the lipids in the surfactant. Consequently, the type II pneumocytes, 
whose primary role is the production of surfactant protein and phospholipids are particularly 
prone to damage. 
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A groundswell of research is emerging which implicates the role of BA reflux in Barrett’s 
oesophagus and cancer (Attwood et al., 1992; Stamp, 2002). Increased bile exposure was 
found in Barrett’s metaplasia patients, as well as heightened levels of secondary BAs within 
their refluxate (Nehra et al., 1998). By comparison, Barrett’s patients with more advanced 
conditions, such as early adenocarcinoma exhibited increased BA exposure (Stein et al., 
1999). 
Studies of rabbits have shown that macrophage function can be inhibited by bile acids which 
affect lipopolysaccharide (LPS) mediated cytokine production and phagocytosis. Bile acids 
may also cause down-regulation of Interferons (IFNs)-mediated signal transducers. By 
implication, it has been inferred that innate immunity receptors on both monocytes and 
macrophages may be generally down-regulated (D’Ovidio and Keshavjee, 2006). If this is the 
case, then the risk of local infection may be increased, triggering an up-regulation of a more 
aggressive adaptive immune response (D’Ovidio and Keshavjee, 2006). This may be further 
exacerbated by damage to the surface epithelial cells (D’Ovidio et al., 2005). Bile acids have 
also been associated with elevated neutrophils, IL-8, bacterial and fungal presence, decreased 
pulmonary surfactant and higher inflammatory scores on transbronchial biopsy (D’Ovidio and 
Keshavjee, 2006; Blondeau et al., 2008b). 
Studies into the pathogenesis of cholestatic liver injury in rats, hamsters and rabbits have 
identified the monohydroxy- bile acid, LCA, as hepatotoxic (Palmer and Ruban, 1966; Miyai 
et al., 1977; Hofmann, 1999b). The research into LCA-induced cholestasis has yielded 
important understandings of: bile canalicular membrane biochemistry (Kakis and Yousef, 
1978); low solubility of LCA causing crystalline plug formation (Miyai et al., 1977); and 
greater knowledge around the transport of canalicular export pumps to and from the 
canalicular membrane (Kubitz et al., 2004). 
Cystic Fibrosis (CF) causes acid GOR in both children and adults, which can damage and 
compromise  pulmonary functioning (Robinson and DiMango, 2014). Studies of CF patients 
have detected bile acids in the lower airway via tandem mass spectrometry. Their presence 
poses a threat of injury even after lung transplantation (Brodlie et al., 2015). In chronic 
bronchitis, airway wall destruction and the build-up of intraluminal secretions also lead to 
reduced lung function in CF patients (Rowe and Clancy, 2006). As a consequence, the need 
for antibiotics and bronchodilators increases and this may further affect the gastric and 
duodenal flora and may impair lower oesophageal sphincter (LES) function, leading to the 
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worsening of GOR (Blondeau et al., 2010). Bile acids have been found in the saliva of a third 
of child CF patients (Blondeau et al., 2010), indicating a potentially heightened aspiration 
risk. Studies have never clarified whether GOR is a primary phenomenon of CF, or secondary 
to cough or physiotherapy. The link between this and GOR, aspiration and CF-related 
respiratory systems is still under debate (Vic et al., 1995; Blondeau et al., 2010).  
Reflux-related aspiration has also been diagnosed through analysis of sputum BAs (Perng et 
al., 2007). GOR patients were made to produce sputum, which was then analysed to compare 
the concentrations of BA and TGF-beta 1 levels. It was found that GOR patients had higher 
bile acid concentrations in comparison to controls (p<0.005), which also correlated to TGF-
beta 1. TGF-beta 1 can play a role in fibroblast proliferation. It has been found recently that 
over half of CF patients have BAs in their sputum (Pauwels et al., 2012). 
GOR in children has been linked with wheezing and chronic coughing (Bauman et al., 1996). 
Neuro-disabled children often exhibit high incidences of GOR and are often admitted to 
hospital due to recurrent respiratory problems (Trinick et al., 2012). In these cases, aspiration 
may occur either directly, or result from reflux. Nevertheless, there remains some uncertainty 
around the relationship between GOR, aspiration, and respiratory symptoms.  Increased BA 
levels have been found in ventilator-assisted pneumonia (VAP) patients, indicating that 
neutrophilic inflammation in patient airways may be caused by CDCA-induced IL-8 
production via the activation of mitogen-activated protein (MAP) kinases (Wu et al., 2009). 
Recently, a study conducted by McDonnell assessed the inflammatory and cytotoxic effects of 
chenodeoxycholic, cholic, deoxycholic and lithocholic acids at concentrations 0, 12.5, 25, 50 
and 100 µmol/L showing they present a challenge to human bronchial epithelial cells (HBEs).  
IL-8 was measured by ELISA within culture supernatants, wherein the viability of the cells 
was analysed using MTT. It was also found that exposure to BA reduced the viability of the 
cells in a concentration-dependent manner. The BA-induced IL-8 release was more significant 
at lower acidic levels up-to the point of full cell deterioration. Given these results, this model 
would suggest that BA cytotoxicity within the pulmonary epithelium are affected by acidity 
as well as being dependent on the concentration level (O'Toole et al., 2015).  
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Song et al (2011) have reported that in human oesophageal epithelial cells conjugated bile 
acid are potent inducers of MUC5AC expression, a mucin that is usually only produced in the 
stomach and tracheobronchial epithelium. They demonstrated that the conjugated bile acid 
glycochenodeoxycholate, taurocholic acid, glycocholic acid and taurodeoxycholic acid, which 
are major components of bile refluxate in the oesophagus, are strong inducers of MUC5AC 
mucin expression in the oesophageal cells. Since MUC5AC is an important mucin in the 
airway, this finding may be relevant for understanding how bile acid could affect mucin 
secretion and mucociliary clearance in the lung (Song et al., 2011).  
There is considerable variability in the levels of detection of bile acids in reflux studies. This 
is not only due to the different methods of detection but variability between individuals and 
the time of day samples were collected. A common assay is the 3α hydroxylase method 
described by Fausa & Skalhegg (Fausa and Skålhegg, 1977). This assay is not affected by pH 
but the presence of food or colourants can interfere with results (Collins et al., 1984). Mass 
spectrometry assays are useful method. However, kits developed to look at pathological levels 
in blood may not be suitable for detection of the lower levels found in aspiration. 
There is considerable variability in the lower limit of detection of mass spectrophotometric 
assays; Collins et al suggested 62.5μmol/L (Collins et al., 1985), Klokkenburg claims 5μmol/l 
(Klokkenburg et al., 2009), Biostat, who produce the commercially available assay claim a 
lower limit of detection 1μmol/L and the Leuven group have claimed an accuracy of 
0.2μmol/L  (Blondeau et al., 2008a). These levels are lower than serum bile acid levels 
(<8μmol/L) (D’Ovidio et al., 2005). One group have found this type of assay to be unreliable 
(Gotley et al., 1990). Certain operations can affect the concentration of intra-gastric bile acid 
concentrations; 90% of the normal population will have intra-gastric bile acids concentrations 
of less than 250μmol/L (Gotthard et al., 1985). Intra-gastric levels up to 34,260μmol/L have 
been reported after the formation of a gastro-jejunostomy (Watt et al., 1984). 
Duodenogastric reflux can occur early in the morning or following a meal (Klokkenburg et 
al., 2009). Oesophageal bile acid levels which are considered normal – even in Barrett’s 
oesophagus – are between 0 and 200μmol/L and very rarely exceed 1000μmol/L. No bile 
acids are detected at all in about 25% of patients with reflux (Gotley et al., 1991). If bile acids 
are detected above stomach level, this indicates duodenogastric reflux, in which both bile and 
gastric reflux are combined, making for a weak-acid refluxate (pH 4-7). 
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Individuals who fast have exhibited serum bile levels of between 1-10µM, although these 
levels are known to spike under certain conditions, such as food ingestion, or intrahepatic 
cholestasis of late pregnancy (ICP). The latter is related to a hormone imbalance, which 
causes BA clearance from serum to be less effective. If ICP is left unchecked, this may cause 
foetal BAs to accumulate, which can be dangerous. In ICP, bile acid concentrations in the 
bloodstream can reach 40-60 µM in the mother and 60-120µM in the new born (Zecca et al., 
2004; Zecca et al., 2008; Keely, 2010). ICP new born exhibiting respiratory distress 
syndrome (RDS) have been found to have BAs in their BAL, which was not found in non-
RDS controls (Zecca et al., 2008). BAs are taken up for circulation, indicated by increased 
serum BA levels, then reach the lung. 
Due to the lack of reliable assay techniques, there is a paucity of in-depth studies on specific 
types and levels of BA in lungs and airways. Indeed, BAL analysis has been the most popular 
form of study so far. This method has inherent problems as it involves perfusion of the 
airways with 100-200 ml of fluid (180ml common), resulting in BAL appearing more dilute 
in terms of BAs. Furthermore, out of the many different conjugations of BA, it is not yet 
known which type is most common in the lungs. Age, diet or medication can also have an 
effect on the type of BA in circulation and can alter taurine-conjugated secondary BA ratios. 
Pathogenic colonisation of the airways may also cause conjugated primary BAs to degrade, 
thereby increasing the levels of unconjugated secondary BAs in the lung. Most research 
therefore has concentrated on the presence in the airways of the major BA forms in 
circulation, which are CA, CDCA or DCA (Perng et al., 2008; Zecca et al., 2008; Aseeri et 
al., 2012).  
1.5.2 Bile Acid receptors (BARs) 
BARs are responsible for regulating the homeostasis of BAs. They are found throughout the 
enterohepatic system and include the G-protein coupled receptor (TGR5) and the Farnesoid X 
receptor (FXR). Macrophages  including liver Kupffer cells and T-lymphocytes also have 
BARs and indeed, FXR is believed to have a counter-regulatory effect on such cells (Renga et 
al., 2009; Vavassori et al., 2009). For example, the presence of FXR on macrophages 
suppresses IL-6 and IL1β production (Vavassori et al., 2009), suggesting a modulatory role 
for BARs in the immune system. If this is the case, then this may have  a bearing on the role 
of inflammation in a number of GOR-related disorders, such as Barrett’s oesophagus or 
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chronic lung allograft rejection, which presents clinically as obstructed lung function or BOS 
(Ward et al., 2005; Hodge et al., 2007). 
1.6 Inflammation  
Following mechanical or chemical trauma, or an infection, inflammation is the body’s 
response and involves a broad range of physiological reactions, such as: enhanced release of a 
range of cytokines which cause the activation and migration of leukocytes, plasma protein 
seepage, proximal vasodilation and distal constriction of blood vessels. The role of 
inflammation is vital to pathogen clearance and wound healing. Visible symptoms include 
swelling and redness, as well as increased body temperature and pain. Monocytes 
(macrophages are monocyte that have entered tissue)  and neutrophils travel towards the 
inflamed tissue (Malmström et al., 2013). 
1.6.1 Cytokines and chemokines  
Structural cells and immunocytes, such as epithelial and endothelial cells, as well as 
fibroblasts, release proinflammatory cytokines and chemokines. These are released in 
response to a range of stimuli, such as damage-associated molecular patterns (DAMPs) and 
pathogen-associated molecular patterns (PAMPs), nitric oxide (NO) and other cytokines. 
Cells communicate on both the paracrine and autocrine levels via cytokines, which include 
peptides, proteins and glycoproteins. These are either pro- or anti-inflammatory, or they may 
also serve a chemotactic or growth function (Borthwick et al., 2013). 
1.6.2 Main cytokines implicated in chronic inflammatory lung diseases 
Many studies have documented that  IL-6, IL-8 and GMCSF play a role  in the regulation of 
airway inflammation and pathophysiology of lung disease  (Ruiz et al., 2002). In vitro studies 
have shown that these pro-inflammatory cytokines inhibit apoptosis of granulocytes (Brach et 
al., 1992; Lee et al., 1993; Leuenroth et al., 1998; Castro-Alcaraz et al., 2002). In addition IL-
8 has been of specific interest in studies investigating the pathogenesis of airway diseases , 
due to its important effects on neutrophil cell biology (Keatings et al., 1996). 
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1.6.2.1 Interleukin-6 (IL-6) 
IL-6 is a 22-27 kDa protein with a variable molecular mass according to its glycosylation state 
and whose cytokine function may be either pro- or anti-inflammatory (Shain et al., 2009). As 
a proinflammatory, IL-6 plays a role in the activation of monocytes, T-cell differentiation and 
B-cell maturation. It also serves as a pyrogen, inducing fever in response to infection. Non-
leucocytes, including fibroblasts, astrocytes, endothelial, epithelial and malignant cells also 
secrete IL-6 (Rincon and Irvin, 2012). As an anti-inflammatory cytokine, IL-6 can upregulate 
the production of interleukin-1 receptor antagonist (IL-1RA) and IL-10, as well as inhibit the 
activity of IL-1 and tumour necrosis factor alpha (TNF-α). Macrophages, fibroblasts, T-cells 
and muscle cells are all able to secrete IL-6 (Hirano, 1998). 
Research into lung diseases is beginning to identify IL-6 as a key player. Previous research 
has focussed on other cytokines such as IL-4, IL-5, IL-13 and IL-17, while IL-6 was 
overlooked, simply being considered a by-product of airway inflammation. Recently however, 
IL-6 has been implicated in the development of both asthma and possibly COPD. It has 
therefore taken centre stage in the research and treatment of these and similar chronic lung 
diseases (Rincon and Irvin, 2012). 
1.6.2.2 Granulocyte-macrophage colony-stimulating factor (GM-CSF)  
GM-CSF is synthesised by fibroblasts, macrophages, endothelial, epithelial and mast cells. It 
is a 14 kDa glycosylated protein which forms homodimers that play a role in the 
transformation of stem cells into granulocytes (such as eosinophils, basophils and 
neutrophils), as well as monocytes. Viral, bacterial, fungal or protozoal infections cause blood 
serum concentrations of GM-CSF to increase. Increased levels have also been observed in 
tumour-bearing animals and also following irradiation of bone marrow. GM-CSF production 
– observed in vitro – is stimulated by IL-1 and TNFα. In bone marrow, GM-CSF is involved 
in haematopoiesis (Lim et al., 2013). 
The granulocyte macrophage colony-stimulating factor receptor, which is also called cluster 
of differentiation 116 (CD116), is used for GM-CSF signalling. CD116 is a dimer produced 
by myeloblasts and neutrophils. It comprises an α chain, specific to CD116, whose role is to 
recognise and bind to ligands, and a β chain, responsible for signal transduction – the β chain 
is also part of the IL-3 and IL-5 receptors. Α chain ligand binding causes the α and β subunits 
to dimerise, as well as phosphorylation of the β chain on tyrosine residues via JAK kinases. 
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An Shc adaptor protein associated with the phosphorylated β subunit, leads to activation of 
other downstream signalling molecules (Broughton et al., 2012).  
As a strong chemoattractant for neutrophils and macrophage activator, GM-CSF plays a key 
role in oxidative metabolism as well as stimulating both phagocytic and microbicidal 
responses, improving the cytotoxicity of macrophages (Sorgi et al., 2012) and neutrophils 
(Katano et al., 2010).  
GM-CSF is also heavily involved in host defence and surfactant homeostasis regulation in the 
lung. Deficiency or signal pathway disruption of GM-CSF in mice potentially leads to 
impaired macrophage capacity, phagocytosis, cell adhesion and pathogen killing, which can 
lead to pulmonary alveolar proteinosis (PAP) (Ohashi et al., 2012). 
1.6.2.3 Interleukin 8 (IL-8) 
IL-8 is produced by mesenchymal, airway and parenchymal cells in the lungs. It stimulates 
angiogenesis, regulates leukocyte trafficking and causes mucin secretion (Strieter, 2002). IL-8 
production indicates the occurrence of damage. BO positive patients were found to have 
increased IL-8 levels, although the stage of BO development was not found to make a 
difference to the IL-8 levels (D'Ovidio et al., 2005). The lowest IL-8 levels in BAL were 
found in control subjects; higher levels were found in stable lung transplant patients; and the 
highest levels were detected in BOS patients (Zheng et al., 2000). IL-8 is produced as a 
damage response by fibroblasts, alveolar macrophages, smooth muscle, epithelial and 
endothelial cells. In this context, IL-8 is a neutrophilic chemoattractant and an angiogenic 
factor.  
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Figure 1-7: The airway epithelium. In response to injury, epithelial cells produce inflammatory chemokines and 
cytokines that recruit and activate immune cells. These cells include: neutrophils, eosinophils, macrophages, T-
lymphocytes and natural killer (NK) cells which are activated to amplify host responses and regulate innate 
immunity ( Adapted from Varielle., 2011 (Vareille et al., 2011) ). 
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1.7 Airway mucus  
Airway mucus forms a physical protective barrier between the epithelial surface and the 
external world. Mucins – either secretory or tethered to a membrane – are glycoproteins 
which form part of the constituents of respiratory mucus, along with lipids, proteins, ions and 
water. Submucosal tracheobronchial glands and epithelial goblet cells secrete these 
components to form mucus. Mucus is a significant part of the innate immune system as well 
as mucociliary defence. It is antibacterial and has a humidifying effect in inhaled air. It also 
physically traps and ejects particles, pathogens and other foreign bodies from the respiratory 
tract (Rose and Voynow, 2006). When inhaled particles or microbes reach the lung they 
become attached to the mucus gel layer and are cleared from the lungs by the action of the 
cilia moving the mucus layer up and out of the lungs (Pearson et al., 2016). When mucus 
production is inhibited or disordered, this is implicated in a number of diseases, including CF, 
COPD and asthma. Overproduction of mucus leads to chronic airflow limitation, neutrophilia 
and suppuration. Lung transplant patients have sometimes exhibited disordered mucus 
homeostasis (Veale et al., 1993), although further research is required into this subject.  
Coughing and ciliary activity are the primary governors of mucus homeostasis, and lungs 
should contain very little or no mucus (Kim, 1997). Various complications may arise from 
hypersecretion, such as obstruction, infection, discomfort and higher mortality rates. Excess 
mucus may also transport foreign particles into the bronchial tree, rather than ejecting them 
from the airway (Kim, 1997). Diseases of the respiratory tract lead to increased mucus 
secretion, which can cause obstruction and in fact, the inflammatory/immune response can 
lead to airway remodelling (including goblet cell hyperplasia) and mucin gene regulation 
(Rose and Voynow, 2006). 
1.7.1  Effect of aspiration 
There is a dearth of research on the effects of aspiration on the mucus layer. Aspirated pepsin 
and bile salts can lead to increased vulnerability of the epithelium by disrupting the mucus 
layer which protects it. One consequence of this is increased mucus production, which may 
lead to airway obstruction. 
Mucus is made up of mucins, which are a family of macromolecules (usually > 2x106 Da), 
high in carbohydrate (50-90%). These complex glycoproteins exhibit heavy glycosylation, of 
which O-glycosylation causes numerous tandem repeats of proline, serine and/or threonine. 
The MUC backbone is made up of between 1.1 and 15 kilobases and can contain up to 11,000 
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amino acids, which make up 10-50% of the weight of the MUC (Rose and Voynow, 2006). At 
least 21 different types of mucin are produced by humans. In human airways, predominant 
mucins include MUC5AC, produced by goblet cells and MUC5B, produced by glandular 
mucosal cells. MUC7 is generated by both mucosal and serosal cells in the salivary glands, 
although saliva itself contains predominantly MUC5. Localised serous cells in the submucosal 
glands produce MUC5 in the larger airways of 15-20% of healthy individuals. As a result, 
mucociliary clearance and coughing are ineffective in terminal and respiratory bronchioles. 
Two layers combine to form the airway mucus barrier: the periciliary layer (PCL) overlies the 
cells and the cilia, and is around 10 μm thick. Sitting on top of this is the mucus gel layer, 
which is around 60μm thick. It was previously believed that the PCL was a low viscosity fluid 
that allowed free movement of the cilia. However, it has been shown by Kesimer et al. 
(Kesimer et al., 2013) and Button et al. (Button et al., 2012) that mucins (MUC5AC and 
MUC5B) from the gel layer do not enter the PCL, although keratan sulphate, a 
glycosaminoglycan associated with membrane-bound mucins, MUCs 1, 4 and 16, is found in 
the PCL. Furthermore, MUCs 4 and 20 were expressed on the cilia, whilst the goblet cell 
surface exhibited MUC16, with MUC1 in the microvilli. The goblet cells appeared to have 
broad pillars of MUC16 extending through the PCL and into the gel layer and because 
MUC16 is co-released with MUC5B, it has been speculated that these pillars may be a 
mechanism for channelling MUC5B into the gel layer.  
1.7.2 Mucus secretion 
Mucus secretion can be caused by cytokine and leukocyte secretion. Mucins are produced 
under a range of circumstances, including stimulation by smoke, bacteria, matrix 
metalloproteinases, lipopolysaccharide, reactive oxygen species, neutrophil elastase, growth 
factors, triphosphates (cell injury markers) and bacterial by-products. These may have a direct 
effect or they may cause leukocyte stimulation (Kim, 1997; Jackson, 2001). 
Lipopolysaccharide has been shown in vitro, to increase MUC5AC, MUC5B and IL-8. These 
findings implicate goblet cells in playing a key role in mucosal immunity (Smirnova et al., 
2003). Disruption of these regulating factors can cause hypersecretion via the secretory 
cascade within minutes. This can be injurious, leaving the lungs vulnerable to damage or 
infection (Rose and Voynow, 2006). 
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1.8 Epithelial to Mesenchymal Transition (EMT  (  
1.8.1 What is Epithelial to Mesenchymal Transition (EMT)?  
EMT allows epithelial cells to acquire a mesenchymal phenotype via multiple biochemical 
changes. This elevates its capacity for migration, resistance to apoptosis, invasiveness and 
boosts extracellular matrix (ECM) component production (Figure 1-8) (Kalluri and Neilson, 
2003). 
 
Figure 1-8: The changes in epithelial cells during EMT. EMT includes a change of a polarized epithelial cell 
into a movable and ECM component secreting mesenchymal cell (Kalluri and Weinberg, 2009). 
The EMT comprises three different subtypes:  
Type 1: Occurring during implantation, embryogenesis and organ development;  
Type 2: Linked with tissue regeneration and organ fibrosis;  
Type 3: Linked with cancer development. 
In summary, type 1 EMT can lead to the generation of secondary epithelial cells by forming 
mesenchymal cells, which may undergo Mesenchymal Epithelial Transition (MET). 
However, there is no link between this and any circulatory proliferation of an invasive 
phenotype. Type 2 EMT however, generates fibroblasts and similar cells related to the post-
inflammatory repair system and tissue reconstruction. It stops when the inflammation is 
subdued. If inflammation continues unabated, then so does the type 2 EMT; fibroblasts 
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continue to be generated and organ fibrosis and destruction may ensue. Type 3 EMT is found 
in cancer cells, enabling them to metastasize and invade (Kalluri and Weinberg, 2009). 
1.8.2 Molecular Markers 
Mesenchymal properties are gained only after the epithelial cell has passed through a number 
of stages. Further to this, markers on the epithelial cell, including E-cadherin and cytokeratins 
are expressed at a lower rate. These play a role in maintaining structural integrity as well as in 
intercellular contact. When adhesion proteins are no longer expressed, cellular organisation 
breaks down, resulting in enhanced fibroblastic protein expression, including fibronectin and 
vimentin (Ward et al., 2005). 
1.8.2.1 E-cadherin  
Of the epithelial cell markers, E-Cadherin is a major structural protein. It plays a significant 
role in intercellular adhesion and in adherens junction maintenance. One of the primary EMT 
events is the inhibition of E-cadherin expression, which is caused by a number of EMT-
inducing transcription factors (Daniele et al., 2016). The adherens junctions define apico-
basal polarity and are located at the basolateral membrane. Homotypic interactions, which are 
calcium-dependent, occur in the extracellular tail of adherens junctions, serving to connect 
adjacent epithelial cells. At the same time, E-cadherin has a cytoplasmic component, which 
mediates mechanical stability through interaction with the actin and microtubule 
cytoskeletons through linked β-, α-, ᵧ- or p120-catenin proteins (Schmalhofer et al., 2009) . 
E-cadherin expression also plays an indirect role in β-catenin or NF-κB transcription (Solanas 
et al., 2008). It has been established that these proteins are involved in EMTs during tumour 
invasion and that E-cadherin prevents these from reaching the nucleus, thereby suppressing 
their transcriptional activation role (Brabletz et al., 2005; Maier et al., 2010). 
Due to its significant role in both cell adhesion and also EMT-related down-regulation, it is 
suggested that loss of E-cadherin may be used as a prognostic marker for the progress of 
cancers (Fendrich et al., 2009; Tryndyak et al., 2010; Hong et al., 2011), although it does not 
necessarily indicate the risk of mortality (Ucvet et al., 2011). 
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1.8.2.2 Cytokeratins  
Epithelial markers, otherwise known as Cytokeratins, are intermediate filaments that are 
predominantly expressed by epithelial cells: within these are a wide array of proteins that vary 
in affinity, isoelectric pH values and molecular weight (Kirfel et al., 2003). The expression of 
cytokeratins varies among different epithelia types in their different developmental stages, 
and may also be used as an adjunctive tool for histological diagnosis and epithelial 
classification (Chu and Weiss, 2002; Azevedo et al., 2008). ΕΜΤ is a process whereby 
epithelial cells acquire a mesenchymal phenotype and lose their epithelial characteristics.  The 
invasive and metastatic potential of these cells is subsequently increased by EMT (Guarino, 
2007). The EMT process is characterised by the upregulation of mesenchymal markers such 
as fibronectin and vimentin, and the downregulation of epithelial markers such as E-cadherin 
and cytokeratin (Kolijn et al., 2015).   
1.8.2.3 α-smooth muscle actin (α-SMA) 
α-SMA   ) Mesenchymal markers(  has been described as a smooth muscle cell differentiation 
marker (Skalli et al., 1989). EMT-related differentiation and myofibroblasts have been linked 
with increased α-SMA expression, allowing for cell population identification and for EMT 
process assessment in fibrosis (Chai et al., 2003; Wu et al., 2007). α-SMA expression 
involves a small GTPase Rho and its effector, Rho kinase, which are also associated with 
fibrosis-associated EMT, particularly in cytoskeleton reorganisation (Masszi et al., 2003). 
This manifests through stress fibre formation, which are contractile and tension exerting actin 
filaments that play a key role in cell motility (Alberts et al., 2002). 
1.8.2.4 Fibronectin 
Fibronectin )Mesenchymal markers( is involved in cell adhesion (Alberts et al., 2002). A 
glycoprotein, it forms part of the extracellular matrix and is recognized by integrins. It is 
protected, in either it’s soluble or fibrillar form, by Fibroblast-Specific Protein 1 (FSP1) 
expressing cells and plays a critical role in cell attachment and migration, metastasis and 
cytoskeletal assembly. EMT-inducing conditions lead to enhanced fibronectin production and 
it can therefore be used as a marker of EMT (Strutz et al., 2002). 
  
32 
 
1.8.3 Transforming Growth Factor-β (TGFβ) induction of EMT 
Within a range of cell types, including epithelial, endothelial and hematopoietic cells, the 
inhibition of cell proliferation can be caused by the multi-functional cytokine, TGF-β. As well 
as these effects, it is also responsible for inducing a variety of extracellular matrix proteins, 
and subsequently the stimulation of tissue fibrosis. 
However, within the pulmonary microenvironment, the chronic overexpression of TGF-β 
often results in fibrosis (Samet, 2000; Willis and Borok, 2007). In areas where a lung tumour 
does become established, this often leads to the dysregulation of the TGF-β signalling 
cascade, such that an increase in the manufacture of TGF-β contributes to potent EMT 
induction, apoptosis resistance and immune evasion (Roberts and Wakefield, 2003; 
Massagué, 2008). TGFβ in EMT in vitro studies have been demonstrated to down-regulate 
epithelial markers, including cytokeratins and E-cadherin. Conversely, the same studies have 
revealed the regulation of mesenchymal markers, such as α-smooth muscle actin, N-cadherin, 
fibronectin and vimentin (Moustakas and Heldin, 2012).  
As TGFβ mediates EMT via the activation of Smad2 and Smad3, this in-turn mediates EMT 
(Piek et al., 1999; Valcourt et al., 2005), and via the Smad pathway, HMGA2 is also 
regulated, which leads to the elicitation of EMT (Thuault et al., 2006) . In turn, as TFs such as 
Snail1 and Twist1 are up-regulated, the working of HMGA2 and Smads together also leads 
EMT to being induced (Thuault et al., 2008; Tan et al., 2012). Suppressing the expression of 
E-cadherin is possible through the interaction of Snail1 and activated Smads (Vincent et al., 
2009). In alveolar epithelial cells (AECs), TGF-b1 has been reported in recent studies to 
induce EMT, as well as differentiating fibroblasts into myofibroblasts and was also 
demonstrated among IPF patients to be up-regulated (Trulock et al., 2005; Willis et al., 2005; 
Câmara and Jarai, 2010).  
Moreover, following chronic exposure to TGF-β1 in vivo and in vitro, alveolar epithelial cells 
have been demonstrated to undergo EMT: this is found to result in a loss of epithelial proteins 
such as E-cadherin and the cytokeratins; and also leads to the acquisition of mesenchymal 
proteins, including collagen type I and fibronectin (Willis and Borok, 2007). A role for 
differentiation and growth factors in the induction of EMT has been indicated by numerous 
previous studies: these include TGFβ, Notch, Wnt, integrins and receptor tyrosine kinases 
(RTK). The cross-communication that exists between these factors enables the remodelling of 
the architecture and function of the cells via protein networks and gene programmes 
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(Moustakas and Heldin, 2007). The activation of effector proteins, including PI3K, MAPK 
and NFκB, Src, Rho GTPases and integrin-linked kinase (ILK), occurs through signalling 
pathways such as inflammation or hypoxia. In turn, this facilitates the regulation of EMT 
(Moustakas and Heldin, 2007). Further, in the progression of cancer and embryogenesis, 
TGFβ significantly induces EMT (Moustakas and Heldin, 2012). The platelet-derived (PGDF) 
growth factor is induced by TGFβ, whose receptors and ligands are also significant in 
inducing EMT, metastasis within the hepatocellular carcinoma and invasion (Fischer et al., 
2007). Furthermore, as the process of EMT begins, the Jagged1, Notch ligand and Hey1 the 
target gene, are induced by TGFβ in a manner that is dependent on Smad3 (Zavadil et al., 
2004). Over the course of the  EMT process, TGFβ also represses the inhibition of the 
differentiation protein (Id3 and Id2) (Thuault et al., 2006). These proteins act as antagonists to 
the proteins of the basic helix-loop-helix (bHLH), which include the EMT-inducing 
transcription factor and Twist1. Further, Id2 and Id3 are also targeted by the BMP7 signalling 
pathway, which may to some extent explain the role BMP7 has in the TGFβ-induced 
inhibition of EMT, in-turn resulting in MET (Kowanetz et al., 2004). 
1.8.4 Matrix metalloproteinase (MMP)-9 and EMT 
The deterioration of various components in extracellular remodelling is caused by an enzyme-
group known as MMPs. These are synthesised and released by neutrophils, airway epithelial 
cells and alveolar macrophages (Kim et al., 2008b). In studying COPD patients, a correlation 
has been identified between the activity of MMP-12 and emphysema levels (Chaudhuri et al., 
2012), and it has also been demonstrated that FEV1 is reduced by polymorphisms in MMP12 
and MMP1 (Tzortzaki et al., 2006). Furthermore, an elevated level of gelatinase B MMP-9 
and neutrophil collagenase MMP-8 has also been identified among COPD patients (4). While 
the former mostly originates from macrophages and neutrophils, these may also be 
manufactured by epithelial cells, mast cells, smooth myocytes and fibroblasts. Due to its 
collagen-lytic and elastolytic activity, extracellular matrix turnover is critically dependent on 
MMP-9. Furthermore, the activity of several biological factors, such as proteinases (e.g., 
MMP-13), cytokines (e.g., IL-1, VEGF) and/or their inhibitors (e.g., a1-antitrypsin) are 
moderated under MMP-9. 
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This is because of its broad substrate specificity that also allows it to cleave extracellular 
matrix components. Further, the BAL fluid of COPD patients has been found to contain 
heightened levels MMP-9, which was found to come from BAL macrophages that express an 
increased level of MMP-9 when compared to control subjects (Barnes and Hansel, 2004).  
A similar case can be observed in the serum of COPD patients, where the inflammatory 
response can be found to involve  MMP-9 , that indicates the COPD stage (Piesiak et al., 
2011). Further, MMP-9 is becoming the target of the ongoing research into COPD therapy 
(Wu et al., 2012). Among certain lung diseases, a neutrophil-predominant response is 
exhibited, in which the MMP-9 produced by the neutrophil is able to obscure epithelial and 
other cell-produced MMP-9; a process that may be instrumental in the pathogenesis of the 
COPD. Levels of MMP-9 are elevated, and are found to be involved in asthma, inflammation, 
IPF and emphysema (Daniele et al., 2016). Moreover, EMT has recently come to appear as a 
set of changes in sequence that may lead to migratory and invasive properties becoming 
expressed by epithelial cells.  
It has been demonstrated in vivo on tumour biopsies and on developmental models, as well as 
in a range of tumoural and non tumoural in vitro systems, that the expression of MMPs (and 
MMP9 in-particular) is most evidently instrumental to processes of EMT. In accordance to 
this, the use of transcription factors (snail, ETS, β-catenin) to regulate MMPs, that are known 
to regulate pathways of EMT, have now been firmly established. As a consequence, MMPs 
are rather considered as target genes of EMT pathways and MMP expression as a late event of 
the EMT. In part, this may be because of direct up-regulation of the gene transcription of 
MMP by the factors driving EMT (Gilles et al., 2005). 
 Nevertheless, changes in EMT have been shown to be initiated by MMP9. Also, the ability to 
cleave E-cadherin  has been demonstrated among certain MMPs, thereby inducing the 
fragility of E-cadherin complex and changes in EMT (Coussens et al., 2002; Overall and 
López-Otín, 2002). As MMP-9 is a Type IV collagenase, it is therefore able to distort 
basement membranes, which has been identified to cause EMT among patients of the lung 
transplant procedure (Ward et al., 2005).  
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1.9 Overall aim 
Gastroesophageal reflux (GOR) and subsequent BA aspiration have been implicated in 
several disorders of airways, including lung transplant rejection, COPD, CF and asthma. 
Taken together, the studies described in (1.5) provide evidence to support the existence of bile 
acid in the airways. Bile acids are present and can sometimes be associated with decreasing 
lung function, no direct correlation has yet emerged to indicate whether bile acids play a 
pathophysiological role in the airways.  
My research focused on the hypothesis that bile acids may induce inflammatory lung disease. 
This thesis brings together a series of experiments to investigate the possible links between 
any primary bile acids (cholic acid and chenodeoxycholic acid) and secondary bile acids 
(lithocholic acid and deoxycholic acid) present in the lung and damage caused to the 
epithelium. 
 There are three overall aims of this study. The first is to investigate the effects of bile acids 
on the expression of inflammatory markers that are important in airway diseases. The second 
is to investigate the link between bile acids that may injure airway epithelial cells and 
epithelial–mesenchymal transition (EMT) that may leading to airway fibrosis. Finally, to 
explore the use of the NCI-H292, Calu-3 cell lines as potential in vitro models to test the 
hypothesis that the presence of bile acids causes mucus hypersecretion.  
The thesis was divided into chapters as follow: 
Chapter one: General introduction  
Chapter two: Material and methods  
 
Chapter three: Establishing an in-vitro model of human bronchial epithelial cell injury using 
cell lines 
- In chapter three, human bronchial epithelial cell lines BEAS-2, 16HBE14o-, NCI-
H292 and Calu-3 cell lines will be cultured to assess the effect of bile acids challenge. 
The effect of cholic acid, chenodeoxycholic acid, deoxycholic acid and lithocholic 
acid will be measured by assessment of inflammatory cytokine production. Markers 
will include IL-8, IL-6 and GMCSF which are important in inflammatory lung 
disease.  
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Chapter four: Bile acid Induced Epithelial to mesenchymal transition (EMT) 
- In chapter four, human bronchial epithelial (PHBE) cells, primary human epithelial 
cells from the subglottis area, BEAS-2B and 14HBE14-O cell lines will be cultured. 
The cells will be stimulated to investigate the role of BAs in instigating EMT by 
evaluate E-cadherin expression (epithelial marker) and fibronectin expression (a 
mesenchymal marker). The effect of primary bile acids (Cholic acid and 
chenodeoxycholic acid) and secondary bile acids, lithocholic acid and deoxycholic 
acid) will be measured by assessment using ELISA of TGFβ1, (TGF-βl is a potent 
EMT inducer), MMP9 and Pro-collagen production (can cause inflammation, 
translocation, further EMT and other damage).  
Chapter five: The role of duodeno-gastro-oesophageal refluxate in mucus production from 
NCI-H292 and Calu-3 cell lines  
- In chapter five the NCI-H292 and Calu-3 cell lines that have been used as an in vitro 
model system were used to study MUC5 gene regulation. Cells were stimulated with 
bile acids and mucin content of the culture medium measured using a periodic acid-
Schiff’s (PAS) assay. To confirm and extend the PAS findings MUC5AC and 
MUC5B will be measured using indirect ELISA. Finally, quantitative real-time PCR 
will be used to evaluate MUC5AC and MUC5B expression in NCI-H292, Calu-3 cell 
lines.   
Chapter six: General discussion and conclusion  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Cell culture 
2.1.1 General practice 
As per the University’s policy on Health and Safety, the work as follows has been performed 
within a biosafety level II laboratory. Further, the form Control of Substances Hazardous to 
Health (COSHH) and the form Biological Control of Substances Hazardous to Health 
(BIOCOSH) were both reviewed before the work was conducted and were signed off by the 
University’s Committee on Biological safety.   
Cell culture procedures were performed in a containment level II microbiological safety 
cabinet. This was routinely cleaned with 70% ethanol prior to use. Additionally, all tissue 
culture equipment was sprayed with 70% ethanol before use. For routine culture, cell lines 
were grown in either 25cm² or 75cm² plastic tissue culture flasks (Corning, UK).  
The cell types were cultured in specific medium according to American Type Culture 
Collection (ATCC) recommendations, which were incubated in a humidified atmosphere of 
5% CO2 at 37°C. Adherent cell lines were placed horizontally in the incubator to allow for 
cell adherence, while suspension cells were grown in flasks.  
2.1.2 Culture medium 
2.1.2.1 RPMI 1640 Medium 
To support the growth of suspension cell lines, RPMI 1640 medium (Sigma, 5886) was used. 
Cells were grown in this medium after the addition of 10% Fetal Calf serum (FCS), 2 mM L-
glutamine, 100U/ml penicillin, 100µg/ml streptomycin (Sigma, UK), and 50μg/ml 
amphotericin B (Lonza, USA).  
2.1.2.2 Eagle's Minimum Essential Medium (EMEM) 
EMEM with Earle’s acid medium was used to support the growth of the cell lines. Complete 
medium was obtained after the addition of 10% FCS, 50μg/ml amphotericin B (Lonza, USA), 
100U/ml penicillin, 2 mM L-glutamine and 100 µg /ml streptomycin (Sigma, UK). 
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2.1.2.3 Bronchial Epithelial Cell Growth Medium (BEGM) 
In order to prepare BEGM complete medium (Lonza) supplements supplied by Lonza were 
added into 500ml BEBM base medium: these were bovine pituitary extract 2ml (final 
concentration 0.004 ml/ml), insulin 0.5 ml (5 μg/ml), hydrocortisone 0.5 ml (0.5 μg/ml), 
retinoic acid 0.5 ml (0.1 ng/ml), transferrin 0.5 ml (10 μg /ml), triiodothyronine 0.5 ml (6.7 
ng/ml), epinephrine 0.5 ml (0.5 μg/ml), Epidermal Growth Factor human recombinant 0.5 ml 
(10 ng/ml), L-glutamine (to 100 U/ml) and penicillin/streptomycin (Final concentration 
100U/mL) (Sigma, UK). 
2.2 Cell lines and Primary cells  
2.2.1 Normal human bronchial epithelial cells 
By using normal human bronchial epithelial (NHBE) cells as to primary cultures, it is 
possible to provide an in vitro representation of the native airway epithelium. Numerous key 
attributes of the normal airway epithelium are exhibited by such (NHBE) cell cultures. 
Furthermore, research into the biology of cells within the airway can be facilitated through the 
use of an expanded pool of in vitro-like epithelial cells (Gray et al., 1996).  
During bronchoscopies, airway brushings were taken from lung transplant patients and these 
bronchial epithelial cells were suspended in RPMI 1640 basal medium. Following 
centrifugation at 1000 rpm, for 5 minutes at room temperature cell pellets were re-suspended 
in 4 ml of complete BEGM (Lanza). Cell suspensions were transferred to a collagen pre-
coated T25cm flask 30 μg/ml PureCol (Advanced BioMatrix, San Diego, CA, USA) and 
incubated in 5% CO2 at 37C°. Growth medium replaced every subsequent 48 hours until 
(PHBECs) reached a confluence of 80-95%. 
2.2.2 BEAS-2B 
Derived from normal human epithelial cells immortalised through the hybridisation of simian 
virus 40 adenovirus 12 (Reddel et al., 1988). BEAS-2B is considered a human bronchial 
epithelial cell line. BEAS-2B cells are maintained as sub-confluent, otherwise they induce 
squamous differentiation and BEAS-2B is available from the ATCC (CRL-9609). 
Furthermore, these are popular for research on the function and structure of airway epithelial 
cells as they were used to maintain the morphology of an epithelial cell in vitro as well as 
release IL-8 and IL-6 in addition to other cytokines (Swanson et al., 2009). Within a 
humidified atmosphere containing 5 % CO2 at a temperature of 37°C, the BEAS-2B cells 
39 
 
were grown in 75-cm
2
 flasks in BEGM medium. The cells were passaged every 4-6 days to 
maintain sub-confluent. The cells were cultured and used for experiments at passage 6-23 and 
at density of 1 x 10
5
 cells/cm
2
 on 24 well. 
2.2.3 Calu-3 
Calu-3 (ATCC HTB-55) is a human bronchial epithelial cell line originally sourced from a 
bronchial adenocarcinoma in a 25-year-old Caucasian male (Itani et al., 2007; Zhu et al., 
2010). Calu-3 cells structurally can form organised cell layers with tight junctions. They show 
typical airway epithelial properties, for example, generation of high levels of secretion parts 
that are similar to those of the serous cells of the tracheobronchial organ. Further, the 
expression of mucus genes MUC1 and MUC5AC and the secretion of MUC5/5AC mucins 
and secretory granules are also attributes that these cells feature (Berger et al., 1999). Within 
an EMEM medium containing 2mM L-glutamine, 10% FCS, streptomycin (100 μg/ml) and 
penicillin (100 U/ml); the Calu-3 cells were cultured in a humidified atmosphere containing 
5% CO2 and at a temperature of 37°C.  The cells were cultured and used for experiments at 
passage 2-33 and at density of 1 x 105 cells/cm2 on 24 well plates.  
2.2.4 NCI-H292  
NCI-H292 cells (ATCC; CRL-1848), are a bronchial epithelial cell line derived from a 
mucoepidermoid carcinoma. NCI-H292 cells react to an assortment of airway injuries 
including tobacco smoke. This leads to up regulation of different endpoints connected with 
inflammation IL-6 and IL-8, airway remodelling MMP-1, GM-CSF, and mucin 
overproduction MUC5AC (Newland and Richter, 2008). In addition NCI-H292 cells have 
been widely utilized as a lung model for toxicological assessment (Newland et al., 2011). The 
NCIH292 cells were grown in RPMI-1640 medium supplemented with 10% FCS, 2 mM L-
glutamine, penicillin (100U/ml), streptomycin (100 μg/ml) and 50μg/ml amphotericin B in a 
humidified 5% CO2 climate at 37C°. Monolayer cells were routinely subcultured each 3-4 
days. Cells were washed twice with sterile PBS and passaged using a 5 mL 0.05% trypsin: 
0.02% EDTA 1x solution. The cells were cultured and used for experiments at passage 14-52 
and at density of 1 x 10
5
 cells/cm
2
 on 24 well plates. 
 
40 
 
2.2.5 16HBE14o- Cells  
16HBE14o- cells were acquired from Dr. Dieter Gruenert, University of California, San 
Francisco USA. The cell line 16HBE14o- was derived from an infant male heart-lung patient 
(at 1 year of age) by transforming (large T-antigen SV40) cultured bronchial epithelial cells. 
While this cell line is neither licenced nor commercially available, epithelial polarised cell 
mono layers are formed and epithelial morphology is maintained. This includes tight junction 
formation and high trans-epithelial resistance (Cozens et al., 1994). Further, other 
differentiated features that characterise the native epithelium are also found to be expressed 
(Gruenert et al., 1995). Moreover, over the course of many passages, high viability is also 
demonstrated. What is controversial however is their ability to secrete mucus and form cilia 
(Ehrhardt et al., 2008; Pohl et al., 2009). Within an EMEM medium containing 2mM L-
glutamine, 10% FCS, streptomycin (100 μg/ml) and penicillin (100 U/ml); the 16HBE14o- 
cells were cultured in a humidified atmosphere containing 5% CO2 and at a temperature of 
37°C.  Furthermore, a fibronectin coating solution was used to pre-coat the T75 flasks. At a 
confluency of 80-90%, the cells were passaged by first washing with Hepes buffered saline 
(HBS), following by allowing the cells to detach using 5 mL 0.05% trypsin: 0.02% EDTA 
solution. The cells were cultured and used for experiments at passage 62-108 and at density of 
1 x 10
5
   cells/cm
2 
on 24 well plates. 
2.3 Cell count 
Cells were counted using an improved Neubauer chamber haemocytometer (Figure 2-1). Ten 
microlitres of cells suspended in medium were placed onto the chamber secured with a glass 
cover slip. The number of cells at each corner was counted, as well as the middle square in the 
centre. The average was taken and multiplied by 5 to include all 25 squares and multiplied 
104 to obtain the number of cells per ml.  
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Figure 2-1: Illustration of a hemocytometer slide. After placing the coverslip on the slide, a cell suspension is 
loaded and cells are counted in each square. Cells touching the middle line on the top and left are included in the 
counting (green) while those touching right and bottom are excluded from the count (red) (Martin, 1994). 
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2.4 Cell cryopreservation 
 Keeping in mind the end goal to maintain a supply of the cell lines and to hold cells from an 
early passage, cryopreserved cells were frozen in liquid nitrogen. Cells in their log 
development stage (70-80% confluent in flask) were re-suspended in freezing medium, which 
comprises of 10% dimethylsulphoxide (DMSO-Sigma) in complete medium or FCS. Cells 
were frozen in batches of 5-10 million cells for each cryovial (Corning, UK). The vials were 
set in a Nalgene cell freezing container filled with isopropyl alcohol which provides a 
progressive reduction in temperature of 1 degree Celsius per minute when stored at - 80°C 
overnight. On the second day, the cells were moved into a liquid nitrogen tank for long term 
tissue banking. For cell recovery, cells were defrosted by quick warming in a 37°C water 
bath. Once defrosted, the cells were moved promptly into 10-15 ml of fresh pre-warmed 
medium and incubated at 37°C. 
2.5 Epithelial Cell passage 
When the cells in the culture flask approached 75-80% confluence, they were passaged, 
permitting further propagation. Five ml of 0.05% trypsin; 0.02% EDTA was added to the 
flask, then incubated at 37ºC for 2-5 minutes until cells detached . Five ml of complete 
medium that contain FCS was then added to inhibit the trypsin and to help re-suspend the 
cells. Thereafter, in order to pellet the cells, the solution was centrifuged at 1100rpm for 7 
minutes and at a temperature of 10ºC; before seeding into 6 and 24 well plate, these were 
mixed carefully with 12ml of complete epithelial medium. 
2.6 Primary bronchial epithelial Cell (PHBECs), tracheal epithelial cells and cell lines 
stimulation 
At about 85-90% confluence, plates containing primary cells or cell lines were rested for 24 
hours in serum free medium. Bile acids (cholic acid, chenodeoxycholic acid, deoxycholic acid 
and lithocholic acid) were dissolved in methanol to prepare stock solution that was (100 
mmol/L) in this experiment. To achieve the experimental concentration different 
concentrations were prepared by diluting stock solution in resting medium. These dilutions 
were at least 1000 fold leaving vanishingly small amounts of methanol. After this process, 
they were added to PHBECs, tracheal epithelial cells and cells lines to achieve stimulation. A 
total of three repeated cultures and four repeated wells of PHBECs, tracheal epithelial cells 
and cell lines (n= 12) was carried out. The following bile acid concentrations were used: 1, 2, 
5, 10, 15, 16, 17, 18, 20, 30, 50, 75, and 100μmol/L at incubation times of 24 and 48h. After 
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these times, samples of the cell culture supernatants, as well as control samples, were 
collected to measure cytokine concentrations using ELISA assays (R&D Systems). The 
control samples consisted of cells incubated with resting medium. The data presented in the 
thesis are all 48 hour results because stimulation for 24 hours did not produce any changes in 
the cell viability compared to control suggesting damage was time dependent. Moreover, in 
developing an ELISA, secretion was measured in cell supernatants that were treated for 24 hr 
with bile acids, but this did not significantly induce secretion of pro-inflammatory mediators 
suggesting damage and bile acid stimulation was time dependent. This fits in with other 
studies by our group. In these studies the effect of individual primary and secondary bile acids 
were evaluated on PBECs after stimulation for 24 and 48 hours. Cell death, Interleukin 8 (IL-
8) and Interleukin 6 (IL-6) production were measured by ELISA. They found that 48 hours 
treatment was more effective compared to 24 hour (Aseeri, 2012). A time course for mRNA 
studies was not performed. It might be predicted that peak mRNA effects would occur before 
the 48 hour time point and further studies could evaluate this. 
2.7 Cell viability assay 
2.7.1 CellTiter-Blue™ Assay 
2.7.1.1 Assay principle 
The CellTiter-Blue™ Assay (Promega, USA) is based on cellular reduction of resazurin to the 
absorption product resorufin. It is based on the principal that viable cells are able to 
metabolize and reduce the dye; whereas the capacity to reduce the dye of dead cells rapidly 
diminishes once their membranes are compromised (Rich Moravec and Riss, 2003). 
2.7.1.2 Titre-blue Assay 
Cells were incubated, under experimental conditions, for 48h, before being assessed using the 
Titre-blue Assay (Promega, USA).The medium in the 48 well plate was discarded and cells in 
4 wells were killed using 200µl ice-cold methanol for 5 minutes. 100µl of CellTiter-Blue was 
added to each well followed by 500µl of resting medium (serum- free medium).  The plate 
was incubated for 2-4 hours, after which the 24 well plate was plated out in the 96-well 
microtiter plate. The ratio of live to dead cells was used to generate a standard curve (Figure 
2-2), divided into five regions: 100% live cells (resting medium); 25:75% dead: live cells; 
50:50%; 75:25% dead: live cells; and 100% dead cells (positive control). Absorbance 
measurements were used to monitor results. As the absorption maximum is 600nm for 
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resazurin and 573 nm for resorufin according to the manufacturer’s data, absorbance was 
measured at 560nm and 600nm was used as the reference wavelength. 
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Figure 2-2: Standard curve of methanol killed cells measured via cell viability assay (Promega USA) (mean ± 
SD; n=6). 
2.7.2 MTT assay   
2.7.2.1 Assay principle 
Behind the MTT (3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide) assay is 
the principle that mitochondrial activity is steady for the majority of viable cells and that a 
reduction or increase in the viable cell count can therefore be correlated linearly to the 
mitochondrial activity. When formazan crystals are reduced from the tetrazolium salt MTT, 
this is seen to reflect the level of mitochondrial activity within the cells that can be solubilised 
for homogenous measurement. As a result, measuring the formazan concentration reflected in 
optical density (OD) using a plate reader at 570 and 690 nm can be used to identify the 
decrease or increase in the number of viable cells (van Meerloo et al., 2011). 
2.7.2.2 Assay procedure  
The MTT assay was used for several experiments. This is mainly used to assess cell viability 
in the presence of a drug or toxin. MTT (TOXI Sigma, St. Louis, USA) was dissolved at 
5mg/mL in Hank’s salt solution and filtered to avoid MTT aggregates. The solution was 
added to each well in an amount equal to 10% of the culture medium volume and the plate 
was incubated for a further 2-4 hours. Formazan crystals developed which were dissolved in 
MTT Solubilisation Solution equal to the original culture medium volume. A gyratory shaker 
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was then employed to accelerate dissolution. Spectrophotometric measured absorbance of 570 
and background at 690nm was used to measure well absorbance. It is noted, that although this 
procedure was employed, these metabolic assays do not distinguish between cytotoxic and 
cytostatic drugs or compounds, therefore the accuracy surrounding low cell numbers is 
questionable. The standard curve was made up of: 100% live cells (resting medium); 25:75%; 
50:50%; 75:25% dead: live cells; and 100% dead cells. This was used to determine the 
percentages of viable cells.  
2.8 Secretion analysis 
2.8.1 Enzyme-Linked Immunosorbent Assay (ELISA)  
To measure levels of cytokine and chemokines DuoSet ELISA kits were purchased from 
R&D systems. ELISA kits provide a sandwich ELISA. The assay was carried out as detailed 
in the kit protocol and is described below. 
- Coating with capture antibody 
A 96-well microplate was prepared with a 1/100 solution of capture antibody (100µl, R&D 
Systems, USA) and reagent buffer (0.1% BSA, 0.05% Tween 20 in Tris-buffered saline 
(20mM Trizma base, 150mM NaCl), pH 7.2-7.4) at 100µl per well. The plate was incubated 
overnight at room temperature. 
- Wash step 
The contents of the plate were discarded and wells were then emptied and washed three times 
using 300µl wash buffer per well (0.05% Tween 20 in phosphate buffer solution, pH 7.2-7.4). 
The plate was dried by inversion and by patting the plate with force on paper towels. 
- Blocking step 
The plate blocked with 1% bovine serum albumin solution in phosphate buffer (PBS) (300µl). 
The plate was incubated at room temperature for 1 hour.  
- Standards and samples 
After the plate was aspirated and blotted dry as in wash step, 100µl of standards diluted in 
100µl of PBS or 100µl of cell culture supernatant samples were added in duplicate. An 
adhesive plate sealer was applied to the plate, which was then incubated at room temperature 
for a further two hours and the washing stage was repeated. 
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- Detection antibody 
  100µl of detection antibody was added to each well, a new adhesive strip applied, and the     
plate was incubated for two hours at room temperature. 
- Development 
Following a further wash step, 100μl of streptavidin horseradish peroxidase (HRP) diluted in 
reagent diluent was added to each well and incubated for 20 minutes out of direct light at 
room temperature. A substrate solution (1:1 mixture of colour reagent A (H202) and colour 
reagent B (tetramethylbenzidine)) was added to each well (100µl) and the plate was incubated 
away from direct light for a further 20 minutes at room temperature. The addition of 50µl stop 
solution (2N H2 SO4) was required for each well and the plate was placed on the plate shaker 
for 1 minute at 100rpm.  
- Analysis 
The optical density (OD) of the contents of each well was immediately determined using a 
microplate reader set at 450nm and corrected at 570nm to correct for optical imperfections. 
- Determination of cytokine and chemokines in sample from standard 
The average OD value was derived for the standard and sample wells, the blank cytokine and 
chemokines standard OD value was subtracted from each mean value. GraphPad (version 6) 
was used to create a standard curve with a 4 parameter logistic curve fit. The sample values 
were interpolated from the standard curve.  
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Table 2-1: Composition and concentrations of reagents and antibodies used in ELISA. TMB- 3,3’,5,5’-
Tetramethylbenzidine. 
 
  
Protein 
name  
Capture 
antibody 
origin and 
concentration  
Detection 
antibody 
origin and 
concentration  
Reagent 
diluent  
Substrate  Detection 
range  
Supplier  
& 
catalogue 
number 
IL-8  Mouse anti-
human IL-8 
4μg/ml  
Biotinylated 
goat anti-
human IL-8 
20ng/ml  
0.1% BSA in 
PBS (0.05% 
Tween20 in 
TBS), pH 
7.2-7.4  
TMB  31.3-2000 
pg/ml  
R&D 
Systems  
& 
DY208 
IL-6  Mouse anti-
human IL-6  
2μg/ml  
Biotinylated 
goat anti-
human IL-6 
50ng/ml  
1% BSA in 
PBS (0.05% 
Tween20 in 
TBS), pH 
7.2-7.4 
TMB  9.38-600 
pg/ml  
R&D 
Systems  
& 
DY206 
GM-CSF  Mouse anti-
human GM-
CSF 2μg/ml  
Biotinylated 
mouse anti-
human IL-8 
0.5μg/ml  
1% BSA in 
PBS (0.05% 
Tween20 in 
TBS), pH 
7.2-7.4 
TMB  15,62-
1000 
pg/ml  
R&D System  
& 
DY215 
MMP9  Mouse anti-
human MMP9 
1μg/ml  
Biotinylated 
goat anti-
human MMP9 
12.5ng/ml  
1% BSA in 
PBS (0.05% 
Tween20 in 
TBS), pH 
7.2-7.4 
TMB  31.3-2000 
pg/ml 
R&D 
Systems  
& 
DY911 
Pro-
collagen  
Mouse anti-
human Pro- 
Collagen 
4μg/ml  
Biotinylated 
goat anti-
human Pro- 
Collagen 
100ng/ml  
1% BSA in 
PBS (0.05% 
Tween20 in 
TBS), pH 
7.2-7.4 
TMB  31.3-2000 
pg/ml 
R&D 
Systems  
& 
DY6220-05 
TGFβ1  Mouse anti- 
TGFβ1 
antibody 
2μg/ml  
Biotinylated 
chicken anti-
human TGFβ1 
antibody 
100ng/ml 
1% BSA in 
PBS (0.05% 
Tween20 in 
TBS), pH 
7.2-7.4 
TMB  31.3-2000 
pg/ml  
R&D 
Systems  
& 
DY240 
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2.8.2 Determination of MUC5B mucin concentration by indirect ELISA 
The concentration of MUC5B mucin within the medium that was collected from stimulated 
Calu-3 and NCI-H292 cells was measured in duplicate:  
 Sample and Standard coating 
100μl of the sample was coated onto a 96 well plate (Maxisorp, NUNC). At the same time, 
the standard of purified human saliva MUC5B mucin was diluted in PBS ranging from 0 - 
8µg/ml, was coated onto the well by 100μl. Further, the plate was incubated at room 
temperature and covered overnight. 
 The washing stage 
On the following day, the plate was washed three times (0.05% Tween 20 in PBS), and was 
then blotted dry by using paper towels. 
 The blocking stage 
After incubating the plate overnight, the plate was carefully dried and the residue was 
discarded. Accompanying this, 300µl of 1% casein in PBS was added to block unoccupied 
binding sites. The plate was then incubated at room temperature for 2 hours.  
 Primary antibody  
100µl of the primary monoclonal antibody for MUC5B (EPR6920 raised in rabbit (Abcam); 
(1:200 dilution in 05% Tween20 in PBS and 0.1% casein) was added to each well. The plate 
was then incubated at room temperature for 2 hours.  
 Secondary antibody 
The washing stage was repeated, and then 100 µl of the secondary antibody was added to 
each well and incubated for 2 hours at room temperature (horseradish peroxidase-conjugated 
goat anti-rabbit (Dako); in this stage, 1 in 5000, diluted using an antibody diluent (0.1% 
casein and 0.05% Tween20 in PBS). 
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 The development stage 
The solution was discarded following incubation and the washing stage was repeated to dry. 
Additionally, this stage saw the inclusion of 100µl of peroxidase substrate ABTS (2, 2’-azino-
bis (3-ethylbenzthiazoline-6-sulphonic acid) was added and left to develop at room 
temperature for 20 minutes. As a final step, at 20 minutes the reaction was stopped with 1% 
SDS and a plate reader was used to measure an absorbance at 405 nm (Tecan M200). 
2.8.3 The quantification of MUC5AC mucin concentration through indirect ELISA 
MUC5AC mucin in cell culture supernatant collected from stimulated Calu-3 and NCI-H292 
cells was detected using indirect ELISA.  
 Standard and sample coating 
The standard of purified pig gastric mucin was diluted in PBS ranging from 0 - 8µg/ml, 100μl 
was coated onto 96 well plate in duplicate (Maxisorp, NUNC). Similarly 100μl of each 
sample was coated onto the plate. The plate was covered and incubated overnight at room 
temperature. 
 The washing stage 
The following day the plate was emptied and washed three times with the wash buffer (0.05% 
Tween 20 in PBS) and blotted dry on clean paper towels.  
 The blocking stage 
Following its incubation overnight, the residue was discarded from the plate followed by a 
thorough dry. 300µl of 1% casein in PBS was added to block unoccupied binding sites. The 
plate was then incubated at room temperature for 2 hours.  
 Primary antibody 
100µl of the primary mouse monoclonal antibody for MUC5AC (45M1 epitope Life 
Technologies); diluted 1 in 100 in antibody diluent (0.1% casein and 0.05% Tween20 in 
PBS)) which was added. The plate was then left to incubate at room temperature for 2 hours. 
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 Secondary antibody 
The washing stage was repeated, and then 100 µl of the secondary antibody (horseradish 
peroxidase-conjugated goat anti-mouse (Dako); (1:5000 dilution in 05% Tween20 in PBS and 
0.1% casein) was added for a total of 2 hours.  
 The development stage 
After washing as previously described, 100µl of peroxidase substrate ABTS (2, 2’-azino-bis 
(3-ethylbenzthiazoline-6-sulphonic acid) was added and incubated at room temperature for 20 
minutes. The reaction was stopped after 20 minutes, with 1% SDS and a plate reader was used 
to measure absorbance at 405 nm (Tecan M200). 
2.8.4 Periodic Acid Schiff (PAS) assay 
2.8.4.1 Principle of PAS Staining 
PAS is a staining method used to detect glycoproteins, such as mucins, through the 
oxidisation of glucose or sugar with adjacent –OH groups by periodic acid. Periodic acid 
oxidises compounds having free hydroxyl group (-OH group), resulting in aldehydes, which 
react with the Schiff reagent to form a purple or red stain that can be detected by 
spectrophotometry. The glycoprotein content of the apical fluid was measured using a 
periodic acid-Schiff’s (PAS) assay (Mantle and Allen, 1978).  
2.8.4.2 Assay procedure 
Aliquots of cell culture supernatant were thoroughly mixed diluted 1:10 in deionised water 
and 200µl sample in duplicate was located into 96 well plate for each PAS analysis. For the 
standard curve, purified papain digested porcine mucin was used (1mg/ml in deionised water; 
mucin obtained from Professor Jeff Pearson, Newcastle University) and diluted into 200, 100, 
80, 60, 40, 20 and 0 µg/ml samples. The cell supernatant sample and mucin standard curve 
were combined with 20µl of periodic acid mixture (made from 2.5 ml of 7% acetic acid plus 5 
µl of 50% periodic acid). The plate was incubated at 37°C for 45 min. Schiff’s solution was 
made by combining 6 ml of Schiff’s reagent with 0.1g sodium metabisulfite, which was also 
incubated in the 37°C water bath for 45min. 20µl of Schiff’s solution was then added to each 
sample (including mucin standard curve and negative control samples) and left to develop for 
30 minutes at room temperature. The absorbance in each sample was read using a Tecan plate 
reader at a wavelength of 555 nm.    
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2.9 Molecular biology techniques 
2.9.1 RNA biology 
Based on the function, RNA can be divided into three main types. Firstly, (i) Messenger RNA 
(mRNA) is transcribed from DNA by RNA polymerase and serves as a template for the 
synthesis of proteins. Second, (ii) Ribosomal RNA (rRNA) is one of 2 main components of 
ribosomes; the other is proteins (ribosomes = rRNA + proteins). These ribosomes become 
associated with mRNA in the cytoplasm. Lastly, (iii) Transfer RNA (tRNA) contains a 
specific amino acid at one end and anticodon region which can recognise and bind mRNA. 
The tRNA binds to the mRNA codon and transfers amino acids to the ribosomes, in order to 
synthesise protein. For this particular study, the focus was mRNA, since it represents potential 
gene expression in physiological and pathological conditions. Therefore, it allows 
measurement of changes in gene expression after the treatment of cells with a variety of 
cytokines.  
2.9.2 Molecular biology  
A level of precaution is required, specifically when RNA isolation and amplification is 
performed. All reagents used for this procedure and other molecular biology use, should have 
a high degree of purity. These reagents are also RNase free which provides protection during 
the RNA isolation process. All reagents used for RNA isolation in this project were available 
commercially and at a molecular biology grade. All areas used for RNA isolation were 
decontaminated by using RNase removal spray (Sigma). Pipettes were cleaned with 70% 
ethanol. Filter sterile tips and autoclaved sterile Eppendorfs were used throughout. 
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2.9.3 RNA extraction 
Gene expression modulation, which may be caused by a particular stimulus or disease, can be 
analysed by isolating RNA. This study used the RNEasy Mini-kit (Qiagen) to extract RNA 
longer than 200 nucleotides from cultured cells. This kit takes advantage of the selective 
binding properties of a silica-gel membrane. Cells were pelleted and homogenised in 350μl 
Buffer RLT. To this, 350μl of 70% ethanol was added via pipette. The lysate was then added 
to an RNEasy mini-column and centrifuged for 15 seconds at 10,000rpm (MIKRO 200, 
Hettick Zentritugen, DJB Labcare Ltd, Bucks, UK). A proportion of the mixture flowed 
through, and was discarded. To the remaining mixture, 350μl of RW1 buffer (Qiagen) was 
added and the column was centrifuged for 15 seconds at 1000 rpm. The Flow-through was 
again discarded and DNase digestion was carried out on the column. The wash buffer, 
centrifugation and flow-through discard process were repeated and 500μl RPE elution buffer 
(Qiagen) was then added. The centrifuge and flow-through discard process were repeated 
once again and another 500μl RPE elution buffer added. This time, the column was 
centrifuged for two minutes at 10,000rpm. Flow-through was once again discarded and the 
mixture was transferred to a fresh tube, which was centrifuged at 13,000rpm to dry. The 
mixture was transferred once again and 50μl RNase-free water was added by pipette to the 
membrane. This was centrifuged once more for one minute at 10,000rpm. The eluate was 
removed from the tube and passed through the column once more as described to obtain a 
higher RNA concentration. RNA was stored at -80°C. 
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2.9.4 Analysis of RNA concentration and purity  
The RNA sample should be free from contaminating substances, including proteins, DNA, 
phenol, ethanol and salts. It is known that any contamination can decrease the efficiency of 
reverse transcription, leading to reduced amplification. A Nanodrop spectrophotometer (No- 
1000 NanoDrop®) was used for determination of RNA concentration and purity. The 
machine measures the absorbance at 230, 260 and 280 nm and uses these values as a guide to 
nucleic acid purity and concentration. One microliter of extracted RNA was applied to the 
Nanodrop after blanking with 1 μl of RNase-free water. The concentration was obtained in 
ng/μl. The purity of isolated RNA sample was evaluated by examining 260/280 and 260/230 
ratios. The reading around 2 for both of the ratios is considered as a pure sample free from 
protein and phenol contamination and suitable for cDNA synthesis. Figure 2-3 shows an 
example of RNA concentration measurement and purity using the Nanodrop. 
 
Figure 2-3: Examination of RNA purity and concentration using a Nanodrop instrument. 
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2.9.5 Reverse-Transcriptase PCR (cDNA) 
A Tetro cDNA synthesis kit (Bioline) was used in accordance with the manufacturer’s 
guidelines to reverse transcribe the RNA isolated in the above process to obtain 
complementary DNA (cDNA) within a 20μl reaction mixture. The reaction mixture was made 
up of 4μl 5X RT buffer, 1μl (0.5 μg/μL) oligo-dT Random Primer, 1μl (200 U/µL) Tetro 
reverse transcriptase enzyme, 1μl (10U/µL) RNase Inhibitors, 1μl (10 mM) dNTP mix, 200ng 
RNA sample and the rest RNase-free H2O (see table 2-2). These mixtures were vortexed, 
then centrifuged briefly to collect the contents at the bottom of the tube. A thermal cycler (G-
Storm, Surrey, UK) was used to incubate the samples at 25°C for 10 min. These were then 
transcribed in the same device at 42°C for 15 minutes followed by heating at 95°C for 5 
minutes. This produced cDNA, which was then stored at -20°C and used as a q-PCR template. 
 
 
 
 
 
 
 
Table 2-2: Contents of first strand Tetro cDNA synthesis reaction.  
components Tetro cDNA synthesis 
RNA 2μl equivalent 
5X RT buffer 4μl 
10 mM dNTP mix 1μl 
Oligo (dT) 18 Primer Mix (0.5 μg/μL) 1μl 
RNase Inhibitor (10 U/µL) 1μl 
Tetro reverse Transcriptase (200 U/µL) 1μl 
RNase free water Variable  
 20 µl total volume 
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2.9.6 Real time-polymerase chain reaction 
2.9.6.1 General principle 
Quantitative polymerase chain reaction (q-PCR) is a precise technique for the measurement of 
changes in gene expression. This procedure requires a specific sequence of DNA to be 
amplified in a geometric way, producing many copies of the original sequence. The amplified 
product can be measured either at the end point of the reaction in "traditional" PCR or during 
the amplification process in the real-time PCR method. Q-PCR has many advantages in 
comparison to the traditional in the context of the processing time and accuracy. Traditional 
PCR is regarded as a qualitative method in determining the presence or absence of a particular 
gene of interest at the end point of the reaction, q-PCR is able to detect small differences in 
the level of the expression between examined samples. In contrast to traditional PCR, in q-
PCR the amplification and quantification occur simultaneously. An ideal amplification plot 
has an exponential, linear and plateau phases, in which the amplicon is quantified as the 
amplification is in progress and reaches plateau when the reaction components are depleted. 
The PCR product is determined in the exponential phase and crosses the threshold level in a 
cycle known as the threshold cycle. The detection process in this method requires the 
presence of fluorescent reagents that detect the amount of the amplified product. These 
reagents are either sequence specific or non-sequence specific. An example of sequence 
specific reagent is the 5' nuclease probe such as the Taqman assay.  
2.9.6.2 TaqMan assay 
Modulation in gene expression was determined using TaqMan® Gene Expression Assays, 
primer-probes (or 5' nuclease assay). This assay, in the presence of exonuclease activity of 
TaqMan DNA polymerase, uses two primers and a probe. This probe is a non-extendable 
DNA sequence, modified to include a quencher at the 3' end and a fluorescence reporter at the 
5' end. It is capable of binding in either an exon boundary spanning or non-exon spanning 
manner to the desired gene’s complementary sequence. The proximity of the reporter 
(fluorescence emitting) to the quencher (fluorescence absorbing) prevents excess light from 
escaping. 
 
56 
 
2.9.6.3 PCR efficiency  
PCR efficiency is defined as the rate at which a PCR product is generated, it is represented as 
a percentage value with a maximum PCR amplification efficiency of almost 100%. If the PCR 
amplicon is doubled during each cycle, it is seen to reflect 100% efficiency. This value is 
estimated from a standard curve specific for each reaction, prepared by serial dilutions of 
cDNA sample. In this curve, a log of input nucleic acids on X-axis is plotted against CT 
values on the y-axis. The gradient of the semi-log regression is determined to evaluate the 
amplification efficiency by this equation: efficiency = 10^ (-1/gradient)-1. The gradient value 
equal to -3.32 represents 100% amplification efficiency. A value that is more negative than 
this reflects an amplification process less than 100%, while more positive value reflects 
sample quality or pipetting problems. In this project five human primer/probe combinations 
were used; E-Cadherin (Hs01023894-m1-CDH1), fibronectin (Hs00365052m-1FN1), 
MUC5AC (Hs00873651_mH), MUC5B (Hs00861595_m1) and HPRT1 (Hs02800695-m1) 
(Life Technologies). The expression of each test gene was normalised against expression of 
the housekeeping gene, HPRT1. Figure 2-4 shows the efficiency curves for these 
primer/probe combinations performed using 10 times serial dilution from cDNA sample. 
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Figure 2-4: The standard curve for tenfold dilution series of cDNA for E-Cadherin, fibronectin, MUC5AC, 
MUC5B and HPRT transcripts.  The reactions were run on an Applied Biosystems instrument (StepOnePlus) for 
40 cycles. For gradient and efficiency values, the data were analysed by linear regression converting x values to 
a log scale. 
2.9.6.4 Real-time PCR detection  
To determine the change in expression of a particular gene at a molecular level a quantitative 
PCR reaction was performed. This was done by using a cDNA template transcribed from the 
isolated RNA. PCR reaction was prepared in 20 μl total volume by mixing 10 μl of 2X master 
mix (SensiFAST™ Probe Hi-ROX Kit (Bioline)), containing TaqMan DNA polymerase 
enzyme and buffers essential for its activity, 7 μl distilled water molecular grade, 2 μl of 
cDNA and 1 μl of desired primer mix (purchased from Life Technologies, ready to use). The 
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mixture was amplified using an Applied Biosystems StepOnePlus. The amplification process 
was carried out for 40 cycles, in the following sequential steps: 95°C for 5 minutes followed 
by 40 cycles of 95°C for 10 seconds followed by 20 seconds 60°C. Each PCR run contains a 
target gene in parallel with a housekeeping gene. In addition, each run had negative control 
wells where the RNA sample and master mix mixture were checked separately for any 
contamination. 
2.9.6.5 Data analysis-comparative ΔΔCT value 
The comparative or relative method of quantification requires the CT (Cycle threshold) value 
and arithmetic or application formulas in order for a result to be achieved. The CT is defined 
as the number of cycles that are needed for the background level to be exceeded by the 
fluorescence signal. Calculating the target gene’s level of expression is made by comparing 
the CT values of both control and activated cells. The CT values of both the samples of 
interest and the control are first normalised to the reference gene or endogenous housekeeping 
gene. In order for a valid result to be obtained, the efficiency or amplifying both the reference 
and the target used in the experiment must be greater than 90% and approximately or close to 
equal. Here are the below steps in order to calculate the comparative CT (ΔΔCT): 
Step 1: To calculate the standard deviation and mean values of the replicate samples. 
The mean standard deviations and CT values are calculated by using Microsoft® Excel 
software. 
Step 2: In order to calculate the ΔCT value. 
The ΔCT is calculated as the following: 
ΔCT = CT (target) - CT (reference) 
Step 3: To calculate the ΔCT value’s standard deviation. 
The standard deviation (SD) of the ΔCT value is calculated from the standard deviations of 
the reference and the target values with the formula below: 
SD = (SD target 2 + SD reference 2)1/2 
Step 4: Calculating the ΔΔCT values. 
The ΔΔCT value is calculated as: 
ΔΔCT = ΔCT (treated sample) - ΔCT (non-treated sample) 
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Step 5: Calculating the standard deviation of ΔΔCT values. 
The calculation of ΔΔCT requires the subtraction of the ΔCT calibrator (un-treated) sample. 
This is a subtraction of an arbitrary constant; thus, the SD of the ΔΔCT value is comparable to 
the SD of the ΔCT value. 
2.10 Statistical analysis  
All data are represented as mean ± Standard Error of the Mean (S.E.M), and in this study, n = 
the number of repeat experiments. GraphPad Prism v6 (Windows) was used for statistical 
analysis, with comparison between two groups using unpaired Student's t-test. Experiments 
comparing three or more matched groups used a repeated one-way analysis of variance 
(ANOVA), next a Bonferroni post-hoc test, comparing all pairs. As is standard, P values of ≤ 
0.05 were considered significant. In this study, * refers to p<0.05, ** refers to P<0.01 and *** 
p<0.001.  
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CHAPTER 3:  ESTABLISHING AN IN-VITRO MODEL OF 
HUMAN BRONCHIAL EPITHELIAL CELL INJURY USING 
CELL LINES 
3.1 Introduction 
The airway epithelium plays a critical role in healthy as well as diseased lungs, primarily by 
providing a physical barrier to foreign particles, such as particulates and smoke, in addition to 
viruses and bacteria. Moreover, it enables a range of pro-inflammatory, anti-microbial and 
regulatory functions, and has the capacity to regenerate. Studies of the airway epithelium have 
been carried out since the late 1970s (Mathias et al., 1996). It has long been known that 
bronchial secretions are also involved in the initiation and augmentation of pulmonary host 
defence mechanisms. The latter involves generating and disseminating a range of mediators 
for various responses, including chemotaxis, inflammatory cell differentiation and activation 
in both diseased and non-diseased conditions (Brown et al., 2008). 
Many chronic degenerative diseases, such as lung allograft rejection, are characterised by 
epithelial damage related to pro-inflammatory cytokines. Symptoms include bronchial cell 
injury and necrosis, alongside leukocyte, neutrophil and macrophage infiltration, followed by 
accelerated inflammatory lung disease (Todd and Palmer, 2011). 
IL-8 is a neutrophilic chemoattractant and an angiogenic factor. Immunostaining has been 
used to identify IL-8 localisation in peribronchial lesions (Zheng et al., 2000). IL-6 plays a 
role in the activation of monocytes, T-cell differentiation and B-cell maturation. It also serves 
as a pyrogenic factor, inducing fever in response to infection (Rincon and Irvin, 2012). GM-
CSF is involved in macrophage activation and is a strong chemoattractant for neutrophils. It 
stimulates microbicidal and phagocytic activity, oxidative metabolism and improves 
cytotoxicity of both macrophages (Sorgi et al., 2012) and neutrophils (Katano et al., 2010). 
Evaluation of a broad array of epithelial cell lines has found that those mimicking adult 
human airway epithelial behaviours can be used to expand knowledge of the airway 
epithelium. 
This study investigated four such cell lines to compare inflammatory mediator expression, 
both basal and inducible. The most physiologically relevant cell type to evaluate airways 
damage was arguably primary human bronchial epithelial cells (PHBECs). However, these 
61 
 
are costly and not easy to culture (Stewart et al., 2012). Consequently, cell lines were 
investigated in terms of their ability to provide a useful model to complement the use of 
PHBECs. It was found that BEAS-2B cells were able to secrete IL-6, IL-8 and other 
cytokines while maintaining epithelial cell morphology in-vitro. These qualities make BEAS-
2B a popular cell line for airway epithelial structure and functional studies (Swanson et al., 
2009). 
The mucoepidermoid carcinoma-derived NCI-H292 cell line responds to cigarette smoke in 
the same way as PHBECs and provides a useful model for mucus production studies (Binker 
et al., 2009). The virally transformed bronchial epithelial line, 16HBE14o-, is used frequently 
in studies of ion transportation and barrier function (Gruenert et al., 1988; Cozens et al., 
1994). Finally, the human bronchial submucosal gland-derived Calu-3 cell line provides a 
model for the study of airway surface liquid, mucins and similar immunologically active 
substances (Shen et al., 1994), alongside pro-inflammatory cytokines involved in airway 
inflammation and epithelial damage (Hamid et al., 1999). 
Asthma and (COPD) are common, chronic airway pathophysiologies that include airflow 
obstruction. This airflow obstruction is associated with endothelin(s) production, peptides that 
cause significant vaso and broncho-constriction (Ucvet et al., 2011). Furthermore, the 
metabolism of arachidonic acid generates certain mediators, including cysteinyl leukotrienes, 
which cause smooth muscle contraction, which consequently changes cell chemo-attraction 
and vascular permeability, thereby resulting in excess mucus production. 
Therefore, the findings described in this chapter aim to establish a model for airway epithelial 
cell injury that is relevant to chronic degenerative diseases. Primary and secondary bile acids 
(BAs) were introduced to the cell lines described above to shed light on this. Pro-
inflammatory cytokine levels (IL-8, IL-6 and GM-SCF) were measured by Enzyme-Linked 
Immuno-Sorbent Assay (ELISA) with the aim of establishing a connection between BAs and 
epithelial damage. These candidate marker cytokines were chosen on the basis of prior studies 
which had found these factors to be released by damaged cells, and that showed they are 
upregulated during infection. For patients with inflammatory lung diseases, these are some of 
the primary exacerbating factors (damage and infection).  
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3.2 Aims of the study 
On the basis of the evidence for the role of epithelial-derived cytokines and other mediators in 
the evolution of airway inflammation, this study aims to: 
- Determine the sensitivity of BEAS-2B, Calu-3, 16HBE14-O  and NCI-H292 human 
airway epithelial cell lines to primary and secondary BAs 
- From this, to determine the optimum BAs concentration profile that may injure cells 
or stimulate them to an inflammatory phenotype 
- To therefore investigate the effects of primary and secondary BAs on the basal 
expression of inflammatory mediators in the human airway epithelial cells, using the 
data established by preliminary experimentation in the cell lines to make the best use 
of the limited primary cells. 
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3.3 Methods 
3.3.1 Cell line stimulation 
After reaching 80-95% confluence in 24-well plates, cell lines were rested for 24 hours as 
described in chapter 2, section 2.2. They were then exposed to individual primary and 
secondary BAs, at the concentrations reported in section (see chapter 2, section 2.6). 
3.3.2 Cell viability assay 
The Titer-Blue Assay and MTT assays were used. A standard curve was produced using 
known ratios of live to dead cells, and cells were killed using a five-minute exposure to ice-
cold methanol. The standard curve was used to determine the percentages of viable cells and 
comprised: 100% live cells (resting medium); 25:75% dead:live cells; 50:50%; 75:25% 
dead:live cells; and 100% dead cells (see chapter 2, sections 2.7.1 and 2.7.2). 
3.3.3 ELISA 
A commercially available ELISA method based on antibody pairs was used to determine 
human IL-8, IL-6 and GM-CSF concentrations in cell culture supernatants from differentiated 
cell lines (see chapter 2, section 2.8.1). This assay uses an analyte-specific monoclonal 
antibody pre-coated onto a microplate. After adding the sample, the relevant protein binds to 
the antibody. Following the addition of an enzyme-linked analyte-specific detection antibody, 
the substrate solution develops colour (via enzyme digestion) in proportion to the protein 
concentration in the sample. The signal intensity was then measured. 
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3.4 Results and discussion 
3.4.1 Morphology of cell lines used in this study 
One of the aims of this project was to culture and process bronchi-derived 16HBE14o-, 
BEAS-2B (virally transformed for immortality), Calu-3 and NCI-H292 (cancerous) human 
cell lines. These lines all have different transformation properties. Different conditions were 
used for different cell lines; their morphology are illustrated Figure 3-1. The ‘cobblestone’ 
morphology indicates healthy cells in submerged culture. The cells are clearly adherent with 
very few floating or fibroblast-like cells; nevertheless, they have a tendency to clump and 
expand towards other colonies, rather than migrating. Furthermore, I was able to re-establish 
these cells in culture, even after cryopreservation. 
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Figure 3-1: Morphology of cell lines used in the study. 10x magnification of (A) NCI-H292, (B) BEAS-2B, (C) 
Calu-3 and (D) 16HBE14o- cell lines cultured in complete medium in 24 or 6-well cell cultures at 37°C with 5% 
CO2 for 24 hours. These cells have the typical appearance of healthy cell lines in submerged culture. 
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3.4.2 Influence of individual bile acid on 16HBE14o- cell viability and inflammatory 
cytokine (IL-8, IL-6 and GM-CSF) release 
16HBE14o- cell monolayers at about 80-90% confluence were cultured in resting medium 
with 15-100 μmol/L cholic acid (CA), deoxycholic acid (DCA) and chenodeoxycholic acid 
(CDCA) for 48 hours. Lithocholic acid (LCA) was used in concentrations of 1 to 20 μmol/L, 
also for 48 hours. 
Both CellTiter-Blue (repeated culture n=3 with repeated wells n=12; overall n=12) and MTT 
(repeated culture n= 3 with repeated wells n=12; overall n=12) were used to assess cell 
viability. Both the CellTiter-Blue and MTT assays were used to calculate viability for two 
plates. The results revealed no significant difference between the two assessment methods. 
The cell viability was found to be affected depending on the BAs concentration. There was an 
inverse relationship between BAs concentration and measured cell viability, with increasing 
concentration and decreasing cell viability in a dose-dependent manner. 
The results revealed that cell viability reduced significantly in response to exposure to 10 
μmol/L of LCA to 73±3% of control and then decreased with 15 µmol/L LCA to 50±3% of 
control. This decreased further to the lowest cell viability level at 20 µmol/L LCA with 
28±3% viable cells (Figure 3-2A). 
The cell viability was reduced significantly by DCA at 50 µmol/l (73±3%) and the cell 
viability then decreased with 75 µmol/L DA to 41±3%. This decreased further to the lowest 
cell viability level at 100 µmol/L DA with 26±2% viable cells (Figure 3-2B). 
Furthermore, cell viability decreased significantly in response to exposure to 75 μmol/L of 
CA with 85±3%. This decreased further to the lowest cell viability level at 100 µmol/L CA 
(73±3%). CA did not affect cell viability at concentrations 15, 30 and 50 µmol/L (Figure 
3-3A). 
Furthermore, cell viability decreased significantly by CDCA at 50 µmol/L with 82±2%. The 
cell viability than reduced with 100 µmol/L CDCA to 50±3%. No difference was found in the 
cell viability at lowest CDCA concentrations, 15 and 30 µmol/L, compared with the control 
(Figure 3-3 B). 
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Figure 3-2: Effects of BAs on 16HBE14o- cell proliferation. 16HBE14o- cell viability following stimulation 
with secondary Bas, (A) Lithocholic and (B) Deoxycholic acids at varying concentrations. Viability is measured 
as a percentage of the control after 48h. Bars represent mean ± S.E.M. Statistical analysis was performed to test 
the effect of BAs compared with control. P values of 0.05 or less were regarded as significant. Negative controls 
were measured by fixing the cells in methanol before adding the CellTiter-Blue or MTT reagent. The data are 
representative of three independent experiments (n=12). *= p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001 indicate levels of significant change in viability comparing cells after the treatment compared to control, 
ANOVA).  
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Figure 3-3: Effects of BAs on 16HBE14o- cell proliferation. 16HBE14o- cell viability following stimulation 
with primary BAs (A) Cholic (B) Chenodeoxycholic acids at varying concentrations. Viability is measured as a 
percentage of the control after 48h. Bars represent mean ± S.E.M. Statistical analysis was performed to test the 
effect of BAs compared with control. P values of 0.05 or less were regarded as significant. Negative controls 
were measured by fixing the cells in methanol before adding the CellTiter-Blue or MTT reagent. The data are 
representative of three independent experiments (n=12). *= p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001 indicate levels of significant change in viability comparing cells after the treatment compared to control, 
ANOVA. 
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IL-8, IL-6 and GM-CSF production by the 16HBE14o- cell line was analysed following 
stimulation by BAs. The 16HBE14o- cells were cultured and stimulated with primary BAs 
(CA and CDCA) and the secondary BA (LCA and DCA). 
IL-8 levels increased by a significant amount when stimulated with 10 and 15 μmol/L LCA 
but not at 1, 5 and 20 μmol/L. IL-8 levels increased significantly at 10 µmol/L LCA to 
136±24 pg/mL compared to the control, 41±12 pg/mL, and increased to the maximum level at 
15 µmol/L LCA of 340± 3 pg/mL  
IL-6 levels also significantly increased following stimulation by 1 μmol/L or above of LCA. 
The result revealed that the highest level of IL-6 production was at 10µmol/L LCA with 
294±30 pg/mL compared with the control (33±3 pg/mL), and then declined as concentration 
of LCA increased to 20 µmol/L. 
GM-CSF levels increased significantly at 5 µmol/L LCA with 284±15 pg/mL and increased 
further to the maximum level at 10 µmol/L LCA with 707±35 pg/mL. The level of GM-CSF 
production than fell off at 15 µmol/L LCA with 258±37 pg/mL but remained significantly 
higher than the control, 14±3 pg/mL. LCA at concentration 20 µmol/L did not cause a 
significant increase in GM-CSF level (Figure 3-4 and Table 3-1). 
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Figure 3-4: Measurement of IL-8, IL-6 and GM-CSF production from 16HBE14o- cells treated with LCA. 
ELISA was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA. The data are representative of three independent experiments (n=6) (see table 3-1). 
Bars represent mean ± S.E.M values of each group. 
 
  Lithocholic acid  
Concentration 
μmol/L 
1 5 10 15 20 
IL-8 (pg/ml) _______ _______ ↑**   ↑*** _______ 
IL-6 (pg/ml)   ↑** ↑**   ↑***   ↑*** ↑* 
GM-CSF (pg/ml)   ↑**   ↑***     ↑****   ↑*** _______ 
 
Table 3-1: The effect of different levels of Lithocholic acid on the 16HBE14o- cell line following stimulation 
for 48 hours, ↑ Increase demonstrated * Significant stimulation of cytokine release. (* = p<0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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IL-8, IL-6 and GM-CSF production by the 16HBE14o- cell line was analysed following 
stimulation with DCA. The IL-8 levels at 30, 50 and 75 μmol/L DCA increased significantly, 
but 15 and 100 μmol/L DCA displayed no increase. The highest level of IL-8 release occurred 
with 75 µmol/L DCA to 864±32 pg/mL, compared with the control (41± 8 pg/mL). 
IL-6 levels were elevated significantly by 30, 50, 75 and 100 μmol/L DCA concentrations. 
The highest level of IL-6 production was at 50 µmol/L DCA to 330±3 pg/mL compared with 
the control 36± 2 pg/mL and then declines as the concentration of DCA increases up to 100 
µmol/L. DCA at concentration 15 µmol/L did not cause a significant increase in IL-6 levels. 
16HBE14o- cells also produce GM-CSF. These cells were exposed to DCA for 48 hours at 
concentrations ranging from 15 to 100μmol/L. The GM-CSF levels increased significantly at 
30 µmol/L DCA with 153±5 pg/mL and increased further to the maximum level at 50 µmol/L 
DCA with 318±15 pg/mL. The level of GM-CSF production than fell off at 100 µmol/L DCA 
with 47±2 pg/mL but was still significantly higher than the control at 12±2 pg/mL. DCA at 
concentration 15 µmol/L did not cause a significant increase in GM-CSF levels (Figure 3-5 
and Table 3-2). 
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Figure 3-5: Measurement of IL-8, IL-6 and GM-CSF production from 16HBE14o- cells treated with DCA. 
ELISA was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA. The data are representative of three independent experiments (n=6) (see table 3-2). 
Bars represent mean ± S.E.M values of each group. 
 
   Deoxycholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) _______ ↑** ↑***        ↑**** _______ 
IL-6 (pg/ml) _______ ↑** ↑***  ↑*   ↑* 
GM-CSF (pg/ml) _______ ↑** ↑***  ↑*   ↑* 
Table 3-2: The effect of different levels of Deoxycholic acid on the 16HBE14o- cell line following stimulation 
for 48 hours, ↑ Increase demonstrated. * Significant stimulation of cytokine release. (* = p<0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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IL-8, IL-6 and GM-CSF production by 16HBE14o- cells increased at 48 hours after 
stimulation with CA concentrations ranging from 15 to 100 µmol/l. IL-8 levels at 15, 30, 50, 
75 and 100μmol/L CA were significantly increased. The highest level of IL-8 release 
occurred with 100 µmol/L CA to 825±32 pg/mL compared with the control (50±9 pg/mL). 
The IL-6 levels increased significantly at 15 µmol/L CA with 103±5 pg/mL and increased 
further to the maximum level at 75 µmol/L CA with 413±16 pg/mL. The level of IL-6 
production then fell off at 100 µmol/L CA with 322±22 pg/mL but remained significantly 
higher than the control at 32±3 pg/mL. 
The GM-CSF levels also significantly increased following stimulation by 30 μmol/L or above 
of CA. The result revealed that the highest level of GM-CSF production was at 100µmol/L 
CA with 330±20 pg/mL compared with control at 31±5 pg/mL. CA at concentration 15 
µmol/L did not cause a significant increase in GM-CSF levels (Figure 3-6 and Table 3-3). 
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Figure 3-6: Measurement of IL-8, IL-6 and GM-CSF production from 16HBE14o- cells treated with CA. 
ELISA was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=6) (see table 3-3). Bars 
represent mean ± S.E.M values of each group. 
 
 Cholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) ↑**   ↑**   ↑***   ↑*** ↑*** 
IL-6 (pg/ml) ↑**   ↑***   ↑***   ↑**** ↑**** 
GM-CSF (pg/ml) _______   ↑**   ↑***   ↑**** ↑**** 
Table 3-3: The effect of different levels of cholic on the 16HBE14o- cell line following stimulation for 48 hours, 
↑ Increase demonstrated * Significant stimulation of cytokine release. (* = p<0.05, ** = p < 0.01, *** = p < 
0.001, **** = p < 0.0001 compared with control, ANOVA).  
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CDCA stimulation of cultured 16HBE14o- at concentrations from 15 to 100μmol/L for 48 
hours was compared with controls without CDCA. The IL-8 levels increased significantly at 
15 µmol/L CDCA to 577±22 pg/mL and rose further to the highest level at 75 µmol/L CDCA 
to 1075±32 pg/mL compared to the control (41±12 pg/mL). The level of IL-8 production then 
decreased at 100 µmol/L CDCA but remained significantly higher than the control. 
Moreover, the findings showed a significant increase in IL-6 at 15, 30, 50, 75 and 100 μmol/L 
of CDCA. The highest level of IL-6 production was at 50 µmol/L CDCA with 423±20 pg/mL 
compared with control (29±3 pg/mL) and then declined as the concentration of CDCA 
increased up to 100 µmol/L. 
ELISA detected the GM-CSF following CDCA stimulation of 16HBE14o- cells. The CDCA 
significantly upregulates GM-CSF production at 30, 50, 75 and 100 μmol/L, but not at 15 
μmol/L. GM-CSF production increased significantly at 30 µmol/L CDCA TO 65±9 pg/mL 
and rose further to a maximum level at 100 µmol/L CDCA to 640±20 pg/mL compared with 
the control at 14±3 pg/mL (Figure 3-7 and Table 3-4). 
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Figure 3-7: Measurement of IL-8, IL-6 and GM-CSF production from 16HBE14o- cells treated with CDCA. 
ELISA was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=6) (see table 3-4). Bars 
represent mean ± S.E.M values of each group. 
 
 Chenodeoxycholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) ↑***     ↑*** ↑***   ↑*** ↑** 
IL-6 (pg/ml) ↑***     ↑***   ↑****   ↑***   ↑*** 
GM-CSF (pg/ml) _______ ↑* ↑***   ↑***     ↑**** 
Table 3-4: The effect of different levels of Chenodeoxycholic acid on the 16HBE14o- cell line following 
stimulation for 48 hours, ↑ Increase demonstrated * Significant stimulation of cytokines release. (* = p<0.05, ** 
= p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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3.4.3 Influence of individual BAs on BEAS-2B cell viability and inflammatory (IL-8, 
IL-6 and GM-CSF) release 
Both the CellTiter-Blue and MTT assays were used to calculate viability. The results revealed 
no significant difference between the two methods of assessment. BEAS-2B cells were 
exposed to CA, DCA and CDCA in concentrations from 15 to 100 µmol/L for 48 hrs, and 
LCA concentrations from 1 to 20μmol/L. 
The cell viability was found to be affected, depending on the BAs concentration. There was 
an inverse relationship between BAs concentration and measured cell viability, with 
increasing concentration and decreasing cell viability in a dose-dependent manner. 
The results showed that cell viability reduced significantly in response to exposure to 5 
μmol/L LCA to 78±3% of control and then decreased further with 10 µmol/L LCA to 46±3%. 
This decreased further to the lowest cell viability level at 20 µmol/L LCA with 7± 3% (Figure 
3-8 A). 
Cell viability was reduced significantly by DCA at a concentration of 50 µmol/l (94±3%). 
However, 15 and 30 µmol/l DCA did not affect cell viability (Figure 3-8 B). 
Cell viability reduced significantly in response to exposure to 50 μmol/L CA to 88±3% of 
control. This decreased further to the lowest cell viability level at 100 µmol/L CA (53±3%). 
The lowest concentrations (15 and 30 µmol/L) of CA did not affect cell viability (Figure 3-9 
A). 
Cell viability was reduced significantly by CDCA at concentration 50 µmol/l to 88±2% of 
control. The cell viability was greatly reduced by 100 µmol/L of CDCA to 53±3% of control. 
No difference was found in the cell viability at 15 and 30 µmol/L CDCA compared with the 
control (Figure 3-9 B). 
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Figure 3-8: Effects of BAs on BEAS-2B cell proliferation. BEAS-2B cell viability following stimulation with 
secondary BAs (A) Lithocholic (B) Deoxycholic acid, at varying concentrations. Viability is measured as a 
percentage of the control after 48h. Bars represent mean ±S.E.M. Statistical analysis was performed to test the 
effect of BAs compared with control. P values of 0.05 or less were regarded as significant. Negative controls 
were measured by fixing the cells in methanol before adding the CellTiter-Blue or MTT reagent. The data are 
representative of three independent experiments (n=6). *= p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001 indicate levels of significant change in viability comparing cells after the treatment compared to control, 
ANOVA. 
 
 
. 
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Figure 3-9: Effects of BAs on BEAS-2B cell proliferation. BEAS-2B cell viability following stimulation with 
primary BAs (A) Cholic (B) Chenodeoxycholic acids at varying concentrations. Viability is measured as a 
percentage of the control after 48h. Bars represent mean ±S.E.M. Statistical analysis was performed to test the 
effect of BAs compared with control. P values of 0.05 or less were regarded as significant. Negative controls 
were measured by fixing the cells in methanol before adding the CellTiter-Blue or MTT reagent. The data are 
representative of three independent experiments (n=6). *= p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001 indicate levels of significant change in viability comparing cells after the treatment compared to control, 
ANOVA. 
 
 
. 
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BAs affect IL-8, IL-6 and GM-CSF secretion by BEAS-2B cells, which was investigated by 
treating cells with LCA in concentrations from 1 to 20 µmol/l. The experiment showed a 
significant increase in IL-8, IL-6 and GM-CSF released by bile acid challenged BEAS-2B 
cells compared to untreated controls. LCA caused IL-8 levels to increase significantly, but 
this was not observed at a concentration of 1 µmol/L. 
IL-8 levels increased significantly at 5 µmol/L LCA to 608±3 pg/mL and increased further to 
the maximum level at 10 µmol/L LCA (905±12 pg/mL). The level of IL-8 production 
subsequently fell off at 20 µmol/L LCA, but was still significantly higher than the control. 
There was a significant increase in IL-6 levels with LCA at concentrations of 10, 15 and 20 
μmol/L, but not at 1 and 5 µmol/L. The result revealed that the highest level of IL-6 
production was at 10µmol/L LCA to 206±2 pg/mL compared with the control at 15±2 pg/mL 
and then declines as the concentration of LCA rose to 20 µmol/L. 
The GM-CSF levels increased significantly at 5 µmol/L LCA to 208±4 pg/mL and rose 
further to the maximum level at 10 µmol/L LCA to 332±11 pg/mL compared with the control 
23±3 pg/mL. The level of GM-CSF production then fell off at 20 µmol/L LCA, but was still 
significantly higher than the control. LCA did not cause GM-CSF levels to increase (Figure 
3-10 and Table 3-5). 
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Figure 3-10: Measurement of IL-8. IL-6 and GM-CSF production from BEAS-2B cells treated with LCA. 
ELISA was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=6) (see table 3-5). Bars 
represent mean ± S.E.M values of each group. 
 
 Lithocholic acid 
Concentration 
μmol/L 
1 5 10 15 20 
IL-8 (pg/ml) _______ ↑**** ↑****   ↑**** ↑*** 
IL-6 (pg/ml) _______ _______ ↑****   ↑**** ↑** 
GM-CSF (pg/ml) _______ ↑**** ↑****   ↑*** _______ 
Table 3-5: The effect of different levels of Lithocholic acid on the BEAS-2B cell line following stimulation for 
48 hours, ↑ Increase demonstrated * Significant stimulation of cytokines release. (* = p<0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Cells were treated with DCA in concentrations ranging from 15 to 100 µmol/l. IL-8, IL-6 and 
GM-CSF release from BEAS-2B cells also increased significantly. It can be observed that IL-
8 levels increased significantly at 30 µmol/L DCA to 243±16 pg/mL and increased further to 
the maximum level at 75 µmol/L DCA of 955±15 pg/mL compared with the control: 56±6 
pg/mL. The level of IL-8 production than fell off at 100µmol/L DCA but were still 
significantly higher than the control. However, no significant increase was seen using a 
concentration of 15 µmol/L DCA. 
There was a significant increase in IL-6 levels with DCA at concentrations of 50, 75 and 100 
μmol/L, but not at 15 and 10µmol/L. The highest level of IL-6 secretion was with 100µmol/L 
DCA, 218±8 pg/Ml, compared with the control 17±5 pg/mL. 
Furthermore, the GM-CSF levels increased significantly at 30 µmol/L DCA to 175±3 pg/mL 
and increased further to the maximum level at 75 µmol/L DCA, 343±2 pg/Ml, compared with 
the control, 31±3 pg/mL. The level of GM-CSF production than decreased at 100µmol/L 
DCA but remained significantly higher than the control. However, no significant increase was 
observed using a concentration of 15 µmol/L DCA (Figure 3-11 and Table 3-6). 
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Figure 3-11: Measurement of IL-8, IL-6 and GM-CSF production from BEAS-2B cells treated with DCA. 
ELISA was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=6) (see table 3-6). Bars 
represent mean ± S.E.M values of each group. 
 
 Deoxycholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) _______  ↑*** ↑**** ↑****   ↑**** 
IL-6 (pg/ml) _______ _______ ↑** ↑****   ↑**** 
GM-CSF (pg/ml) _______  ↑* ↑** ↑***   ↑*** 
Table 3-6: The effect of different levels of Deoxycholic acid on the BEAS-2B cell line following stimulation for 
48 hours, ↑ Increase demonstrated. * Significant stimulation of cytokine release. (* = p<0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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ELISA analysis detected IL-8, IL-6 and GM-CSF in conditioned medium following CA 
stimulation of BEAS-2B. IL-8 levels increased significantly with CA at concentrations of 50, 
75 and 100 μmol/L, but not at 15 and 30 µmol/L. The highest level of IL-8 secretion was with 
100 µmol/L CA, 243±6 pg/Ml, compared with the control, 51±3 pg/mL. 
IL-6 levels were significantly elevated by all CA concentrations except 15 μmol/L. The 
highest level of IL-6 secretion was with 100µmol/L CA, 277±3 pg/Ml, compared with the 
control, 18±2 pg/mL. 
Furthermore, the GM-CSF levels increased significantly at 30 µmol/L CA and increased 
further to the maximum level at 75 µmol/L CA of 326±2 pg/mL compared to the control 29±3 
pg/mL. The level of GM-CSF production than decreased at 100µmol/L CA while remaining 
significantly higher than the control. However, no significant increase was observed using a 
concentration of 15 µmol/L CA (Figure 3-12 and Table 3-7). 
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Figure 3-12: Measurement of IL-8, IL-6 and GM-CSF production from BEAS-2B cells treated with CA. ELISA 
was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA the data are representative of three independent experiments (n=6) (see table 3-7). Bars represent 
mean ± S.E.M values of each group. 
 
 Cholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) _______ _______  ↑** ↑** ↑** 
IL-6 (pg/ml) _______ ↑**   ↑***     ↑****     ↑**** 
GM-CSF (pg/ml) _______   ↑***     ↑****     ↑****     ↑**** 
Table 3-7: The effect of different levels of Cholic acid on the BEAS-2B cell line following stimulation for 48 
hours, ↑ Increase demonstrated. * Significant stimulation of cytokine release. (* = p<0.05, ** = p < 0.01, *** = 
p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Concentrations from 15 to 100 µmol/l CDCA were tested. IL-8 levels increased significantly, 
but this was not observed at concentration of 15 µmol/L CDCA. IL-8 levels increased 
significantly at 30 µmol/L CDCA to 373±6 pg/mL and increased to the maximum level at 50 
µmol/L CDCA of 759±12 pg/mL compared to the control, 56±9 pg/mL. The level of IL-8 
production than fell off at 100 µmol/L CDCA but was still significantly higher than the 
control. 
IL-6 levels were increased with CDCA at concentrations of 30, 50, 75 and 100 μmol/L, but 
not at 15 µmol/L. However, the maximum output of IL-6 occurred at 100µmol/L CDCA to 
272± 3 pg/mL compared with the control 27±3 pg/mL. 
The GM-CSF was detected by ELISA following CDCA stimulation of BEAS-2B cells. The 
CDCA significantly upregulates GM-CSF production at 30, 50, 75 and 100 μmol/L. GM-CSF 
production increased significantly at 30 µmol/L CDCA to 50±4 pg/mL and increased further 
to the maximum level at 50 µmol/L CDCA of 234±7 pg/mL compared to the control, 27±3 
pg/mL. The level of GM-CSF production then decreased at 100µmol/L CDCA but was still 
significantly higher than the control (Figure 3-13 and Table 3-8). 
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Figure 3-13: Measurement of IL-8, IL-6 and GM-CSF production from BEAS-2B cells treated with CDCA. 
ELISA was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=6) (see table 3-8). Bars 
represent mean ± S.E.M values of each group. 
 
 Chenodeoxycholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) _______     ↑***     ↑****     ↑****     ↑*** 
IL-6 (pg/ml) _______   ↑**   ↑***   ↑***     ↑*** 
GM-CSF (pg/ml) _______ ↑*   ↑*** ↑** ↑* 
Table 3-8: The effect of different levels of Chenodeoxycholic acid on the BEAS-2B cell line following 
stimulation for 48 hours, ↑ Increase demonstrated. * Significant stimulation of cytokines release. (* = p<0.05, 
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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3.4.4 Influence of individual BAs on NCI-H292 cell viability and inflammatory (IL-8, 
IL-6 and GM-CSF) release 
Cultured NCL-H292 in complete medium (RPMI) in 24-well cell plates, were stimulated with 
both primary and secondary BAs at a range of concentrations. After 48h, cell viability was 
calculated by counting, using the CellTiter-Blue Cell Viability and MTT Assays. 
The results revealed that cell viability reduced significantly in response to exposure to 10 
μmol/L LCA with 93±43% viability and the cell viability then decreased at 15 µmol/L LCA 
with 85±4%. This decreased further to the lowest cell viability level at 20 µmol/L LCA with 
14±6%. LCA at 1 to 5 µmol/L did not cause any cell death (Figure 3-14A). 
Furthermore, cell viability reduced significantly in response to exposure to 30μmol/L DCA 
with 90±3% and the cell viability then decreased with 75 µmol/L DCA to 50±5%. This 
decreased further to the lowest cell viability level at 100 µmol/L DCA (13±3 %) (Figure 
3-14B). 
CA and CDCA at 15 to 100 µmol/L did not cause any cell death, which suggests that 
secondary BAs have greater cytotoxicity than primary BAs. Both the CellTiter-Blue and MTT 
assays were used to calculate viability for two plates. The results analysis found no significant 
difference between the two assessment methods (Figure 3-15 A & B). 
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Figure 3-14: Effects of BAs on NCI-H292 cell proliferation. NCI-H292 cell viability following stimulation with 
secondary BAs (A) Lithocholic and (B) Deoxycholic acids, at varying concentrations. Viability is measured as a 
percentage of the control after 48h. Bars represent mean ±S.E.M. Statistical analysis was performed to test the 
effect of BAs compared with control. P values of 0.05 or less were regarded as significant. Negative controls 
were measured by fixing the cells in methanol prior to adding the CellTiter-Blue and MTT reagent. The data are 
representative of three independent experiments (n=6). *= p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001 indicate levels of significant change in viability comparing cells after the treatment compared to control, 
ANOVA. 
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Figure 3-15: Effects of BAs on NCI-H292 cell proliferation. NCI-H292 cell viability following stimulation with 
primary BAs (A) Cholic and (B) Chenodeoxycholic acids at varying concentrations. Viability is measured as a 
percentage of the control after 48h. Bars represent mean ±S.E.M. Statistical analysis was performed to test the 
effect of BAs compared with control. P values of 0.05 or less were regarded as significant. Negative controls 
were measured by fixing the cells in methanol before adding the CellTiter-Blue and MTT reagent. The data are 
representative of three independent experiments (n=6). *= p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 
0.0001 indicate levels of significant change in viability comparing cells after the treatment compared to control, 
ANOVA. 
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IL-8, IL-6 and GM-CSF production by the NCL-H292 cell line lung carcinoma was also 
analysed following stimulation by BAs. NCI-H292 cells were cultured and stimulated with 
primary BAs (CA and CDCA) and the secondary BAs (DCA) at a range of concentrations 
from 15 to 100μmol/L for 48 hours. LCA at 1 to 20μmol/L was also used and the results 
compared with the control. 
At concentrations of 1, 5, 10, 15 and 20μmol/L LCA significantly increased IL-8 levels. 
However, the highest level was 690±24 pg/mL with 1 µmol/L LCA compared with the 
control, 61±4 pg/mL. The level subsequently fell to 107±3 pg/mL with 20 µmol/L LCA. 
A significant increase was observed in IL-6 levels with LCA at concentrations of 5, 10 and 15 
μmol/L, 20 µmol/L LCA did not significantly increase IL-6 output due to cell death. The 
result revealed that the highest level of IL-6 production was at 15µmol/L LCA to 304±2 
pg/mL compared with the control, 17±2 pg/mL. 
GM-CSF production by NCL-H292 cells increased significantly following stimulation with 
LCA at 1, 5, 10 and 15 μmol/L, but this was not observed at 20μmol/L LCA due to cell death. 
The highest level of GM-CSF secretion was at 5 µmol/L LCA with 327±2 pg/mL compared 
with the control, 18±2 pg/mL (Figure 3-16 and Table 3-9). 
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Figure 3-16: Measurement of IL-8, IL-6 and GM-CSF production from NCI-H292 cells treated with LCA. 
ELISA was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=6) (see table 3-9). Bars 
represent mean ± S.E.M values of each group. 
 
 Lithocholic acid 
Concentration 
μmol/L 
1 5 10 15 20 
IL-8 (pg/ml)        ↑****       ↑****   ↑****        ↑**** ↑** 
IL-6 (pg/ml) _______   ↑** ↑***      ↑*** _______ 
GM-CSF (pg/ml) ↑*       ↑****   ↑****  ↑* _______ 
Table 3-9: The effect of different levels of Lithocholic acid on the NCL-H292 cell line following stimulation for 
48 hours, ↑ Increase demonstrated.  * Significant stimulation of cytokine release. (* = p<0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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IL-8, IL-6 and GM-CSF production by the NCL-H292 cell line lung carcinoma was also 
analysed following stimulation by DCA. 
DCA at concentrations of 15, 30, 50, and 75μmol/L significantly increased IL-8 levels. The 
highest level of IL-8 secretion was at 1 µmol/L DCA with 670±23% compared with the 
control, 32±4%. The IL-8 levels than decreased to a level not significantly different from 
control at 100 µmol DCA. 
The IL-6 levels at 30, 50 and 75 μmol/L DCA increased significantly, but 15 and 100 μmol/L 
DCA did not. The highest level of IL-6 production was at 218±3 pg/mL with 75 µmol/L DCA 
compared with the control (19±2 pg/mL). 
GM-CSF levels increased significantly at 30 µmol/L DCA with 251±3 pg/mL and increased 
to the maximum level at 50 µmol/L DCA with 439±8 pg/mL. The level of GM-CSF 
production then fell off at 75 µmol/L DCA with 132±2 pg/mL but remained significantly 
higher than the control 24±3 pg/mL. DCA at concentration 15 and 100 µmol/L did not cause a 
significant increase in GM-CSF levels (Figure 3-17 and Table 3-10). 
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Figure 3-17: Measurement of IL-8, IL-6 and GM-CSF production from NCI-H292 cells treated with DCA. 
ELISA was use to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=6) (see table 3-10). 
Bars represent mean ± S.E.M values of each group. 
 
 Deoxycholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) ↑****   ↑**** b↑**** ↑*** _______ 
IL-6 (pg/ml) _______ ↑*** ↑***   ↑**** _______ 
GM-CSF (pg/ml) _______ ↑***   ↑****   ↑**** _______ 
Table 3-10: The effect of different levels of Deoxycholic acid on the NCL-H292 cell line following stimulation 
for 48 hours, ↑ Increase demonstrated * Significant stimulation of cytokines release. (* = p<0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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IL-8, IL-6 and GM-CSF production by the NCL-H292 cell line lung carcinoma was also 
analysed following stimulation by CA. 
CA at concentrations of 15, 30 and 50 μmol/L significantly increased IL-8 levels. The highest 
level of IL-8 secretion was at 15 µmol/L CA at with 516±2pg/mL compared to the control, 
37±3pg/mL. 
IL-6 levels at 50, 75 and 100 μmol/L CA increased significantly, but 15 and 30 μmol/L CA 
did not increase it. The highest level of IL-6 release occurred with 100µmol/L CA, to 124±2 
pg/mL compared with the control (21±2 pg/mL). 
All CA concentrations significantly elevated GM-CSF levels except 15 μmol/L. The highest 
level of GM-CSF secretion was with 100µmol/L CA to 429±3 pg/mL compared with the 
control, 21±2 pg/mL (Figure 3-18 and Table 3-11). 
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Figure 3-18: Measurement of IL-8, IL-6 and GM-CSF production from NCI-H292 cells treated with CA. ELISA 
was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA the data are representative of three independent experiments (n=6) (see table 3-11). Bars represent 
mean ± S.E.M values of each group. 
 
 Cholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) ↑***  ↑***  ↑** _______ _______ 
IL-6 (pg/ml) _______ _______  ↑***   ↑*** ↑**** 
GM-CSF (pg/ml) _______  ↑***  ↑***   ↑**** ↑**** 
Table 3-11: The effect of different levels of Cholic acid on the NCL-H292 cell line following stimulation for 48 
hours, ↑ Increase demonstrated. * Significant stimulation of cytokine release. (* = p<0.05, ** = p < 0.01, *** = 
p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
 
  
97 
 
IL-8, IL-6 and GM-CSF production by the NCI-H292 cell line was analysed following 
stimulation by CDCA. NCI-H292 cells were cultured and stimulated with CDCA. 
IL-8 levels increased by a significant amount when stimulated with 15, 30, 50, 75 and 100 
μmol/L CDCA. IL-8 levels increased significantly at 15 µmol/L CDCA to 433±21 pg/mL 
compared with the control, 41±5 pg/mL and increased to the maximum level at 30 µmol/L 
CDCA to 508±17pg/mL. 
Moreover, IL-6 levels significantly increased following stimulation by 30 μmol/L or above of 
CDCA. The result revealed that the highest level of IL-6 production was at 100µmol/L CDCA 
with 265±3 pg/mL compared with the control (33±3 pg/mL). 
The GM-CSF levels increased significantly with CDCA at concentrations of 50, 75 and 100 
μmol/L, but not at 15 and 30µmol/L. However, the highest level of GM-CSF secretion with 
100µmol/L CDCA to 319± 9  pg/mL compared with the control 13±2 pg/mL (Figure 3-19 and 
Table 3-12). 
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Figure 3-19: Measurement of IL-8, IL-6 and GM-CSF production from NCI-H292 cells treated with CDCA. 
ELISA was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-
paired-one-way ANOVA the data are representative of three independent experiments (n=6) (see table 3-12). 
Bars represent mean ± S.E.M values of each group. 
 
 Chenodeoxycholic acid 
Concentration  
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) ↑****     ↑****   ↑*** ↑** ↑** 
IL-6 (pg/ml) _______ ↑** ↑**     ↑****     ↑**** 
GM-CSF (pg/ml) _______ _______   ↑***     ↑****     ↑**** 
Table 3-12: The effect of different levels of Chenodeoxycholic acid on the NCL-H292 cell line following 
stimulation for 48 hours, ↑ Increase demonstrated. * Significant stimulation of cytokine release. (* = p<0.05, ** 
= p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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3.4.5 Influence of individual bile acids on Calu-3 cell viability and inflammatory (IL-8, 
IL-6 and GM-CSF) release 
Caul-3 cells were exposed to LCA, DCA, CA and CDCA in concentrations ranging from 15 
to 100mol/l for 48 hrs. Their viability was then assessed using CellTiter-Blue and MTT 
assays. The results revealed no significant difference between the two methods of assessment. 
The cell viability was found to be affected depending on the BAs concentration. There was an 
inverse relationship between BAs concentration and measured cell viability, with increasing 
concentration and decreasing cell viability in a dose-dependent manner. 
The results revealed a significant reduction in cell viability in response to 30μmol/L of LCA 
with 81± 3%. Subsequently, the cell viability decreased with 75 µmol/L LCA to 23±3%. This 
fell further to the lowest cell viability level at 100 µmol/L LCA with 2±2% (Figure 3-20A). 
Cell viability was reduced significantly by DCA at concentration 50 µmol/l (84±2%). 
However, cell viability was not affected by 15 and 30 µmol/l DCA (Figure 3-20 B). 
Furthermore, cell viability reduced significantly in response to exposure to 50μmol/L CA with 
93±3%. This decreased further to the lowest cell viability level at 100 µmol/L CA (73±3%). 
The lowest concentration (15 and 30 µmol/L) of CA did not affect cell viability (Figure 
3-21A). 
Cell viability was also decreased significantly by CDCA at concentration 50 µmol/l with 
87±3%. The cell viability then reduced by 100µmol/L CDCA with 65±6%. No difference was 
found in the cell viability at lowest CDCA concentrations, 15 and 30 µmol/L, compared with 
the control (Figure 3-21 B). 
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Figure 3-20: Effects of BAs on Calu-3 cell proliferation. Calu-3 cell viability following stimulation with secondary 
BAs (A) Lithocholic (B) Deoxycholic acids, at varying concentrations. Viability is measured as a percentage of the 
control after 48h. Bars represent mean ±S.E.M.. Statistical analysis was performed to test the effect of BAs 
compared with control. P values of 0.05 or less were regarded as significant. Negative controls were measured 
by fixing the cells in methanol before adding the Titer-Blue or MTT reagent. The data are representative of three 
independent experiments (n=6). *= p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 indicate levels of 
significant change in viability comparing cells after the treatment compared to control, ANOVA. 
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Figure 3-21: Effects of BAs on Calu-3 cell proliferation. Calu-3 cell viability following stimulation with primary 
BAs (A) Cholic (B) Chenodeoxycholic acids, at varying concentrations. Viability is measured as a percentage of 
the control after 48h. Bars represent mean ±S.E.M.. Statistical analysis was performed to test the effect of BAs 
compared with control. P values of 0.05 or less were regarded as significant. Negative controls were measured 
by fixing the cells in methanol before adding the Titer-Blue or MTT reagent.  The data are representative of three 
independent experiments (n=6). *= p < 0.05,** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 indicate levels of 
significant change in viability comparing cells after the treatment compared to control, ANOVA. 
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Calu-3 cells produced significantly higher levels of IL-8 following LCA stimulation at 
concentrations of 15, 30, 50 and 75 μmol. The IL-8 levels increased significantly at 15 
µmol/L LCA with 571±13 pg/mL and increased further to the maximum level at 50 µmol/L 
LCA with 1289±2 pg/mL. The level of IL-8 production than fell off at 75 µmol/L LCA with 
318±9 pg/mL but remained significantly higher than the control 41±5 pg/mL. LCA at 
concentration 100 µmol/L did not cause a significant increase in GM-CSF levels. 
There was significant increase in IL-6 levels with LCA at concentrations of 50, 75 and 100 
μmol/L, but not at 15 and 30 µmol/L. The result revealed that the highest level of IL-6 
production was at 50 µmol/L LCA to 206±2 pg/mL compared with control 12±2 pg/mL. 
GM-CSF production by Calu-3 cells increased significantly after stimulation with LCA at 15, 
30, 50 and 75 μmol/L, but this was not observed at 100 μmol/L LCA due to cell death. The 
highest level of GM-CSF secretion was at 50 µmol/L LCA with 632±12 pg/mL compared 
with the control 14±3 pg/mL (Figure 3-22 and Table 3-13). 
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Figure 3-22: Measurement of IL-8. IL-6 and GM-CSF production from Calu-3 cells treated with LCA. ELISA 
was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA the data are representative of three independent experiments (n=6) (see table 3-13). Bars represent 
mean ± S.E.M values of each group. 
 
 Lithocholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) ↑*** ↑*** ↑****    ↑** _______ 
IL-6 (pg/ml) _______ _______ ↑****    ↑**** ↑*** 
GM-CSF (pg/ml) ↑*** ↑*** ↑****    ↑** _______ 
Table 3-13: The effect of different levels of Lithocholic acid on the Calu-3 cell line following stimulation for 48 
hours, ↑ Increase demonstrated. * Significant stimulation of cytokine release. (* = p<0.05, ** = p < 0.01, *** = p 
< 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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DCA stimulation of cultured Calu-3 at concentrations from 15 to 100μmol/L for 48 hours was 
compared with controls without DCA. The IL-8 levels increased significantly at 15 µmol/L to 
388±24 pg/mL and rose further to the highest level of 75 µmol/L to 1199±22 pg/mL 
compared to the control (41±12 pg/m-L). The level of IL-8 production then decreased to 100 
µmol/L but remained significantly higher than the control. 
IL-6 levels significantly increased following stimulation by 30 μmol/L or above of DCA. The 
result revealed that the highest level of IL-6 production was at 100 µmol/L with 218±8 pg/mL 
compared with control 6±2 pg/mL.  DCA at concentration 15 µmol/L did not cause a 
significant increase in GM-CSF levels. 
Furthermore, the GM-CSF levels increased significantly at 30 µmol/L of DCA and increased 
further to the maximum level at 75 µmol/L of 680±22 pg/mL compared with the control 
12±2pg/mL. The level of GM-CSF production then decreased at 100µmol/L DCA but 
remained significantly higher than the control. However, no significant increase was observed 
using concentrations of 15 µmol/L DCA (Figure 3-23 and Table 3-14). 
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Figure 3-23: Measurement of IL-8. IL-6 and GM-CSF production from Calu-3 cells treated with DCA. ELISA 
was used to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-
one-way ANOVA the data are representative of three independent experiments (n=6) (see table 3-14). Bars 
represent mean ± S.E.M values of each group. 
 
 Deoxycholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml) ↑***   ↑***   ↑*** ↑****   ↑**** 
IL-6 (pg/ml) _______ ↑**   ↑*** ↑****   ↑**** 
GM-CSF (pg/ml) _______   ↑***   ↑*** ↑**** ↑*** 
Table 3-14: The effect of different levels of Deoxycholic acid on the Calu-3 cell line following stimulation for 
48 hours, ↑ Increase demonstrated * Significant stimulation of cytokine release. (* = p<0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Stimulation of Calu-3 cells with CA at concentrations of 15, 30, 50, 75, and 100 μmol/L for 
48 hours caused a significant increase in IL-8. The IL-8 levels increased significantly at 15 
µmol/L to 380±21 pg/mL and increased further to the highest level of 75 µmol/L to 1146±11 
pg/mL compared with the control (41±12 pg/mL). The level of IL-8 production then 
decreased to 100 µmol/L but remained significantly higher than the control. 
The IL-6 levels increased significantly at 15 µmol/L CA with 275±4 pg/mL and increased 
further to the maximum level at 30 µmol/L CA with 422±11 pg/mL. The level of IL-6 
production subsequently decreased at 75 µmol/L CA with 91±2 pg/mL but remained 
significantly higher than the control 17±3 pg/mL. CA at concentration 100 µmol/L did not 
cause a significant increase in IL-6 levels. 
GM-CSF levels increased significantly with CA at concentrations of 50, 75 and 100 μmol/L, 
but not at 15 and 30 µmol/. The highest level of GM-CSF secretion with 100 µmol/L CA to 
165±9 pg/mL compared with the control, 31±2 pg/mL (Figure 3-24 and Table 3-15).    
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Figure 3-24: Measurement of IL-8. IL-6 and GM-CSF production from Calu-3 cells treated with CA. ELISA 
was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA the data are representative of three independent experiments (n=6) (see table 3-15). Bars represent 
mean ± S.E.M values of each group. 
 
 Cholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml)  ↑**    ↑***  ↑***   ↑****  ↑*** 
IL-6 (pg/ml)  ↑***    ↑****  ↑****   ↑** _______ 
GM-CSF (pg/ml) _______ _______  ↑***   ↑****  ↑**** 
Table 3-15: The effect of different levels of Cholic acid on the Calu-3 cell line following stimulation for 48 
hours, ↑ Increase demonstrated * Significant stimulation of cytokines release. (* = p<0.05, ** = p < 0.01, *** = 
p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Stimulation of Calu-3 cells with CDCA at concentrations of 15, 30, 50, 75 and 100 mol/l 
caused a significant increase in IL-8. The IL-8 levels increased significantly at 15 µmol/L 
CDCA with 544±7 pg/mL and increased to the maximum level at 75 µmol/L CDCA with 
1363±20 pg/mL. The level of IL-8 production subsequently decreased at 100 µmol/L CDCA 
with 852±23 pg/mL but remained significantly higher than the control at 39±5 pg/mL. 
Figure 25 illustrates the levels of IL-6 released from Calu-3 cells after stimulation by CDCA 
for 48 hours. The findings showed a significant increase in IL-6 at 15, 30, 50, 75 and 100 
μmol/L CDCA. The highest level of IL-6 production was at 50µmol/L CDCA with 508±7 
pg/mL compared with control (5±2 pg/mL) and then declined as the concentration of CDCA 
increased up to 100 µmol/L. 
The GM-CSF production by Calu-3 cells increased significantly following stimulation with 
CDCA at 15, 30, 50, 75 and 100 μmol/L. The highest level of GM-CSF secretion was at 75 
µmol/L CDCA with 750±3 pg/mL compared with the control, 13±3 pg/mL (Figure 3-25 and 
Table 3-16). 
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Figure 3-25: Measurement of IL-8. IL-6 and GM-CSF production from Calu-3 cells treated with CDCA. ELISA 
was used to measure cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA the data are representative of three independent experiments (n=6) (see table 3-16). Bars represent 
mean ± S.E.M values of each group. 
 
 Chenodeoxycholic acid 
Concentration 
μmol/L 
15 30 50 75 100 
IL-8 (pg/ml)    ↑***   ↑*** ↑****     ↑****     ↑*** 
IL-6 (pg/ml)  ↑** ↑** ↑****   ↑***   ↑** 
GM-CSF (pg/ml)   ↑***   ↑*** ↑****     ↑****     ↑*** 
Table 3-16: The effect of different levels of Chenodeoxycholic acid on the Calu-3 cell line following stimulation 
for 48 hours, ↑ Increase demonstrated * Significant stimulation of cytokines release. (* = p<0.05, ** = p < 0.01, 
*** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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3.5 Discussion 
In this present age, lung disease is still a major cause of the world’s mortality and morbidity, 
and it is on the rise. For example, COPD is the fifth largest cause of death worldwide, while 
interstitial lung disease (ILD) and cystic fibrosis (CF) are common and lead to significant 
consequences for the individuals who have them: this leads to a low quality of life and even 
death. All the above mentioned diseases are contributed by either chronic or acute 
inflammation, which results in using anti-inflammatory medication, such as steroids (Rincon 
and Irvin, 2012). 
The association between lung disease and GORD has been suspected for a long time (Pearson 
and Wilson, 1971), and it is known that high incidences of GORD impact those suffering 
from asthma, idiopathic pulmonary fibrosis, COPD and CF (Feigelson et al., 1987; Tobin et 
al., 1998). Moreover, reflux is commonly discovered among recipients of a lung transplant, 
and the pathogenesis of bronchiolitis obliterans syndrome (BOS) (Stovold et al., 2007) has 
also been associated to  microaspiration of refluxate. 
Furthermore, it has been identified that refluxate from GORD patients contains levels of BA 
at a millimolar level (Lefebvre et al., 2009). Moreover, BAs may be contained in duodeno-
gastro-oesophageal refluxate, which has a wide range of biological consequences (Lefebvre et 
al., 2009). 
Of the bronchoalveolar lavage (BAL) samples from individuals with CF who had undergone 
the lung transplantation procedure, 60% were found by Blondeau et al. to contain bile acids. 
Moreover, a series of other studies from the Leuven group points towards a potential role for 
the aspiration of BAs in the pathophysiology of BOS (Blondeau et al., 2008a). 
In advanced CF lung disease, Brodlie et al. demonstrated recently that BAs measured using 
tandem mass spectrometry can be traced in the lower airway. Moreover, following successful 
lung transplantation (Brodlie et al., 2015), this potential source of injury continues. 
In respiratory infection and inflammation, the role of BAs is undergoing a broader 
investigation, although researchers still poorly understand the underlying mechanisms. Within 
the body, the majority of BAs exist in their conjugated forms (Hofmann, 1999b). 
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A study was conducted by McDonnell et al that assessed the inflammatory and cytotoxic 
effects of primary (chenodeoxycholic and cholic) as well as secondary (deoxycholic and 
lithocholic) BAs at 0, 12.5, 25, 50 and 100 µmol/L on human bronchial epithelial cells 
(HBEs), in addition to and independent of the injury induced by gastric acid, within an 
experimental model of duodeno-gastro-oesophageal aspiration. Furthermore, IL-8 was 
measured by ELISA in culture supernatants, wherein the viability of the cells was analysed 
using an MTT assay. It was also found that the exposure to BA reduced the viability of the 
cells in a concentration-dependent manner. BA-prompted IL-8 release was greater with higher 
combined concentrations and at lower acidic levels up to the point of cell death. Given these 
results, this model suggests that the BA cytotoxicity and inflammation within the pulmonary 
epithelium are both affected by acidity, in addition to being dependent on the concentration 
level (O'Toole et al., 2015). 
The purpose of this chapter was to establish how the presence of BAs impacted the production 
of pro-inflammatory cytokines by airway epithelial cells. This was achieved by analysing the 
changes in the levels of IL-8, IL-6 and GM-CSF produced by epithelial cells. 
Four cell lines were selected in the present study as lung tissue models: BEAS-2B, Calu-3, 
NCI-H292 and 16HBE14o- cells. In this case, the main finding was that cells confronted with 
the presence of BAs at 1, 5.10, 15, 20,30,50,75 and 100 lmol/L released IL-8, IL-6 and GM-
CSF throughout a 48-hour period, but at varying levels. 
It has been reported that BAs lose their toxicity as a result of conjugation (Debruyne et al., 
2002; Blau et al., 2007), although most of the BAs in humans already exist in their conjugated 
form (Hofmann, 1999b). Proton pump inhibitors and acid suppression therapies, used in the 
treatment of GORD, can cause these conjugated BAs to deconjugate (Theisen et al., 2000), 
resulting in higher levels of deconjugated BAs in GORD patients undergoing such 
interventions (Theisen et al., 2000). It has been suggested that therapies which suppress 
stomach acids result in increased bacterial growth in the stomach, causing BAs to deconjugate 
(Dettmar et al., 2011). 
Furthermore, BAs such as DCA, CDCA and LCA detected in airway secretions have all been 
found to be unconjugated (Wu et al., 2009), which is significant to GORD patients. This 
study, therefore, sought to investigate the effects of gastric refluxate on the airway by using 
BA concentrations similar to the physiological bile acid content found in the gastric refluxate 
that reaches the patient’s airway (BA concentrations ranging from 1 µmol/l to 100 µmol/l). 
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Existing knowledge around the effects of BAs on airways is limited. Up to now, research has 
tended to focus on BAL studies, with less attention being given to investigating and 
quantifying specific BA concentrations in the lungs. This may be partly to do with the low 
reliability of acid assays and also difficulties associated with sampling procedures.  
Previously, the highest concentration of BA reported in BAL was 240μmol/L (D’Ovidio et 
al., 2005). BAL samples are diluted by 100-200-fold, meaning that the BA levels detected are 
significantly less than those found in patients’ airways. In this study a range of between 1 - 
100 μmol/L for each individual bile acid was used, so are well within the physiological range 
expected in gastric refluxate. 
According to the results: in NCI-H292, both LCA and DCA have an impact on cell viability. 
It was found that a 50 μmol/L concentration of DCA acid caused cell death of 23±4%, and 
that 100μmol/L results in cell death of 88±4%. Further, it was also found that LCA at ≥ 
5μmol/L presents an impact on cell viability. Conversely, CDCA and CA at 15 to 100 
µmol/ml were not sufficient for cell death to occur; this would indicate that primary BAs have 
lower cytotoxicity than secondary BAs. 
On the other hand, the observed difference in the effect of LCA between other cells and Calu-
3 cells was made clear by this study. In BEAS-2B, NCI-H, and 16HBE14o- cells ,the viability 
of the cells saw a reduction when exposed to concentrations from 5 to 20 μmol/L, as 
lithocholate is normally a minor part of bile acid circulation (Wu et al., 2012). Calu-3 cells 
were only impacted by LCA when the concentration was raised to 30 μmol/L or higher. 
It was further demonstrated by this study the NCI-H292 production of IL-8, GM-CSF and IL-
6 became significantly affected when provoked by BAs. When confronted with BAs, 
significant levels of all three cytokines were released by the Calu-3 cells. Both Calu-3 and 
NCI-H292 cells derive from the lung tissue of humans and were initially considered as a 
useful model for inflammation within the airway. Carcinoma cells express an intercellular 
adhesion molecule-1 (Carney et al., 1985), and secrete IL-8 and IL-6; the manufacture of 
these substances can be increasd by TNF-α and IL-13 within the NCI-H292 cells (Bloemen et 
al., 1993). As this is a tumour cell line, however, this study has acknowledged that certain 
attributes will differ from those found in the normal bronchial epithelium. 
The resulting impacts of both secondary and primary BAs on the viability of BEAS-2B were 
studied. The viability of the cells was to some extent affected by all the bile acids that were 
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used. Most interesting was the finding that the impact of LCA could be observed at 5-10 
times lower concentration than with other bile acids.  
In addition to potentially impacting upon the viability of cells, my data demonstrates that the 
stimulation of BEAS-2B cells by BAs is associated with the release of GM-CSF, IL-6, and 
IL-8. BEAS-2B cells retain the morphology of an epithelial cell in-vitro (Reddel et al., 1988) 
and release IL-8 and IL-6 in addition to other cytokines (Ke et al., 1988). Under submerged 
conditions, BEAS-2B cells are commonly used as an in-vitro model of human airways 
epithelium; especially within studies on inhalation toxicity. BEAS-2B expressed both the 
differentiated epithelial cell marker cytokeratin 8 and the basal epithelial cell marker 
cytokeratin 5 when placed under submerged conditions. Further, the expression of cytokeratin 
8 in BEAS-2B cells when placed under these submerged conditions indicates that, between 
the cells, there does exist some differentiation (Cha et al., 2007; Veranth et al., 2007; 
Petecchia et al., 2009).  
In conjunction with tumour necrosis factor alpha (TNF-α), the impact of IL-17 on the 
expression and manufacture of IL-8, and GM-CSF in BEAS-2B cells has been a focus of 
recent studies. Through these studies, it was revealed that IL-17A and TNF-α demonstrated 
the potential to induce the manufacture of IL-8 and GM-CSF synergistically, possibly via the 
MAPK pathways in human bronchial epithelial cells (Honda et al., 2016). Within the paper 
by Mullol et al, the impact of endothelins (ETs) on the secretion of IL-8, IL-6 and GM-CSF in 
a bronchial epithelial cell line (BEAS-2B) was investigated. The resulting data from this 
paper confirmed that IL-6, IL-8 and GM-CSF (Mullol et al., 1996) are indeed generated by 
BEAS-2B cells. 
Within my study, derived from bronchial surface epithelial cells (Cozens et al., 1994), the 
immortalised cell line 16HBE14o- was introduced to the presence of BAs to assess the extent 
to which the cells would retain viability. One finding was that DCA and LCA (secondary bile 
acids) were much more cytotoxic when compared to CDCA and CA (primary bile acids). 
In fact, Wu et al. echoes these same results, where the human epithelial cells in their study 
were exposed to DCA and LCA, and found that those cells had detached and were floating to 
the surface. At concentrations ≥ 1μmol/L on 16HBE14o-, the impact of LCA on the viability 
of the cells did vary. One example of this variability was where a different curve is observed 
with LCA, whereby 10μmol/L caused a cell death of 26±3%, and 20μmol/L led to a cell death 
of 70±3%. Furthermore, the study on secondary and primary BAs by Wu et al., revealed 
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levels of these BAs that were similar to or greater than those observed in ventilator-associated 
aspiration pneumonia (Wu et al., 2009). 
In addition to potentially impacting upon the viability of the cells, my data demonstrated that 
when 16HBE14o- cells came into contact with BAs, this led to release of IL-6, IL-8 and GM-
CSF; confirming that cytokines are released by 16HBE14o- cells. 
The findings also corroborate the results from other studies, For example, according to a study 
conducted by Chow et et al.,the 16HBE14o- cells and human bronchial epithelial cells 
became ‘‘chemically injured’’ as a result of being exposed to poly-L-arginine as a surrogate 
of the eosinophil cationic protein. Moreover, measured by a real-time PCR, the expression 
levels of IL-8 and IL-6 mRNA were increased. Furthermore, cell culture medium gathered 
from basolateral and apical compartments, and ELISA was used to quantify the levels of IL-8 
and IL-6. Subsequently, this study demonstrated clearly the bronchial epithelia produces a 
polarised secretion of IL-8 and IL-6 when damaged by poly-L-arginine. The orchestration of 
how epithelial cells respond to inflammation may, therefore, be significantly impacted by this 
apically directed secretion of cytokines (Chow et al., 2010). 
Bathoorn et al. examined in a recent study the impact of pepsin in inducing cytotoxicity and 
inflammation to cells within the patient’s airways. To examine this impact, 16HBE14o- cells 
were introduced to pepsin. This study hypothesised that when at a lower pH, concentration of 
pepsin (0.125 mg/mL) would induce a release of pro-inflammatory cytokines and increase 
overall cytotoxicity. This in-vitro model showed that epithelial injury and the release of 
inflammatory mediators, involving IL- 6 and IL-8 can be caused by pepsin (Bathoorn et al., 
2011).  
In my study, one further goal was to compare MTT and CTM assay results for cells that came 
into contact with BAs in similar conditions. However, for all cell lines following exposure to 
BAs, similarities in the viability data from both assays were found. Given the identical 
conditions of the controlled experiment, similar results were expected as mitochondrial 
enzymes reduce the reagents from both MTT and CTB. 
Although the precise mechanisms for this are yet to be established, my study did find that the 
exposure to BAs does have an effect on the BEAS-2B, NCI-H292, 16HBE14o- and Calu-3 
cells. However, what we do know is that BAs do distrupt cationic permeability and cell 
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membranes, as demonstrated in type II pneumocytes in-vitro (D'Ovidio et al., 2005; D'Ovidio 
and Keshavjee, 2006), which could explain the findings of this study to some extent. 
Necrosis and apoptosis are the two broad mechanisms that cause cell death in acute lung  
injury, which is itself a complex pathophysiological process (Jernigan et al., 2004). Necrosis, 
which is rarer in lungs than elsewhere in the body due to the dual pulmonary blood flow and 
ventilation in the alveoli, is thought to be caused by an abrupt decrease in oxygen tension 
leading to ischemia (Walmrath et al., 1994; Sato et al., 2003). Apoptosis, which is a process 
of programmed cell death, can occur in the epithelium in response to environmental toxins, 
allergens, viral infection or drugs (White, 2011). Lung injury can induce apoptosis in 
neutrophils, macrophages and alveolar cells (Jernigan et al., 2004). Bile acids are known to 
induce apoptosis (Lapre et al., 1992), which in turn leads to compensatory cell proliferation, 
thereby implicating bile acids in the initiation and promotion of cancers.  Studies of apoptosis 
and necrosis were beyond the scope of my thesis. This would be a very interesting area to 
look into.  
In future work apoptosis could be identified with Annexin V staining. Annexin V has a high 
affinity for the phosphatidylserine that becomes exposed on the outside of the plasma 
membrane of apoptotic cells.  If the Annexin V is labelled with green fluorescent fluorescein 
(FITC) apoptotic cells are stained brightly green. These can be differentiated from necrotic 
cells which stain positively with a nuclear probe. For example Propidium Iodide or Ethidium 
homodimer III (EtD-III) are nucleic acid stains which are not permeant to live or apoptotic 
cells but which stain necrotic cells leading to red fluorescence. Apoptotic and necrotic cells 
can therefore be counted by counting green and red cells (Van Engeland et al., 1998). In 
further work it would be seem very reasonable to speculate that a shorter time course of BA 
stimulation might lead to apoptosis and that prolonged treatment might cause necrosis; this 
would be a good thing to investigate in further studies.  
BAs, in their non-ionised, lipophilic form, are able to traverse the cell membrane at pH levels 
between 3 and 6. Intracellular pH levels are much higher, ionising the BAs and thereby 
trapping them within the cell. BA levels within the cell can reach up to eight times that of 
luminal levels, causing damage to both cells and their tight junctions (Gotley et al., 1991), 
potentially leading to other injuries (Jenkins and Hardie, 2008; Klokkenburg et al., 2009). 
Further to this, BAs can introduce pores or act as mobile carriers in membranes, modify their 
cation permeability and lead to cytotoxicity through excessive influx or release of cations 
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such as Ca
++
. This may result in irreversible damage to the cellular metabolic processes 
(Morgan et al., 1986). Elevated Ca
++ 
has been observed to cause a number of different 
outcomes, including activation of Ca
++
-dependent proteases (Shields et al., 1987), ATP 
depletion, complement attack on the membrane becoming activated (Morgan et al., 1986), 
cytoplasmic or membrane-associated protein cross-linking, and triggering of increased 
phospholipase activity (Tyler et al., 1978). The build-up of intracellular Ca
++
 is widely 
recognised as an early event in certain types of cell injury, although whether this is true for all 
cells remains unanswered (Lauterburg, 1987). 
Ca
2+
signals can be studied in a range of contexts through the use of Ca
2+
 sensitive fluorescent 
dyes. Such indicators are non-invasive and provide a useful way of measuring acute changes 
in Ca
2+
 concentrations. A wide variety of indicators are available, with different spectral 
characteristics, brightness levels, affinities and targeting properties for different cellular 
domains. Such variation enables the exploration of both temporally and specially diverse Ca
2+
 
signals. Furthermore, Ca
2+
 readouts can be multiplexed with other cellular functions 
(Bootman et al., 2013). 
Within this study, the concentrations of LCA covered the range 0 – 20 µmol/L and therefore 
included the concentration of 2.8±0.6μmol/L identified in CF lung disease; the viability of 
PHBECs  (Brodlie et al., 2015) was affected by low, 5μmol/L, concentrations . Additionally, 
when compared to other bile acids, the effect of LCA occurred at a 5-10 times lower 
concentration. Our understanding of LCA-induced cholestasis as a hepatotoxic factor in liver 
injury (Palmer and Ruban, 1966; Hofmann, 1999a) has been enhanced by studies conducted 
on mammals, such as hamsters, rats and rabbits. This could open up future research on factors 
such as: the variation in retrieval or transfer of canalicular export pumps to and from the 
canalicular membrane (Kubitz et al., 2004); the biochemical changes that occur with the bile 
canalicular membrane (Kakis and Yousef, 1978); and also the formation of crystalline plugin 
bile canaliculi due to the poor solubility of LCA (Miyai et al., 1977). Alongside other studies, 
this may contribute to an integrated ‘aerodigestive paradigm’ about reflux-related chronic 
lung diseases. 
In terms of where aspiration and reflux are implicated in lung disease, all cases appear to be 
linked to the presence of either an acute or chronic inflammation, which has led frequently to 
the use of steroids as a form of anti-inflammatory medication (Morehead, 2009). Overall, the 
data gathered from my study supports the hypothesis that a cell’s exposure to BAs can 
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substantially alter the production of the cytokines known to contribute to airway injury. Upon 
reflection, this explains why chronic inflammation and a decrease in lung function are 
associated with aspiration by respiratory disease patients, and may also be a call for new 
approaches to patient therapy. 
Overall, the data presented in this chapter has succeeded in demonstrating that levels of IL-6, 
IL-8 and GM-CSF that are commonly discovered in airways and in cases of lung disease 
where aspiration and reflux have been shown to be a possible cause of injury. Arguably, the 
most physiologically relevant cell type to assess the extent of the damage within the airways 
was the primary human bronchial epithelial cells (PHBECs). Although expensive and 
challenging to culture (Stewart et al., 2012). Therefore four related cell lines were used to 
compare inflammatory mediator expression, both basal and inducible. Following assessment, 
the results confirm that BEAS-2B, NCI-H292, 16HBE14o- and Calu-3-cell lines constitute 
models that are both sensitive and effective for studying the human respiratory process, in 
addition to the diseases associated with lung injury induced by aspiring BAs. 
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CHAPTER 4:  EFFECT OF BILE ACIDS ON EPITHELIAL TO 
MESENCHYMAL TRANSITION (EMT) IN RESPIRATORY 
DISEASES 
4.1 Introduction 
Fibrotic responses can be stimulated by damage to an injured airway epithelium (Adamson et 
al., 1988; Dai et al., 1998). A growing number of experimental lung fibrosis studies have 
shown that cytokines and fibroblast promoting growth factors (which are also involved in 
migration, proliferation, and myofibroblast differentiation) are involved in the process of  
epithelial-mesenchymal transition (EMT), of airway epithelial cells (Kim et al., 2006; Kim et 
al., 2009). 
EMT refers to a phenomenon in which epithelial cells have a plastic quality, which enables 
them to take on mesenchymal form and function. This is critical to embryonic development 
and also in recovery from acute injury in adults (Walser et al., 2015). EMT can become 
pathogenic or unregulated in cases of chronic injury or inflammation and in epithelial derived 
cancers, referred to as Types I, II, or III EMT(Tian et al., 2015).This may lead to pulmonary 
fibrosis, a chronic lung disease which involves extracellular matrix (ECM) accumulation, lung 
architecture remodelling and an increased risk of cancer (Todd et al., 2012). Moreover, ECM 
is involved in the early dissemination of tumour cells through weakening cell-cell contacts, 
increasing migratory tendencies and increasing anoikis resistance. 
The airway epithelial sheet is formed through cell adhesion mechanisms, out of a tightly 
connected mesh of polygonal epithelial cells (Sohal et al., 2014). An initial change when 
epithelial cells transform is the inhibition of E-cadherin synthesis, a transmembrane 
glycoprotein found mainly in adherens junctions (Yang and Liu, 2001). Various studies have 
implicated E-cadherin as a marker of differentiated epithelial phenotype (Arias, 2001; 
Zeisberg et al., 2003). It is also critical in epithelial polarity maintenance and therefore the 
development of tight junctions (Tunggal et al., 2005). EMT consists of a number of steps, of 
which E-cadherin downregulation is the first, in both cancerous and non-cancerous cells. 
Acquisition of the mesenchymal phenotype is characterised by an increase in mesenchymal 
markers, including fibronectin, which plays a role in tissue repair, cell migration and 
adhesion, and a number of other processes (Miettinen et al., 1994). EMT and epithelial 
damage are also characterised by the matrix metalloproteinase (MMP) 9 production from 
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epithelial cells. MMP-9 is a type IV collagenase. Collagen type IV, forms the reticular 
basement membrane, upon which epithelial cells lie. By disrupting the airway epithelium’s 
basement membrane, MMPs can cause inflammation, translocation, further EMT and other 
damage (Kalluri and Neilson, 2003). 
Within the tumour microenvironment, in vivo, various growth factors and cytokines can 
induce EMT. The transforming Growth Factor (TGF)-β1 family of growth factors , which 
consists of  over 30 different types, all with significant biological roles , is a particularly 
effective and well-known EMT inducer in either normal or pathological conditions. TGF- β1 
regulates both cell plasticity and cell proliferation pleiotropically, inhibiting normal epithelial 
cell proliferation on one hand (thereby opposing cancer promotion), but stimulating fibroblast 
proliferation on the other. It also interacts with immune system elements, promotes 
angiogenesis and induces EMT, all of which impact negatively on patients with a fibrotic 
disease and/or with cancer. 
Patients with a range of airway diseases are prone to gastroesophageal reflux (GOR) and 
extra-oesophageal reflux disease (EORD). Given that airway epithelial cells can generate 
fibroblast-promoting growth factors, and that exposure to bile acids (BAs) is known to cause 
a fibrotic response, the hypothesised, causative link between respiratory disorders and GOR is 
biologically plausible. Asthma sufferers are prone to GOR (Hsu et al., 2005), which is 
especially common in severe cases (Leggett et al., 2005). Severe COPD cases have exhibited 
pathologic reflux (Casanova et al., 2004) and a positive correlation is found between GOR 
symptoms and COPD exacerbation (Rascon-Aguilar et al., 2006). Patients with idiopathic 
pulmonary fibrosis are also particularly vulnerable to GOR (Tobin et al., 1998; Raghu et al., 
2006). Even after lung transplantation, aspiration of duodenogastroesophageal refluxate is 
prevalent. This is correlated with bronchiolitis obliterans, which has a fibrotic 
pathophysiology (D’Ovidio et al., 2005). 
It has been suggested that EORD is involved in the pathophysiology of a range of 
otolaryngology illnesses, including laryngitis, cough, hoarseness, postnasal drip disease, 
sinusitis, otitis media, dysphagia, laryngeal cancer and idiopathic subglottic stenosis (ISS) 
(Toohill and Jindal, 1997).  Laryngeal cancer and idiopathic subglottic stenosis (ISS) is 
usually confined to the first two tracheal rings and the subglottic region. This rare, non-
specific inflammatory process, which mainly affects women aged between 30 and 50, is 
120 
 
slowly progressive and has no known cause. It is identified in the upper trachea/lower larynx 
by a short segment of stenosis (Grillo et al., 1993; Benjamin et al., 1997). 
Lung injury and airway fibrosis are associated with bile acid (BA) aspiration (19-23). A 
correlation has been found between BA concentration in bronchoalveolar lavage fluid (BALF) 
and the degree of lung fibrosis in Idiopathic Pulmonary Fibrosis (IPF) patients. It is therefore 
suspected that microaspiration of BAs may play a key role in IPF development and/or 
progression (Savarino et al., 2013).  
It is hypothesised in this chapter that injured airway epithelial cells may undergo EMT, a 
process that may be the mechanism leading to various respiratory diseases, including chronic 
obstructive pulmonary fibrosis (COPD), pulmonary fibrosis (PF), asthma and lung rejection. 
The second hypothesis is that BA aspiration may be a potential link to subglottic airway 
inflammation and ISS, with the potential that this important pathology is reflux-mediated. The 
studies which investigated these hypotheses involved challenge experiments in the epithelial 
cell lines BEAS-2B and 16HBE14o-. These studies were complimented by experiments with 
primary human epithelial cells including human bronchial epithelial cells from lung transplant 
recipients. The experiments involved stimulating the cells with BAs to establish if they 
underwent EMT. 
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4.2 Aims 
The primary experimental aims, described in this chapter are as follows: 
- Investigate the role of BAs in instigating EMT, using primary human bronchial 
epithelial cell cultures (PHBECs) from lung allografts, tracheal epithelial cells (upper 
airway cells) from the subglottic area and immortalized cell lines (BEAS-2B and 
16HBE14o- ) 
- Evaluate E-cadherin expression in primary cells (primary bronchial human epithelial 
cell cultures from lung allografts (PHBECs), Tracheal epithelial cells (upper airway 
cells) from the subglottic area cells and cell lines (BEAS-2B and 16HBE14o-) 
stimulated with BAs, via quantitative real-time PCR.  
- Examine the expression profile of fibronectin (a mesenchymal marker protein) in 
primary cells (primary bronchial human epithelial cell cultures from lung allografts 
(PHBECs), Tracheal epithelial cells (upper airway cells) from the subglottic area cells 
and cell lines (BEAS-2B and 16HBE14o-) stimulated with BAs, via quantitative real-
time PCR. 
- Assess TGF-β1, MMP9 and pro-collagen production from challenged epithelial cells 
using an enzyme-linked immunosorbent assay (ELISA). 
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4.3 Materials and methods 
4.3.1 Cell Culture  
PHBECs were isolated (described in chapter 2, section 2.2) from stable lung transplant 
recipients. The BEAS-2B and 16HBE14o- cell lines were cultured in six-well plates. Dr Jason 
Powell (Newcastle University) supplied Tracheal epithelial cells (upper airway cells) from the 
subglottic area. Bronchial epithelial cell growth medium (BEGM) (see chapter 2, section 
2.1.2.3) was used for PHBECs, tracheal epithelial cells culture and BEAS-2B cells. EMEM 
(see chapter 2, section 2.2.1.2) was used for 16HBE14o- cells culture.  
4.3.2 Stimulation of PHBECs, Tracheal epithelial cells (upper airway cells), BEAS-2B 
and 16HBE14o- cells with bile acids  
The cells were exposed to the following BAs: LCA, DCA, CA and CDCA. A range of BA 
concentrations (1, 5, 10, 15, 20, 30, 50, 75 and 100 μmol/L) were used to stimulate EMT in 
BEAS-2B and 16HBE14o- cell cultures (see chapter 2, section 2.6). The challenge was 
carried out for 48 hours, following which, the cells underwent the MTT and Titre-blue Assays 
to determine cell viability (described in chapter 2, sections 2.7.1 and 2.7.2) 
4.3.3 ELISA  
ELISA was used to determine the presence of TGFβ1, MMP-9 and Pro-collagen peptides 
before and after BS stimulation of the cells (See chapter 2, section 2.8.1). 
4.3.4 Molecular biology 
RNA was extracted using the RNEasy Mini-kit (Qiagen). Isolated RNA was reversibly 
transcribed using a Tetro cDNA synthesis kit (Bioline), and a quantitative PCR reaction was 
performed in order to determine specific gene expression changes at a molecular level (see 
chapter 2, section 2.9).  
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4.4 Results   
4.4.1 Expression of EMT markers and epithelial activation in airway epithelium 
4.4.1.1 Effect of BAs on the regulation of an epithelial marker E-cadherin and a 
Mesenchymal marker fibronectin in primary human bronchial epithelial cell 
cultures from lung allografts (PHBEC) 
EMT can be identified by gene expression changes, notably by a decrease in E-cadherin (an 
epithelial marker) and an increase in Fibronectin (a mesenchymal marker). PHBECs were 
exposed for 48 hours to LCA, DCA, CA and CDCA at 1 and 10 μmol/L, using TGFβ1 at 
5ng/ml as a positive control. These concentrations of the bile acids were the highest 
concentration that did not cause high cell death based on cell viability. Cell viability was 
confirmed at >90% (Figure 4-1) RT-PCR analysis of E-cadherin expression revealed a 
significant (P < 0.001) decrease with CA and CDCA. CA at concentration 10 µmol/L induced 
three-fold decreases and 1 µmol/L induced two-fold decreases, showing a negative 
concentration dependency effect. CDCA at 1 and 10 μmol/L caused a three-fold decrease in 
E-cadherin mRNA, showing no concentration dependency effect. PHBECs treated with LCA 
and DCA at 1and 10μmol/L do not decrease E-cadherin expression (Figure 4-2).  
Because E-cadherin mRNA is downregulated by BA treatment, I also used RT-PCR to 
analyse treated PHBECs for fibronectin expression (a mesenchymal protein). RT-PCR 
analysis of Fibronectin expression revealed that CA at 1 and 10 μmol/L caused a six-fold 
increase in fibronectin mRNA, showing no concentration dependency. CDCA at 10 μmol/L 
caused seven-fold increase in fibronectin mRNA and 1 μmol/L caused five-fold increase in 
fibronectin mRNA, showing a positive concentration dependency effect. PHBECs treated 
with LCA and DCA at 1and 10μmol/L showed no significant increase in Fibronectin 
expression (Figure 4-3). 
In general, looking at Figure 4-2 and Figure 4-3 it can be observed that primary BAs affected 
E-cadherin and fibronectin expression more than secondary BAs. Moreover, this was not 
concentration dependent.  
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Figure 4-1: Effects of BAs on PBEHC cell proliferation. PBEHC cell viability following stimulation with BAs 
Lithocholic, Deoxycholic, Chenodexycholic and Cholic acids, at varying concentrations. Viability is measured 
as a percentage of the control after 48h.  Bars represent mean ±S.E.M. Statistical analysis was performed to test 
effect of BAs compare with control. Negative controls were measured by fixing the cells in methanol before 
adding the Titre-Blue reagent. The data are representative of three independent experiments (n=6). 
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Figure 4-2: E-cadherin mRNA expression following BA and TGF-β1 treatment. Confluent PHBECs were 
cultured for 48 hours under various conditions as follows: medium containing 5ng/ml of TGF-β1 or 1 and 
10μmol/L of LCA, DCA, CA or CDCA. HPRT1 mRNA was used to normalize E-cadherin RNA levels, which 
were presented as mean ±SEM (n=3). The E-cadherin mRNA was significantly downregulated in TGF-β1, CA 
and CDCA treatment groups, whereas E-cadherin gene expression levels were similar to the control in the LCA 
and DCA treatment groups. The data are representative of three independent experiments (each experiment n=6 
wells). (** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared to control, ANOVA). For pairwise analysis 
Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
  
126 
 
c
o
n
tr
o
l
T
G
F
 1
(5
 n
g
/m
l)
L
C
A
 (
1
0
 
m
o
l/
l)
L
C
A
 (
1
 
m
o
l/
l)
D
C
A
 (
1
0
 
m
o
l/
l)
D
C
A
 (
1
 
m
o
l/
l)
C
A
 (
1
0
 
m
o
l/
l)
C
A
 (
1
 
m
o
l/
l)
C
D
C
A
  
(1
0
 
m
o
l/
l)
C
D
C
A
 (
1

m
o
l/
l)
0
2
4
6
8
1 0
F ib r o n e c t in  e x p r e s s io n  in  P H B E C s
F
o
ld
 c
h
a
n
g
e
 n
o
r
m
a
li
se
d
 t
o
 H
P
R
T
1
* *
* *
* * * *
* *
#
N S
N S #  #
 
Figure 4-3: Fibronectin mRNA expression following BA and TGF-β1 treatment. Confluent PHBECs were 
cultured for 48 hours under various conditions as follows: medium containing 5ng/ml of TGF-β1 or 1 and 
10μmol/L of LCA, DCA, CA or CDCA. HPRT1 mRNA was used to normalize Fibronectin RNA levels, which 
were presented as mean ±SEM (n=3). The Fibronectin mRNA was significantly upregulated in TGF-β1, CA and 
CDCA treatment groups, whereas Fibronectin gene expression levels were similar to the control in the LCA and 
DCA treatment groups. The data are representative of three independent experiments (each experiment n=6 
wells). (** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared to control, ANOVA). For pairwise analysis 
Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.4.1.2 Effect of BAs on epithelial marker E-cadherin and mesenchymal marker 
fibronectin regulation in tracheal epithelial cells (upper airway cells) from the 
subglottic area 
EMT can be identified by gene expression changes, notably by a decrease in E-cadherin (an 
epithelial marker) and an increase in Fibronectin (a mesenchymal marker).  
Epithelial cells were exposed for 48 hours to LCA, DCA, CA and CDCA at concentrations of 
1 and10μmol/L, using TGFβ1 at 5 ng/ml as a positive control. These concentrations of the 
bile acids were the highest concentration that did not cause high cell death based on cell 
viability. Cell viability was confirmed at >90% (Figure 4-4). RT-PCR analysis of E-cadherin 
expression revealed a significant (P < 0.001) decrease at both concentrations of CA and 
CDCA and 10µmol/L of LCA. CA at concentration 1 and 10 µmol/L induced three-fold 
decreases, showing no concentration dependency effect. CDCA at 1and10 μmol/L caused 
two-fold decreases, showing no concentration dependency effect. LCA at 10 μmol/L caused a 
two-fold decrease in E-cadherin mRNA. No significant decrease was observed in cells 
stimulated with 1μmol/L LCA (Figure 4-5).  
Because E-cadherin mRNA is downregulated by BA treatment, I also used RT-PCR to 
analyse treated primary human subglottic cells for fibronectin expression (a mesenchymal 
protein). It was found that CA at 1 and 10 μmol/L caused a three-fold increase and 10 μmol/L 
LCA caused a three-fold increase in fibronectin, showing no concentration dependency effect. 
CDCA at 1 μmol/L caused a three-fold increase and CDCA at 10 μmol/L caused a four-fold 
increase in fibronectin mRNA, showing no concentration dependency effect. No significant 
decrease was observed in cells stimulated with DCA at 10μmol/L and LCA at 1μmol/L 
(Figure 4-6).  
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Figure 4-4: Effects of BAs on tracheal epithelial cell proliferation. Tracheal epithelial cell viability following 
stimulation with Lithocholic, Deoxycholic, Chenodexycholic and Cholic acids at varying concentrations. 
Viability is measured as a percentage of the control after 48h.  Bars represent mean ±S.E.M. Statistical analysis 
was performed to test effect of BAs compare with control. Negative controls were measured by fixing the cells 
in methanol before adding the CellTiter-Blue reagent. The data are representative of three independent 
experiments (each experiment n=6 wells).  
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Figure 4-5: E-Cadherin mRNA expression following BA and TGF-β1 treatment. Confluent tracheal epithelial 
cells from the subglottic area were cultured for 48 hours under various conditions as follows: medium 
(unstimulated control), medium containing 5ng/ml of TGF-β1 or 1and10μmol/L of LCA, DCA, CA and CDCA. 
HPRT1 mRNA was used to normalize E-cadherin mRNA levels, which were presented as mean ±SEM (n=3). 
The E-cadherin mRNA was significantly downregulated in TGF-β1, 10μmol/L LCA, 1and10μmol/L CA and 
CDCA treatment groups, whereas E-cadherin gene expression levels were similar to the control in 1μmol/L LCA 
and DCA treatment groups. The data are representative of three independent experiments (each experiment n=6 
wells). (** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared to control, ANOVA). For pairwise analysis 
Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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Figure 4-6: Fibronectin mRNA expression following BA and TGF-β1 treatment. Confluent tracheal epithelial 
cells from the subglottic area were cultured for 48 hours under various conditions as follows: medium 
(unstimulated control), medium containing 5ng/ml of TGF-β1 or 1and10μmol/L of LCA, DCA, CA and CDCA. 
HPRT1 mRNA was used to normalize Fibronectin mRNA levels, which were presented as mean ±SEM (n=3). 
The Fibronectin mRNA was significantly upregulated in TGF-β1, 10μmol/L LCA, 1μmol/L DCA, 1 
and10μmol/L CA and CDCA treatment groups, whereas Fibronectin gene expression levels were similar to the 
control in 1μmol/L LCA and 10μmol/L DCA treatment groups. The data are representative of three independent 
experiments (each experiment n=6 wells). (** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared to 
control, ANOVA). For pairwise analysis Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: 
p<0.0001. (NS- not significant). 
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4.4.1.3 Effect of BAs on regulation of epithelial marker E-cadherin and Mesenchymal 
marker fibronectin in the human bronchial epithelial cell line (BEAS-2B) cells 
EMT can be identified by gene expression changes, notably by a decrease in E-cadherin (an 
epithelial marker) and an increase in fibronectin (a mesenchymal marker). In chapter three, I 
demonstrated that the optimum BAs concentration profile that may injure BEAS-2B cells by 
using CellTiter-Blue to assess cell viability. In this chapter I evaluate E-cadherin and 
fibronectin expression in BEAS-2B cells after stimulated with BAs at concentration which did 
not have significant effect on the cell viability. Cell viability was confirmed at >90%. (Figure 
3-8 and Figure 3-9). BEAS-2B cells were exposed for 48 hours to the following BA 
concentrations: LCA at 1 and 5 μmol/L; DCA at 15 and 30 μmol/L; CA at 30 and 50 μmol/L; 
and CDCA at 30 and 50 μmol/L. The positive control was TGFβ1 at a concentration of 5 
ng/ml.  
A real-time (RT) PCR was used to quantify E-cadherin expression, which significantly (P < 
0.001) decreased in response 5 µmol/L LCA with two-fold decrease. DCA at concentration 30 
μmol/L caused a three-fold decrease in E-cadherin mRNA and 15 μmol/L caused five-fold 
decrease in E-cadherin mRNA, showing a positive concentration dependency effect. CA at 
concentration 50 µmol/L induced a two-fold decrease. CDCA at 50 μmol/L caused a two-fold 
decrease and 30 μmol/L caused a three-fold decrease in E-cadherin mRNA, showing no 
concentration dependency effect. However, 1 μmol/L LCA and 30 μmol/L CA had no 
significant effect (Figure 4-7).  
Having established that exposure to BAs causes a downregulation of E-cadherin mRNA, I 
then used RT-PCR to test for fibronectin expression. Treatment with 5 μmol/L LCA caused a 
three-fold increase and 1 μmol/L LCA caused a two-fold increase in fibronectin mRNA, 
showing a positive concentration dependency effect. DCA at 15 μmol/L caused a three-fold 
increase and CA at 50 μmol/L caused a two-fold increase in fibronectin mRNA. CDCA at 30 
μmol/L caused a three-fold increase in fibronectin mRNA. However, 30 μmol/L DCA, 30 
μmol/L CA and 50 μmol/L CDCA had no significant effect (Figure 4-8).   
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Figure 4-7: E-Cadherin mRNA expression following BA and TGF-β1 treatment. Confluent BEAS-2BS cells 
were cultured for 48 hours under various conditions as follows: medium (unstimulated control), medium 
containing 5ng/ml of TGF-β1 (positive control) or 1 and 5 μmol/L of LCA, 15 and 30 μmol/L of DCA, 30 and 
50 μmol/L of CA and CDCA. HPRT1 mRNA was used to normalize E-cadherin RNA levels, which were 
presented as mean ±SEM (n=3). The E-cadherin mRNA was significantly downregulated in TGF-β1, DCA 
,CDCA, 5 μmol/L  LCA and  50 μmol/L CA  treatment groups, whereas E-cadherin gene expression levels were 
similar to the control in 1 μmol/L  LCA and   30 μmol/L  CA treatment groups. The data are representative of 
three independent experiments (each experiment n=6 wells). (** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 
compared to control, ANOVA). For pairwise analysis Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and 
####: p<0.0001. (NS- not significant). 
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Figure 4-8: Fibronectin mRNA expression following BA and TGF-β1 treatment. Confluent BEAS-2BS cells 
were cultured for 48 hours under various conditions as follows: medium (unstimulated control), medium 
containing 5 ng/ml of TGF-β1 or 1 and 5μmol/L of LCA, 15 and 30 μmol/L of DCA, 30 and 50 μmol/L of CA 
and CDCA. HPRT1 mRNA was used to normalize Fibronectin mRNA levels, which were presented as mean 
±SEM (n=3). The Fibronectin mRNA was significantly unregulated in TGF-β1, LCA, 15 μmol/L DCA,50 
μmol/L CA and 30μmol/l CDCA treatment groups, whereas Fibronectin gene expression levels were similar to 
the control in 30 μmol/L  DCA ,30 μmol/L CA and 50 μmol/L CDCA treatment groups. The data are 
representative of three independent experiments (each experiment n=6 wells). (** = p < 0.01, *** = p < 0.001, 
**** = p < 0.0001 compared to control, ANOVA). For pairwise analysis Student's t-test #: p<0.05, ##: p<0.01, 
###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.4.1.4 Effect of BAs on epithelial marker E-cadherin and mesenchymal marker 
fibronectin regulation in 16HBE14o- cells 
EMT can be identified by gene expression changes, notably by a decrease in E-cadherin (an 
epithelial marker) and an increase in Fibronectin (a mesenchymal marker). In chapter three, I 
demonstrated that the optimum BAs concentration profile that may injure 16HBE14o- cells 
by using CellTiter-Blue to assess cell viability. In this chapter I evaluate E-cadherin and 
fibronectin expression in 16HBE14o- cells after stimulating with BAs at concentrations which 
did not have significant effect on the cell viability. Cell viability was confirmed at >90% 
(Figure 3-2 and Figure 3-3). 
16HBE14o- cells were exposed for 48 hours to LCA at concentrations of 1 and 10μmol/L, 
DCA at 15 and 30 μmol/L, CA at 50 and 75 μmol/L and CDCA at 30 and 50 μmol/L, using 
TGFβ1 at 5 ng/ml as a positive control. RT-PCR analysis of E-cadherin expression revealed a 
significant (P < 0.001) decrease at all concentrations. LCA at concentration 10 μmol/L caused 
five-fold decreases and at 1 µmol/L caused a three-fold decreases in E-cadherin mRNA, 
showing no concentration dependency effect. DCA at concentration 30 μmol/L caused a five -
fold decrease and 15 μmol/L caused two-fold decreases in E-cadherin, showing no 
concentration dependency effect. CA at concentration 75 μmol/L caused a five-fold decrease 
and 50 μmol/L caused four-fold decrease in E-cadherin mRNA. CDCA at 50 μmol/L caused a 
five-fold decrease and 30 μmol/L caused a two-fold decrease in E-cadherin mRNA, showing 
no concentration dependency effect (Figure 4-9).  
Because E-cadherin is downregulated by BA treatment, I also used RT-PCR to analyse treated 
16HBE14o- cells for fibronectin expression. It was found that fibronectin expression 
increased at all concentrations of LCA, DCA, CA and CDCA. Treatment with 10 μmol/L 
LCA caused a two-fold increase and 1 μmol/L LCA caused a three-fold increase in 
fibronectin mRNA, showing a negative concentration dependency effect. DCA at 30 μmol/L 
caused a four-fold increase and 15 μmol/L caused a three-fold increase in fibronectin mRNA, 
showing a positive concentration dependency effect. CA at concentration 75 μmol/L caused a 
four-fold increases and 50 μmol/L caused three- fold increases in fibronectin mRNA, showing 
a positive concentration dependency effect. CDCA at 50 μmol/L caused a five-fold increase 
and 30 μmol/L caused a four-fold increase in fibronectin mRNA, showing a positive 
concentration dependency effect (Figure 4-10).   
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Figure 4-9: E-cadherin mRNA expression following BA and TGF-β1 treatment. Confluent 16HBE14o- cells 
were cultured for 48 hours under various conditions as follows: medium (unstimulated control), medium 
containing 5ng/ml of TGF-β1 or 1-10 μmol/L LCA, 15-30 μmol/L DCA, 50-75μmol/L CA and 30-50 μmol/L 
CDCA. HPRT1 mRNA was used to normalize E-cadherin mRNA levels, which were presented as mean ±SEM 
(n=3). The E-cadherin mRNA was significantly downregulated in TGF-β1, LCA, DCA, CA and CDCA 
treatment groups. The data are representative of three independent experiments (each experiment n=6 wells). (** 
= p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared to control, ANOVA). For pairwise analysis Student's 
t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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Figure 4-10: Fibronectin mRNA expression following BA and TGF-β1 treatment. Confluent 16HBE14o- cells 
were cultured for 48 hours under various conditions as follows: medium (unstimulated control), medium 
containing 5ng/ml of TGF-β1 or 1-10 μmol/L LCA, 15-30μmol/L  DCA, 50-75 μmol/L CA and 30-50 μmol/L 
CDCA. HPRT1 mRNA was used to normalize Fibronectin mRNA levels, which were presented as mean ±SEM 
(n=3). The Fibronectin mRNA was significantly upregulated in TGF-β1, LCA, DCA, CA and CDCA treatment 
groups. The data are representative of three independent experiments (each experiment n=6 wells). (** = p < 
0.01, *** = p < 0.001, **** = p < 0.0001 compared to control, ANOVA). For pairwise analysis Student's t-test 
#: p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.4.2 Measurement of TGFβ1 expression 
4.4.2.1 Measurement of TGFβ1 protein expression in primary human bronchial 
epithelial cell cultures from lung allografts (PHBEC) 
TGF-β1 is accepted as a master switch driver of EMT (Sime and O'Reilly, 2001; Borthwick et 
al., 2012). TGF-β1 production by PHBECs was assessed using ELISA after BA exposure at 
concentrations of 1 and 10μmol/L (Figure 4-11). These concentrations of the bile acids were 
the maximal concentration that did not cause high cell death based on cell viability. Cell 
viability was confirmed at >90% (Figure 4-1). Little or no TGF-β1 was produced by control 
cells, whereas exposure to LCA, DCA, CA and CDCA (at 1 and 10 μmol/L for 48h) resulted 
in a significant increase in TGF-β1 secretion compared to control as follows: LCA at 1 
μmol/L caused 1106±107 pg/ml TGF-β1 to be produced (p < 0.001) and LCA at 10 μmol/L 
generated 639±77 pg/ml TGF-β1 (p < 0.001), showing a negative concentration dependency 
effect. DCA at 1 μmol/L caused 269±34 pg/ml TGF-β1 to be produced (p < 0.001) and DCA 
at 10μmol/L generated 527±54 pg/ml TGF-β1 (p < 0.01), showing a positive concentration 
dependency effect. CA at 1 μmol/L caused 773±51 pg/ml TGF-β1 to be produced and CA at 
10 μmol/L generated 856±62 pg/ml TGF-β1 (p < 0.001), showing no concentration 
dependency effect. CDCA at 1μmol/l caused 797±53 pg/ml TGF-β1 to be produced and 
CDCA at 10 μmol/L generated 585±44 pg/ml TGF-β1 (p < 0.001, showing a negative 
concentration dependency effect. The mean level of TGF-β1 production in control cells was 
90±18 pg/ml. 
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Figure 4-11: ELISA of TGFβ1 levels in culture medium produced by primary human bronchial epithelial cell 
cultures from lung allografts (PBEC) treated with LCA, DCA, CA and CDCA. Statistical analysis was 
conducted by repeated-measures-paired-one-way ANOVA to compare to control. The data are representative of 
three independent experiments (each experiment n=6 wells). Bars represent mean ± S.E.M values of each group, 
*: p<0.05, **: p<0.01 and, ***: p<0.001. For pairwise analysis Student's t-test #: p<0.05, ##: p<0.01, ###: 
p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.4.2.2 Measurement of TGFβ1 protein expression in tracheal epithelial cells (upper 
airway cells) from the subglottic area 
In order to ascertain if damaged tracheal epithelial cells released TGF-β1, I carried out an 
experiment in which primary human epithelial cells from human subglottic cells were 
exposed to 1 and 10 μmol/L concentrations of LCA, DCA, CA and CDCA for 48 hours. 
Maximal non-lethal conditions for bile acid stimulation were determined via cell viability 
assay. Cell viability was confirmed at >90% (Figure 4-4). TGF-β1 levels were measured 
using ELISA. TGF-β1 production by tracheal epithelial cells after BA exposure is shown in 
Figure 4-12. BA exposure was shown to significantly increase TGF-β1 levels in comparison 
to the control. LCA at 1 μmol/L caused 243±25 pg/ml TGF-β1 to be produced and LCA at 10 
μmol/L generated 344±31 pg/ml TGF-β1, showing a positive concentration dependency 
effect. DCA at 1 μmol/L caused 187±25 pg/ml TGF-β1 to be produced and DCA at 10 
μmol/L generated 190±25 pg/ml TGF-β1, showing no concentration dependency effect. CA at 
1 μmol/L caused 159±13 pg/ml TGF-β1 to be produced and CA at 10μmol/L generated 
177±33 pg/ml TGF-β1, showing no concentration dependency effect. CDCA at 1 μmol/L 
caused 218 ±22 pg/ml TGF-β1 to be produced and CDCA at 10 μmol/L generated 280±31 
pg/ml TGF-β1, showing a positive concentration dependency effect.  The mean level of TGF-
β1 production in control cells was 23±8 pg/ml (Figure 4-12). 
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Figure 4-12: ELISA of TGFβ1 levels in culture medium produced by tracheal epithelial cells from the 
subglottic area, cells treated with LCA, DCA, CA and CDCA. Statistical analysis was conducted by repeated-
measures-paired-one-way ANOVA to compare to control.  The data are representative of three independent 
experiments (each experiment n=6 wells). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: 
p<0.01 and, ***: p<0.001. For pairwise analysis Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: 
p<0.0001. (NS- not significant). 
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4.4.2.3 Measurement of TGFβ1 protein expression in BEAS-2B epithelial cell lines 
TGF-β1 production by BEAS-2B cells after BA exposure is shown in Figure 4-13. By using 
Cell CellTiter-Blue to assess cell viability, chapter three illustrated the concentration of BAs 
concentration which did not have significant effect on the cell viability. Cell viability was 
confirmed at >90% (Figure 3-8 Figure 3-9) for this reason, cells were exposed for 48 hours to 
the following concentrations: LCA (1 and 5 μmol/L), DCA (15 and 30 μmol/L), CA and 
CDCA (30 and 50 μmol/L). TGF-β1 was measured using ELISA and analysis showed that 
TGF-β1 significantly increases following BAs stimulation as follows: LCA at 5 μmol/L 
caused 1844±40 pg/ml TGF-β1 to be produced and LCA at 1μmol/L generated 370±13pg/ml 
TGF-β1, showing a positive concentration dependency effect. DCA at 30μmol/L caused 
1546±49 pg/ml TGF-β1 to be produced and DCA at 15μmol/L generated 969±5 pg/ml TGF-
β1, showing a positive concentration dependency effect. CA at 50 μmol/L caused 1825±32 
pg/ml TGF-β1 to be produced and CA at 30 μmol/L generated 738±17pg/ml TGF-β1, 
showing a positive concentration dependency effect.  CDCA at 50 μmol/L caused 980±17 
pg/ml TGF-β1 to be produced and CDCA at 30 μmol/L generated 1393±44 pg/ml TGF-β1, 
showing a negative concentration dependency effect. The mean level of TGF-β1 production 
in control cells was 84± 9 pg/ml (Figure 4-13). 
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Figure 4-13: ELISA of TGFβ1 levels in culture medium produced by BEAS-2B treated with LCA, DCA, CA 
and CDCA. Statistical analysis was conducted by repeated-measures-paired-one-way ANOVA to compare to 
control.  The data are representative of three independent experiments (each experiment n=6 wells). Bars 
represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01 and, ***: p<0.001. For pairwise analysis 
Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.4.2.4 Measurement of TGFβ1 protein expression in 16HBE14o- epithelial cell lines 
TGF-β1 production by 16HBE14o- cells after BA exposure is shown in Figure 4-14. By using 
Cell Titer-Blue to assess cell viability, chapter three illustrated the concentration of BAs 
concentration which did not have significant effects on the cell viability. Cell viability was 
confirmed at >90% (Figure 3-2 and Figure 3-3) for this reason, cells were exposed for 48 
hours to the following concentrations: LCA (1 and 10 μmol/L), DCA (15 and 30 μmol/L), CA 
(30 and 75 μmol/L) and CDCA (30 and 50 μmol/L). TGF-β1 was measured using ELISA and 
analysis showed that TGF-β1 significantly increases following BA stimulation as follows: 
LCA at 10 μmol/L caused 340±25 pg/ml TGF-β1 to be produced and LCA at 1 μmol/L 
generated 1460±36 pg/ml TGF-β1, showing a negative concentration dependency effect. 
DCA at 30 μmol/L caused 353±16 pg/ml TGF-β1 to be produced and DCA at 15 μmol/L 
generated 1083±63 pg/ml TGF-β1, showing a negative concentration dependency effect. CA 
at 75μmol/l caused 325±11 pg/ml TGF-β1 to be produced and CA at 50 μmol/L generated 
281±5pg/ml TGF-β1, showing no concentration dependency effect. CDCA at 50 μmol/L 
caused 1070±18 pg/ml TGF-β1 to be produced and CDCA at 30 μmol/L generated 256±14 
pg/ml TGF-β1, showing a positive concentration dependency effect. The mean level of TGF-
β1 production in control cells was 131±7 pg/ml (Figure 4-14). 
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Figure 4-14: ELISA of TGFβ1 levels in culture medium produced by 16HBE14o- treated with LCA, DCA, CA 
and CDCA. Statistical analysis was conducted by repeated-measures-paired-one-way ANOVA to compare to 
control.  The data are representative of three independent experiments (each experiment n=6 wells). Bars 
represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01 and, ***: p<0.001. For pairwise analysis 
Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.4.3 Measurement of MMP9 expression 
4.4.3.1 Measurement of MMP-9 protein expression in primary human bronchial 
epithelial cell cultures from lung allografts (PHBEC) 
MMP9 production by PHBECs following exposure to BAs at concentrations of 1 and 10 
μmol/L was measured using ELISA. This concentrations of the bile acids were the maximal 
concentration that did not cause high cell death based on cell viability. Cell viability was 
confirmed at >90% (Figure 4-1).  Control cells produced little or no MMP9, but exposure to 
5ng/ml TGF-β1 caused a significant increase in MMP9 production. Exposure to BAs caused 
significant increases and these results are shown in Figure 4-15.  48h exposure of PHBECs to 
LCA, DCA, CA and CDCA at 1 and 10 μmol/L have been shown to cause a significant 
increase in MMP9 production. MMP9 production was shown to increase as follows: TGFβ1 
at 5ng/ml caused 1360±56 pg/ml MMP-9 to be produced. LCA at 10μmol/L caused 
1068±32pg/ml MMP-9 to be produced and LCA at 1 μmol/L generated 480±17 pg/ml MMP-
9, showing a positive concentration dependency effect. DCA at 10μmol/L caused 298±17 
pg/ml MMP-9 to be produced and DCA at 1μmol/l generated 451±11 pg/ml MMP-9, showing 
a negative concentration dependency effect. CA at 10μmol/L caused 538±15 pg/ml MMP-9 to 
be produced and CA at 1μmol/L generated 444±25 pg/ml MMP-9, showing no concentration 
dependency effect. CDCA at 10μmol/l caused 660±22 pg/ml MMP-9 to be produced and 
CDCA at 1μmol/L generated 390±19 pg/ml MMP-9, showing a positive concentration 
dependency effect. The mean level of MMP-9 production in control cells was 81±7 pg/ml.  
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Figure 4-15: ELISA of MMP-9 production from primary human bronchial epithelial cell cultures from lung 
allografts (PHBEC) treated with LCA, DCA, CA and CDCA. Statistical analysis was conducted by repeated-
measures-paired-one-way ANOVA to compare to control.  The data are representative of three independent 
experiments (each experiment n=6 wells). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: 
p<0.01 and, ***: p<0.001. For pairwise analysis Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: 
p<0.0001. (NS- not significant). 
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4.4.3.2 Measurement of MMP-9 protein expression in in tracheal epithelial cells (upper 
airway cells) from the subglottic area 
MMP9 production by tracheal epithelial cells following 48h exposure to BAs at 
concentrations of 1 and 10 μmol/L was measured using ELISA. Maximal non-lethal 
conditions for bile acid stimulation were determined via cell viability assay. Cell viability was 
confirmed at >90% (Figure 4-4). Figure 4-16 shows that this treatment caused MMP9 levels 
to significantly increase as follows: TGFβ1 at 5 ng/ml caused 1800±19 pg/ml MMP-9 to be 
produced. LCA at 10μmol/L caused 518±9 pg/ml MMP-9 to be produced and LCA at 
1μmol/L generated 1744±67 pg/ml MMP-9, showing a negative concentration dependency 
effect. DCA at 10μmol/L caused 850± 32pg/ml MMP-9 to be produced and DCA at 1μmol/L 
generated 613±27 pg/ml MMP-9, showing a positive concentration dependency effect. CA at 
10μmol/L caused 261±9 pg/ml MMP-9 to be produced and CA at 1μmol/L generated 121±4 
pg/ml MMP-9 which did not increase significantly competed to control, showing a negative 
concentration dependency effect. CDCA at 10μmol/L caused 236±18 pg/ml MMP-9 to be 
produced and CDCA at 1μmol/L generated 298±18 pg/ml MMP-9, showing no concentration 
dependency effect. The mean level of MMP-9 production in control cells was 65±4 pg/ml.  
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Figure 4-16: ELISA of MMP-9 production from tracheal epithelial cells from the subglottic area cell line 
treated with LCA, DCA, CA and CDCA. Statistical analysis was conducted by repeated-measures-paired-one-
way ANOVA to compare to control.  The data are representative of three independent experiments (each 
experiment n=6 wells). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01 and, ***: 
p<0.001. For pairwise analysis Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- 
not significant). 
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4.4.3.3 Measurement of MMP-9 protein expression in   BEAS-2B epithelial cell lines 
MMP9 production by BEAS-2B cells following 48h exposure to BAs at the following 
concentrations: LCA (1and 5μmol/L), DCA (15 and 30 μmol/L), CA (30 and 50μmol/L) and 
CDCA (30 and 50 μmol/L), was measured using ELISA. These concentrations of the bile 
acids were the maximal concentration that did not cause high cell death based on cell viability 
(Figure 3-8 Figure 3-9). Cell viability was confirmed at >90%. Figure 4-17 shows that this 
treatment caused MMP9 levels to significantly increase as follows: TGFβ1 at 5 ng/ml caused 
925±19 pg/ml MMP-9 to be produced. LCA at 5μmol/L caused 770±27 pg/ml MMP-9 to be 
produced and LCA at 1μmol/L generated 367±22 pg/ml MMP-9, showing a positive 
concentration dependency effect. DCA at 30μmol/L caused 431 ± 43 pg/ml MMP-9 to be 
produced and DCA at 15μmol/L generated 246±8 pg/ml MMP-9, showing a positive 
concentration dependency effect. CA at 50μmol/L caused 558±12 pg/ml MMP-9 to be 
produced and CA at 30μmol/L generated 415±6 pg/ml MMP-9, showing a positive 
concentration dependency effect. CDCA at 50μmol/L caused 414±7 pg/ml MMP-9 to be 
produced and CDCA at 30μmol/L generated 384±11 pg/ml MMP-9, showing no 
concentration dependency effect. The mean level of MMP-9 production in control cells was 
109±8pg/ml. 
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Figure 4-17: ELISA of MMP-9 production from BEAS-2B cell line treated with LCA, DCA, CA and CDCA. 
Statistical analysis was conducted by repeated-measures-paired-one-way ANOVA to compare to control.  The 
data are representative of three independent experiments (each experiment n=6 wells). Bars represent mean ± 
S.E.M values of each group, *: p<0.05, **: p<0.01 and, ***: p<0.001. For pairwise analysis Student's t-test #: 
p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.4.3.4 Measurement of MMP-9 protein expression in 16HBE14o- epithelial cell lines 
MMP9 production by 16HBE14o- cells following 48h exposure to BAs at the following 
concentrations: LCA (1 and 10 μmol/L), DCA (15 and 30μmol/L), CA (50 and 75μmol/l) and 
CDCA (30 and 50μmol/L), was measured using ELISA. This concentrations of the bile acids 
were the maximal concentration that did not cause high cell death based on cell viability 
(Figure 3-2 Figure 3-3). Cell viability was confirmed at >90%. Figure 4-18 shows that this 
treatment caused MMP9 levels to significantly increase as follows: TGFβ1 at 5 ng/ml caused 
1356±11pg/ml MMP-9 to be produced. LCA at 10μmol/L caused 155±7pg/ml MMP-9 to be 
produced and LCA at 1 μmol/L generated 265±8pg/ml MMP-9, showing a negative 
concentration dependency effect. DCA at 30μmol/L caused 402±7pg/ml MMP-9 to be 
produced and DCA at 15 μmol/L generated 269±4 pg/ml MMP-9, showing a positive 
concentration dependency effect. CA at 75μmol/L caused 307±7pg/ml MMP-9 to be 
produced and CA at 50 μmol/L generated 254±12 pg/ml MMP-9, showing no concentration 
dependency effect. CDCA at 50 μmol/L caused 475±7pg/ml MMP-9 to be produced and 
CDCA at 30 μmol/L generated 577±10 pg/ml MMP-9, showing a negative concentration 
dependency effect. The mean level of MMP-9 production in control cells was 101±4pg/ml.   
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Figure 4-18: ELISA of MMP-9 production from 16HBE14o- cell line treated with LCA, DCA, CA and 
CDCA. Statistical analysis was conducted by repeated-measures-paired-one-way ANOVA to compare to control.  
The data are representative of three independent experiments (each experiment n=6 wells). Bars represent mean 
± S.E.M values of each group, *: p<0.05, **: p<0.01 and, ***: p<0.001. For pairwise analysis Student's t-test #: 
p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant).  
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4.4.4 Measurement of pro-collagen expression 
4.4.4.1 Measurement of pro-collagen protein expression in primary human bronchial 
epithelial cell cultures from lung allografts (PHBEC) 
Pro-collagen protein production by PHBECs following exposure to BAs at concentrations of 
1 and 10 μmol/L was measured using ELISA. Maximal non-lethal conditions for bile acid 
stimulation were determined via cell viability assay. Cell viability was confirmed at >90% 
(Figure 4-1). Control cells produced little or no pro-collagen, but exposure to 5ng/ml TGF-β1 
caused a significant increase in pro-collagen production. Exposure to BAs caused a significant 
increase and these results are shown in Figure 4-19. 48h exposure of PHBECs to LCA, DCA, 
CA and CDCA at 1 and 10 μmol/L have been shown to cause a significant increase in pro-
collagen production as follows: TGFβ1 at 5 ng/ml caused 1326±66 pg/ml pro-collagen protein 
to be produced. LCA at 10μmol/L caused 389±32 pg/ml of pro-collagen protein to be 
produced and LCA at 1μmol/L generated 203±28 pg/ml of pro-collagen protein, showing a 
positive concentration dependency effect. DCA at 10μmol/L caused 214±11 pg/ml of pro-
collagen protein to be produced and DCA at 1μmol/L generated 171±19 pg/ml of pro-
collagen protein, showing no concentration dependency effect. CA at 10μmol/L caused 
220±13 pg/ml of pro-collagen protein to be produced and CA at 1μmol/L generated 218±12 
pg/ml of pro-collagen protein, showing no concentration dependency effect. CDCA at 
10μmol/L caused 274±18 pg/ml of pro-collagen protein to be produced and CDCA at 
1μmol/L generated 147±12 pg/ml of pro-collagen protein, showing a positive concentration 
dependency effect. The mean level of pro-collagen protein production in control cells was 
41±12 pg/ml. 
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Figure 4-19: ELISA of Pro-collagen production from primary human bronchial epithelial cell cultures from 
lung allografts (PHBEC) treated with LCA, DCA, CA and CDCA. Statistical analysis was conducted by 
repeated-measures-paired-one-way to compare to control.  The data are representative of three independent 
experiments (each experiment n=6 wells). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: 
p<0.01 and, ***: p<0.001. For pairwise analysis Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: 
p<0.0001. (NS- not significant). 
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4.4.4.2 Measurement of pro-collagen protein expression in tracheal epithelial cells 
(upper airway cells) from the subglottic area  
Pro-collagen protein production by tracheal epithelial cells following exposure to BAs at 
concentrations of 1 and 10 μmol/L was measured using ELISA. These concentrations of the 
bile acids were the maximal concentration that did not cause high cell death based on cell 
viability. Cell viability was confirmed at >90% (Figure 4-4). Control cells produced little or 
no pro-collagen, but exposure to BAs caused a significant increase and these results are 
shown in Figure 4-20 48h exposure of damaged tracheal epithelial cells from the subglottic 
area to LCA at concentration 1 and 10µmol/L and 10 µmol/l DCA have been shown to cause 
a significant increase in pro-collagen production as follows: TGFβ1 at 5 ng/ml caused 927±26 
pg/ml pro-collagen protein to be produced. LCA at 10μmol/L caused 120 ±5 pg/ml of pro-
collagen protein to be produced and LCA at 1μmol/L generated 116±12 pg/ml of pro-collagen 
protein, showing no concentration dependency effect. DCA at 10μmol/L caused 93±18 pg/ml 
of pro-collagen protein to be produced. Production of pro-collagen protein after stimulation 
with DCA at 1μmol/L, CA at 1 and 10 µmol/L and CDCA 1 and 10 µmol/L did not increased 
pro-collagen protein significantly. DCA at 1μmol/L generated 74±6pg/ml of pro-collagen 
protein.CA at 10μmol/L caused 55±7 pg/ml of pro-collagen protein to be produced and CA at 
1 μmol/L generated 67±3 pg/ml of pro-collagen protein. CDCA at 1μmol/L caused 40±5 
pg/ml of pro-collagen protein to be produced and CDCA at 10 μmol/L generated 42 ±6 pg/ml 
of pro-collagen protein. The mean level of pro-collagen protein production in control cells 
was 28±26 pg/ml. 
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 Figure 4-20: ELISA of Pro-collagen production from tracheal epithelial cells from the subglottic area treated 
with LCA, DCA, CA and CDCA. Statistical analysis was conducted by repeated-measures-paired-one-way 
ANOVA to compare to control.  The data are representative of three independent experiments (each experiment 
n=6 wells). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01 and, ***: p<0.001. For 
pairwise analysis Student's t-test #: p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.4.4.3 Measurement of pro-collagen protein expression in BEAS-2B epithelial cell lines 
Pro-collagen protein production by BEAS-2B cells following exposure to BAs at the 
following concentrations: LCA (5 and1μmol/L), DCA (30 and 15μmol/L), CA (50 and 
30μmol/L) and CDCA (50 and 30μmol/L), which did not have significant effect on the cell 
viability (Figure 3-8 Figure 3-9), was measured using ELISA. Exposure to BAs caused a 
significant increase in pro-collagen protein production as shown in Figure 4-21. TGFβ1 at 5 
ng/ml caused 520±6 pg/ml pro-collagen protein to be produced. LCA at 5μmol/L caused 344 
±18 pg/ml of pro-collagen protein to be produced and LCA at 1μmol/L generated 296±8 
pg/ml of pro-collagen protein, showing a positive concentration dependency effect. DCA at 
30μmol/L caused 294±8 pg/ml of pro-collagen protein to be produced DCA at 15μmol/L 
generated 312±6 pg/ml of pro-collagen protein, showing no concentration dependency effect. 
CA at 50 μmol/L caused 205±11 pg/ml of pro-collagen protein to be produced CA at 30 
μmol/L generated 218 ±6 pg/ml of pro-collagen protein, showing no concentration 
dependency effect. CDCA at 50μmol/L caused 208±8 pg/ml of pro-collagen protein to be 
produced CDCA at 30μmol/L generated 185±8 pg/ml of pro-collagen protein, showing a 
positive concentration dependency effect. The mean level of pro-collagen protein production 
in control cells was 47±2 pg/ml. 
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Figure 4-21: ELISA of Pro-collagen production from BEAS-2B cell line treated with LCA, DCA, CA and 
CDCA. Statistical analysis was conducted by repeated-measures-paired-one-way ANOVA to compare to control.  
The data are representative of three independent experiments (each experiment n=6 wells). Bars represent mean 
± S.E.M values of each group, *: p<0.05, **: p<0.01 and, ***: p<0.001. For pairwise analysis Student's t-test #: 
p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.4.4.4 Measurement of pro-collagen protein expression 16HBE14o- epithelial cell lines 
Pro-collagen protein production by 16HBE14o- cells following exposure to BAs at the 
following concentrations: LCA (1 and 10 μmol/L), DCA (15 and 30 μmol/L), CA (50 and 75 
μmol/L) and CDCA (30 and 50 μmol/L), which did not have significant effect on the cell 
viability (Figure 3-2 and Figure 3-3), was measured using ELISA. Exposure to BAs caused a 
significant increase in pro-collagen protein production as shown in Figure 4-22. TGFβ1 at 5 
ng/ml caused 130±19 pg/ml pro-collagen protein to be produced. LCA at 10 μmol/L caused 
152±2 pg/ml of pro-collagen protein to be produced and LCA at 1 μmol/L generated 9±4 
pg/ml of pro-collagen protein, showing a positive concentration dependency effect. DCA at 
30 μmol/L caused 128±4 pg/ml of pro-collagen protein to be produced and DCA at 15 μmol/L 
generated 100±2 pg/ml of pro-collagen protein, showing a positive concentration dependency 
effect. CA at 75 μmol/L caused 79±6 pg/ml of pro-collagen protein to be produced and CA at 
50 μmol/L generated 85±5 pg/ml of pro-collagen protein, showing no concentration 
dependency effect. CDCA at 50 μmol/L caused 128±2 pg/ml of pro-collagen protein to be 
produced and CDCA at 30 μmol/L generated 77±6 pg/ml of pro-collagen protein, showing a 
positive concentration dependency effect. The mean level of pro-collagen protein production 
in control cells was 40±6 pg/ml. 
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Figure 4-22:  ELISA of Pro-collagen production from 16HBE14o- cell line treated with LCA, DCA, CA and 
CDCA. Statistical analysis was conducted by repeated-measures-paired-one-way ANOVA to compare to control.  
The data are representative of three independent experiments (each experiment n=6 wells). Bars represent mean 
± S.E.M values of each group, *: p<0.05, **: p<0.01 and, ***: p<0.001. For pairwise analysis Student's t-test #: 
p<0.05, ##: p<0.01, ###: p<0.001 and ####: p<0.0001. (NS- not significant). 
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4.5 Discussion 
The results in this chapter provide evidence for active epithelial-mesenchymal transition 
(EMT) in primary epithelial cell cultures from lung allograft, tracheal epithelial cells (upper 
airway cells) from the subglottic area, BEAS-2B cell lines and 16HBE14o- cell lines after 
stimulation with both primary and secondary BAs at varying concentrations.   
Gastroesophageal reflux disease (GORD) and extraoesophageal reflux disease (EORD) can 
affect patients with a wide variety of airway diseases. A causative link has been hypothesised 
between respiratory disorders and GORD/EORD. This is based on the facts that airway 
epithelial cells produce fibroblast-promoting growth factors and that bile acid (BA) exposure 
leads to a fibrotic response. GOR symptoms and the pathologic reflux caused by COPD 
exacerbation (Casanova et al., 2004), are strongly correlated (Rascon-Aguilar et al., 2006), 
and GORD is also common among asthma sufferers (Hsu et al., 2005), especially in severe 
cases (Leggett et al., 2005). Idiopathic pulmonary fibrosis patients are especially prone to 
GORD (Tobin et al., 1998; Raghu et al., 2006) and may still aspirate 
duodenogastroesophageal refluxate even after undergoing a lung transplant. In this case, there 
is a correlation with bronchiolitis obliterans, which also is a fibrotic airway disorder 
(D’Ovidio et al., 2005).  
This data supports the hypothesis that human airway epithelial cells exposed to BAs may 
undergo EMT, causing the formation of fibroblasts. To the best of my knowledge, this is the 
first time data of this type has been presented. 
During embryo development, EMT is involved in organogenesis. It also plays a vital role in 
wound healing (Hay, 2005). When EMT becomes dysregulated however, it contributes to 
cancer progression and metastasis, and to the development of chronic degenerative fibrotic 
disorders in the lung as well as several other organs (Thiery, 2002; Wilson and Wynn, 2009). 
This can have several consequences, including COPD, pulmonary fibrosis and lung allografts 
rejection. Therefore, EMT is implicated in the pathogenesis of these conditions (Kalluri and 
Neilson, 2003; Lee et al., 2009). In spite of an increasing evidence base that suggests a 
connection between EMT and fibrotic remodelling in the lungs and other organs, it has not 
been shown to play a role in the airway remodelling and fibrosis and there is little evidence 
that bronchial epithelial cells are affected (Doerner and Zuraw, 2009). 
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Patients with a range of airway diseases often exhibit gastroesophageal reflux (GORD). 
Cytokines and growth factors involved in fibroblast migration, proliferation, and 
myofibroblast differentiation in the lungs are stimulated by BAs, which can be aspirated 
during GORD and therefore GORD may play a prominent role in lung injury and airway 
fibrosis (Zhang et al., 2001; Perng et al., 2003). Airway fluids may contain a number of BAs 
including the unconjugated BAs used in this study (Legendre et al., 2014). BALF has been 
shown to contain BAs at concentrations up to 240 μmol/L (D’Ovidio et al., 2005; Parikh et 
al., 2013). The BAs used in this study therefore have profibrotic effects that are 
pathophysiologically relevant (Chen et al., 2016). 
The results of this study indicate that primary human bronchial epithelial cell cultures from 
lung allografts (PHBEC), when exposed to CA and CDCA at 1 and 10 µmol/L significantly 
reduce E-cadherin expression. On the other hand E-cadherin gene expression levels did not 
decrease after stimulation with LCA and DCA. Moreover, fibronectin expression was 
significantly upregulated by CA and CDCA at 1 and 10 µmol/L, whereas fibronectin 
expression did not increase significantly with 1 and 10 µmol/ LCA and DCA. These findings 
may indicate that CDCA and CA (primary bile acids) were more effective when compared to 
DCA and LCA (secondary bile acids). 
Furthermore, in this study, tracheal epithelial cells (upper airway cells) from the subglottic 
area, which was derived from the subglottic airway and provide a physiological model of the 
upper airway in vitro (Powell J, 2015) was stimulated with BAs to assess E-cadherin and 
fibronectin expression. The most interesting finding was that the E-cadherin expression was 
significantly downregulated in 10 μmol/L LCA, 1 and 10 μmol/L CA and CDCA, whereas E-
cadherin gene expression levels were similar to the control in 1 μmol/L LCA and DCA 
treatment groups. Consequently, it would appear that upper airway cells are affected by BAs, 
which induce EMT. 
These findings show that the upper airway cells and lower airway cells are affected by 
primary bile acids. On the other hand only LCA at 10 µmol/mL caused downregulation in E-
cadherin and increased fibronectin expression in upper airway cells but not lower airway 
cells.  The secondary BAs may be more harmful and the concentration of LCA may be higher 
than other BAs in upper airway. LCA was identified in trachea at concentration of 2.8±0.6 
μmol/L in patients with ventilator associated pneumonia (Wu et al., 2009). 
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Polygonal epithelial cells adhere to form a tight mesh, creating the airway epithelial sheet 
(Sohal et al., 2014). E-cadherin, a synthesis transmembrane glycoprotein found primarily in 
the adherens junctions between epithelial cells, has been implicated as a marker of 
differentiated epithelial phenotype (Arias, 2001; Zeisberg et al., 2003). It is downregulated 
when epithelial cells transform (Yang and Liu, 2001), but plays a key role in maintaining 
epithelial polarity and consequently in tight junction development (Tunggal et al., 2005). 
Epithelial-Mesenchymal Transition (EMT) in both cancerous and non-cancerous cells 
involves several steps, beginning with E-cadherin inhibition. Once the mesenchymal 
phenotype is fully realised, mesenchymal markers, such as fibronectin, proliferate. 
Fibronectin is involved in a range of processes, including cell adhesion and migration, and 
tissue repair (Miettinen et al., 1994). 
EMT like activity was induced in BEAS-2B and 16HBE14o- cells through BA exposure, 
indicating that the effect is not limited to primary cells, but that human bronchial epithelial 
cell lines (in vitro) are also vulnerable. I observed that the 16HBE14o- cells were more 
sensitive to BAs treatment and EMT induction than the BEAS-2B cells.  For example in this 
study, immortalized cell line 16HBE14o-, which was derived from bronchial surface 
epithelial cells (Cozens et al., 1994), were exposed to BAs at different concentration to assess 
E-cadherin and fibronectin expression. The results revealed a significant decrease in E-
cadherin expression at all concentrations, also it was found that fibronectin expression 
increased at all concentrations of BAs. 
On the other hand the E-cadherin expression in BEAS-2B, which significantly decreased in 
response to (15 and 30 μmol/l) DCA, (30 and 50 μmol/l) CDCA, (5 µmol/l) LCA and (50 
µmol/l) CA, but there was no significant effect from 1 µmol LCA and 30 µmol CA exposure. 
Fibronectin expression, was significantly increased with (1 and 5 μmol/l) LCA, (15 μmol/l) 
DCA, (50 μmol/L) CA and (30 μmol/l) CDCA. However, (30 μmol/L CA) and (50 μmol/l) 
CDCA had no significant effect. 
BEAS-2B cells retain the morphology of an epithelial cell in vitro (Reddel et al., 1988) and 
release IL-8 and IL-6 in addition to other cytokines. Under submerged conditions, BEAS-2B 
cells are commonly used as in the in vitro model of human airways epithelium- especially 
within studies on inhalation toxicity (Cha et al., 2007; Petecchia et al., 2009).  
Furthermore, Cells were also stimulated with 5ng/ml TGF‐β1 as a positive control. An 
optimum concentration of TGF‐β1 (5 ng/ml) was used to stimulate primary cells and cell 
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lines. It was assumed that the same concentration was optimum to induce stress in cells as 
well. Published studies suggest that 5ng/ml of TGF‐ β1 induces morphological changes in this 
immortalised cell lines (Doerner and Zuraw, 2009; Câmara and Jarai, 2010; Liu et al., 2013).  
An additional analysis was performed to detect TGFβ1, MMP9 and Pro-collagen secreted by 
primary bronchial human epithelial cell cultures from lung allografts (PHBECs), tracheal 
epithelial cells (upper airway cells) from the subglottic area and cell lines (BEAS-2B and 
16HBE14o-) by using an ELISA. In this experiment, BAs stimulation of cells were associated 
with the release of TGFβ1, MMP9 , but the most interesting finding was the production of 
pro-collagen protein after stimulation of  human subglottic cells with DCA at 1μmol/L, CA at 
1 and 10µ μmol /L and CDCA 1 and 10µ mol/L did not increased significantly. A recent 
study suggested a significantly higher number of reflux events detected in laryngopharyngeal 
reflux (LPR) patients than patients with GERD (Hom and Vaezi, 2013). Moreover, patients 
with LPR may have a high concentration of bile acids and the concentration of BAs that reach 
the lower airway may be diluted (Sifrim, 2015). As a result the upper airway cells may 
become resistant. Furthermore, the secondary BAs can be more cytotoxic than primary BAs to 
upper airway cells.    
Epithelial cells also generate matrix metalloproteinase 9 (MMP-9), a type IV collagenase, the 
presence of which can indicate EMT and epithelial damage. Col4 is the primary structural 
component of the true reticular basement membrane, which epithelial cells sit upon. When 
MMPs disrupt the airway epithelium, various forms of damage can occur, including 
translocation, inflammation and further EMT (Kalluri and Neilson, 2003).  
A recent study has also shown that lung fibroblasts and alveolar epithelial cells (AECs) can be 
activated by BAs through both FXR-dependent and independent pathways. These findings 
have enabled a new perspective on the role of BA microaspiration on IPF development (Chen 
et al., 2016). Mesenchymal trans-differentiation of AECs in pulmonary fibrosis is controlled 
by a number of key mechanisms. TGFβ1 exposure can induce EMT in both rat and human 
AECs in culture (Yao et al., 2004; Willis et al., 2005). Most of the EMT research in 
pulmonary fibrosis has focused on AECs.  
The transcription factor, Farnesoid X receptor (FXR), contains both a DNA binding domain 
and a ligand binding domain, the latter of which is sensitive to BAs (Abu-Hayyeh et al., 
2013), and provides a mechanism for BAs to regulate their own synthesis and metabolism. It 
is interesting to note that apart from a role in BA homeostasis there is widespread expression 
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of FXR in tissues in humans and this includes expression in the airway and lung (Bishop-
Bailey et al., 2004) As a result, the lung’s inflammatory response and its repair processes 
repair are critically dependent on the role of FXR (Zhang et al., 2012). 
There is evidence to suggest that FXR has a novel function in the regulation of hepatic 
inflammation and that its ligands might potentially serve a role in inflammatory liver disease 
treatment as well as the prevention of hepatocarcinogenesis. FXR is a known antagonist in the 
NF-κB1 pathway, whose role in both the inflammatory response and in the mediation of 
tumor promotion therefore implicates FXR as playing a critical role in the inflammatory 
response (Greten et al., 2004; Pikarsky et al., 2004). The NF-κB1 pathway is suppressed by 
FXR – irrespective of the presence of its exogenous ligand – in HepG2 cells at the gene 
transcription level. GW4064, an FXR agonist, inhibits the binding activity between NF-κB1 
and the DNA sequence, resulting in suppressed NF-κB1 regulated gene expression in both 
HepG2 and mouse primary hepatocytes (Wang et al., 2008).  
Hepatocyte BA levels are decreased through the following mechanism: DNA binds with 
activated FXR to form a complex with the retinoid x receptor. In turn, this stimulates the 
transcription of various genes, which code for transporters (e.g. ABC transporters) that 
facilitate BA transfer from hepatocytes to the bile (Holt et al., 2003). It was confirmed 
recently that the expression of CFTR, a member of the ABC transporter family, in epithelial 
cells might be regulated by activated FXR, thereby modulating chronic secretion (Mroz et al., 
2014). FXR has also been implicated in CLˉ secretion downregulation in the colonic 
epithelium and that Na⁺/ K⁺ ATPase inhibition appears to regulate this process (Keating and 
Keely, 2009). 
A study by Lafyatis and Farina explores the involvement of gut microbiota in toll-like 
receptor (TLR – primarily TLR2 and TLR4) signalling, which aggravates metabolic 
inflammation. TLRs play a significant role in the recognition of pathogen-associated 
molecular patterns, which are found on bacterial cell walls. For example, TLR4 is a ligand of 
lipopolysaccharide (LPS) (Lafyatis and Farina, 2012). Vavassori et al. found that an anti-
inflammatory effect can be achieved by activation of FXR-modulated TLR4 (Vavassori et al., 
2009). 
Bogdasarian and Olson first noted the association with reflux subglottic stenosis in 1980 
(Bogdasarian and Olson, 1980) in their article on posterior glottis stenosis, which noted that 
gastric reflux should be added to the list of factors which cause posterior subglottic stenosis. 
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Other studies since then have also confirmed the relationship between acquired subglottic 
stenosis (ISS) and GORD (Little et al., 1984). Koufman has conducted the largest study to 
date, using 197 patients with presumed GERD and a range of associated symptoms including 
laryngitis 48 patients, tracheal and subglottic stenosis 32 patients, tracheal and subglottic 
stenosis 32 patients, carcinoma of the larynx 31 patients, cough 25 patients, globus 
pharyngeus 24 patients, dysphagia 22 patients and miscellaneous 15 patients (Koufman, 
1991).  
Cells under submerged conditions have also been studied. Xie et al.  investigated epithelial 
cells from asthmatic and non-asthmatic donors in two conditions: submerged and air-liquid 
interface conditions. It was found that EMT was induced by TGF-β1 in both conditions (Xie 
et al., 2004). These findings are supported by similar studies, which have found EMT-related 
changes in the polarized layer forming 16HBE-14o- cell line (Zhang et al., 2009). 
These findings have been supported by other studies, which have demonstrated that airway 
epithelial cells undergo EMT in vitro and that epithelial cells from obliterative bronchiolitis 
patients express mesenchymal cell markers, detected by immunohistochemistry (Borthwick et 
al., 2009). Increased mesenchymal marker S100A4 expression in airway epithelial cells from 
lung transplant patients suggests that airway epithelial cells can differentiate into 
mesenchymal cells (Ward et al., 2005). 
Work for this thesis has shown that BA stimulation of airway epithelial cells causes TGF-
β1production to increase. It has been suggested that in many tissues, including the lungs, 
TGF-β1 plays the role of a ‘master switch’ in triggering fibrosis (Sime and O'Reilly, 2001; 
Borthwick et al., 2012). IPF patients are found to exhibit upregulated TGF-β1 levels in their 
lungs. Furthermore, active TGF-β1 expression has been found to cause a ‘dramatic fibrosis 
response’ in rats’ lungs. In addition, the inability to respond to TGF-β1 affords protection 
from bleomycin induced fibrosis (Zhao et al., 2002). In the development, carcinogenesis and 
fibrosis of various isoforms, TGF-β1 is a significant inducer of EMT (Nawshad et al., 2005). 
Given the significant spike in TGF-β1 production in bronchial epithelial cells found by this 
study, it is suggested that these cells could become migratory during fibrosis development. A 
recent study using airway epithelial cells from asthmatics found these cells to be particularly 
sensitized to TGF-β1 induced EMT (Hackett et al., 2009). This, along with my study, builds 
to case for EMT being triggered in the epithelium as well as within the alveoli. Kuroishi 
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report has also shown that mouse tracheal epithelial cells in vitro can also exhibit TGF-β1-
induced EMT (Kuroishi et al., 2009). 
A549 alveolar epithelial cells exhibit an EMT-like process in response to TGF-β1, which is 
thought to be due to initiation of the Smad2 signalling pathway. This further supports the 
hypothesis of EMT occurring in human lung epithelial cells, although further research is 
needed, especially in relation to the expression profile for EMT-induced alveolar cells. This 
research could reveal a deeper understanding of the role of EMT in pulmonary fibrogenesis. 
The use of cultured cells in these EMT studies generates discussion around authenticity (true 
EMT), or if these experiments are simply causing a ‘stress response’ in cells. In light of the 
evidence to date, I believe that ‘true’ transition from epithelial to mesenchymal phenotypes 
can be better demonstrated through studying the functional properties of cells, not just their 
protein expression. Mesenchymal cells can be functionally characterised by their expression 
of MMP9 (Borthwick et al., 2009) and my study found that epithelial cells treated with BAs 
are able to release this enzyme, as well as pro-collagen. These findings provide further 
evidence for the case that EMT may occur in airway cells, which could infiltrate the basement 
membrane and migrate into the subepithelial layer. From this point, cells would be in a 
position to generate disproportionate amounts of connective tissue. 
A range of chronic airway disorders are associated with GORD symptoms. This study has 
shown that airway fibrosis development could be associated with the presence of BAs, which 
trigger excessive cytokine and growth factor production. Experiments in lung fibrosis have 
shown that these substances cause myofibroblasts as well as fibroblast migration and 
proliferation via EMT (Kim et al., 2006; Kim et al., 2009).  
These findings may have translational significance in airways disease and suggest new 
therapeutic possibilities where modifying GORD may have positive effects on airway and 
lung disease. In summary, this study provides evidence of EMT markers in primary epithelial 
cell cultures from lung allograft, tracheal epithelial cells (upper airway cells) from the 
subglottic area, BEAS-2B cell lines and 16HBE14o- cell lines. The EMT procedure may 
instigate a pathway following injury in common diseases characterised by airway remodelling 
and fibrosis. These results confirm that EMT like changes were induced in BEAS-2B and 
16HBE14o- cells through BAs exposure, indicating that the effect is not limited to primary 
human bronchial epithelial cells  and BEAS-2B and 16HBE14O-cell lines are a sensitive and 
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useful model to study human respiratory processes and diseases related to BAs aspiration- 
instigating EMT. 
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CHAPTER 5: THE ROLE OF DUODENO-GASTRO-
OESOPHAGEAL REFLUXATE IN MUCUS PRODUCTION 
FROM NCI-H292 AND CALU-3 CELL LINES 
5.1 Introduction 
A glycoprotein-rich mucus layer lines the luminal epithelial surfaces of the respiratory tract, 
providing barrier protection from noxious and pathogenic agents. It is also involved in 
reactions to inflammation and infection, which result in upregulation mucus production. 
Between the trachea and the bronchioles, in healthy lungs, this mucus comprises secretions 
from both glandular and epithelial cells (mucus/goblet cells) (Sigurdsson et al., 2013). 
Chronic inflammatory airway diseases, such as Cystic Fibrosis (CF), Chronic Obstructive 
Pulmonary Disease (COPD), bronchiectasis and* severe asthma, are characterised by the 
hypersecretion of mucus (Fahy, 2002; Kim et al., 2008a); thereby leading to airway 
narrowing and impaired lung function (Aikawa et al., 1992). 
 Mucin – part of a family of large (several thousand kilodaltons) glycoproteins – is a primary 
component of secreted mucus. These glycoproteins play a fundamental role in determining 
mucus viscoelasticity (Corfield, 2015). The principal glycoproteins in airway mucus 
secretions are expressed by the MUC5AC and MUC5B genes (Thornton et al., 1997; 
Voynow, 2002). MUC5AC is secreted primarily by goblet cells in the surface airway 
epithelium (Suzaki et al., 2016) and MUC5B mainly by mucus and serous cells in the 
submucosal glands (Zanin et al., 2016). 
It has been possible to maintain primary epithelial cells for 2-3 passages on a plastic surface, 
but the populations are heterogeneous, and the mucin expressing phenotype has not been 
observed. Furthermore, it is expensive to maintain rigorous culture conditions. Nevertheless, 
it has been possible to grow, maintain and passage carcinoma cell lines from epithelial 
samples and these have been used as investigative models for diseases including CF, COPD, 
asthma and inflammatory processes (Berger et al., 1999). 
Epithelial carcinoma cell lines have included Calu-3 and NCI H292 cells, which have 
provided useful models for in vitro study of gene regulation. Moreover, these cells carry the 
significant benefit of allowing both MUC5 mRNA and MUC5 glycoprotein regulation to be 
studied within the same model (Berger et al., 1999; Rose et al., 2000). 
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Bile acid (BA) is found commonly in the airways and bronchoalveolar lavage fluid of patients 
with chronic airway diseases, in addition to in murine models. Therefore, it is thought that 
BAs have some involvement in airway disease development (Cohen-Cymberknoh et al., 
2013). BAs may also cause airway obstruction by increasing mucus production (D’Ovidio 
and Keshavjee, 2006). However, further research is required on the role of BAs in the airway 
and their involvement with mucosal membranes. 
Here, I hypothesise that due to the connection between mucus hypersecretion and 
gastroesophageal reflux in diseases such as CF, COPD and asthma, the presence of BAs in the 
lung could be a primary cause of this increased mucin secretion via epithelial cell stimulation. 
Consequently, several cell lines originating from respiratory tract epithelial tissue were 
studied to identify those that expressed MUC genes similar to those displayed in upper and 
lower respiratory tract tissues (Berger, Voynow et al. 1999). In particular, the investigation 
aimed to determine whether MUC5 RNA expressing cell lines also secreted MUC5 mucins. 
These cell lines could then be used to determine the effect of BAs on mucin expression and 
mucus cell differentiation; hence, their role in airway diseases. Mucin gene expression was 
surveyed in two respiratory tract carcinoma cell lines: Calu-3 and NCI-H292. 
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5.2 Aims of the study 
This chapter will explore the potential for using NCI-H292 and Calu-3 cell lines in vitro as 
models for investigating the hypothesis, which states that BAs in the lung could stimulate 
lung epithelial cells to synthesise or secrete mucin. Primary experimental aims are as follows: 
- To measure the mucin content of the culture medium using a periodic acid-Schiffs 
(PAS) assay. 
- To measure MUC5AC and MUC5B using indirect ELISA and to determine the 
concentration of BAs that caused maximum MUC5AC and MUC5B mucin 
production. 
- To evaluate MUC5AC expression in NCI-H292 cells and Calu-3 cells stimulated with 
BAs, by quantitative real-time PCR. 
- To examine the expression profile of MUC5B in NCI-H292 and Calu-3 cells 
stimulated with BAs via quantitative real-time PCR. 
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5.3 Methods 
5.3.1 Cell line culture 
NCI-H292 and Calu-3 were cultured in six-well plates as described in chapter 2, sections 
2.2.3 and 2.2.4. At about 80-90% confluence, these were rested for 24 hours, then exposed to 
primary and secondary BAs at a range of concentrations  
5.3.2 Stimulation of NCI-H292 and Calu-3 cells with BAs 
NCI-H292 and Calu-3 cell cultures were exposed to LCA, DCA, CA and CDCA for 48 hours 
at concentrations of 1, 5, 10, 15, 20, 30, 50, 75 and 100 μmol/L as described in chapter 2, 
section 2.6.  
5.3.3 Detection of MUC5AC and MUC5B mucins 
5.3.3.1 Determination of mucin production by Periodic Acid-Schiff (PAS) assay 
Mucin production by NCI-H292 and Calu-3 cells was examined and measured using a PAS 
assay described in chapter 2, sections 2.8.4.  
5.3.3.2 Quantification of MUC5AC and MUC5B mucin concentration by indirect 
ELISA 
NCI-H292 and Calu-3 cells were cultured and stimulated (described above see chapter 2, 
sections 2.2.3 and 2.2.4). MUC5AC and MUC5B mucins were analysed using indirect ELISA 
as described in chapter 2, sections 2.8.2 and 2.8.3.  
5.3.4 Molecular biology 
RNA was isolated using the RNEasy Mini-kit (Qiagen) and reverse transcribed using a Tetro 
cDNA synthesis kit (Bioline). A quantitative PCR reaction was used to determine specific 
gene expression changes at a molecular level (see chapter 2, section 2.9). 
In studying BAs effect on MUC5B and MUC5AC gene regulation, the cells were stimulated 
with BA concentrations that cause the highest levels of MUC5AC and MUC5B mucin 
production was measured by ELISA. 
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5.4 Results 
5.4.1 Effect of BAs on mucin production in NCI-H292 cells, quantified using the PAS 
method 
NCI-H292 is a mucous producing cell strain (Newland and Richter, 2008). Following 48-hour 
BA exposure, mucin production by NCI-H292 was examined using the PAS assay. 
Figure 5-1 illutrates that high mucin levels were produced significantly by cells stimulated 
with LCA at 1, 5, 10, 15 and 20 µmol/L concentrations. However, no difference was found 
between the five levels of LCA. 
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Figure 5-1: Mucin released by NCI-H292 cells following 48h LCA stimulation. PAS was used to measure 
mucin in cell supernatants, and this was statistically analysed using a one-way ANOVA test. P values of ≤ 0.05 
were regarded as significant. These results are mean ± S.E.M values from (n=6) experiments. (*** = p < 0.001 
compared with control, ANOVA). 
 
  
174 
 
Figure 5-2 shows a significant increase in mucin production by NCI-H292 cells challenged 
with 15, 30, 50 and 75 µmol/L DCA in comparison with unchallenged cells. The highest level 
of mucin production was at concentration 15 µmol/l of DCA. Moreover, there was an inverse 
dose response to DCA and 100 µmol/l DCA did not induce mucin production. 
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Figure 5-2: Mucin released by NCI-H292 cells following 48h DCA stimulation. PAS was used to measure 
mucin in cell supernatants, and this was statistically analysed using a one-way ANOVA test. P values of ≤ 0.05 
were regarded as significant. These results are mean ± S.E.M values from (n=6) experiments. (*** = p < 0.001 
compared with control, ANOVA). 
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Figure 5-3 presents a significant increase in mucin production by NCI-H292 cells challenged 
with 15, 30, 50, 75 and 100 µmol/L CA in comparison with unchallenged cells. There was no 
difference in the level of mucin production by the NCI-H292 between any of the CA 
concentrations. 
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Figure 5-3: Mucin released by NCI-H292 cells following 48h CA stimulation. PAS was used to measure mucin 
in cell supernatants and this was statistically analysed using a one-way ANOVA test. P values of ≤ 0.05 were 
regarded as significant. These results are mean ± S.E.M values from (n=6) experiments. (** = p < 0.01, *** = p 
< 0.001 compared with control, ANOVA). 
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Figure 5-4 demonstrates a significant increase in mucin production by NCI-H292 cells 
challenged with 30, 50, 75 and 100 µmol/L CDCA in comparison with unchallenged cells. 
The highest output of mucin was with 50 µmol/L. However, there was no significant increase 
at 15 µmol/L CDCA. 
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Figure 5-4: Mucin released by NCI-H292 cells following 48h CDCA stimulation. PAS was used to measure 
mucin in cell supernatants and this was statistically analysed using a one-way ANOVA test. P values of ≤ 0.05 
were regarded as significant. These results are mean ± S.E.M values from (n=6) experiments. (* = p<0.05, ** = 
p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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In general, looking at mucin production by NCI-H292 cells measured by PAS assay, it can be 
seen that 15 and 30 µmol/L of DCA had the highest level of mucin released. The second 
highest level of mucin production occurred with 15 µmol/L of CA, 50 µmol/L of CDCA also 
produced a similar level of mucin. Conversely, LCA caused the lowest level of mucin 
secretion due possibly to cell death (see Figure 3-14A), although mucin production by LCA 
remained significantly higher than the control (Figure 5-1 to Figure 5-4). The explanations for 
this fact are unclear yet but some possible explanations exist. Bile acids accumulate in cells 
and may  inhibit intracellular function which does not kill the cell but reduces the rate of all 
cellular processes such as protein synthesis  (Tabas, 2002). Moreover, extracellular matrix 
(ECM) may play a role in downregulation of mucin production. ECM component, type-IV 
collagen, inhibits MUC5AC production via integrin-signalling pathways,(Integrins are 
heterodimers composed of α2- and β-subunit and are the main receptors involved in cell–cell 
and cell–ECM adhesion) (Iwashita et al., 2010). 
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5.4.2 Measurement of MUC5AC and MUC5B mucin in NCI-H292 cells 
MUC5AC and MUC5B secretion by NCI-H292 cells is also affected by BA exposure. Levels 
of MUC5AC and MUC5B secreted by cells into the culture medium were measured using 
indirect ELISA  
Figure 5-5 and Table 5-1 show that NCI-H292 exposure to LCA at concentrations of 1, 5 and 
10 µmol/L caused MUC5AC levels to increase significantly. There was an inverse dose-
response to LCA. However, no significant increase was seen using concentrations of 15 and 
20 µmol/L LCA due to the cell death (see Figure 3-14A). 
NCL-H292 cell line lung carcinoma cells also produce MUC5B. These cells were exposed to 
primary (CA and CDCA) and secondary (LCA and DCA) BAs. Figure 5-5 and Table 5-1 
illustrate that exposure of NCI-H292 cells to LCA at concentrations of 1, 5, 10 and 15 µmol/L 
caused MUC5B mucin levels to increase significantly. The highest response was at 1 µmol/L, 
but at 20 µmol/L LCA there was no increase in MUC5B mucin due to cell viability, which is 
significantly decreased by LCA at 20μmol/L with 93±3% cell death (see Figure 3-14A). 
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Figure 5-5: MUC5AC and MUC5B mucin release by NCI-H292 cells following exposure to LCA for 48 hours. 
Indirect ELISA was used to measure MUC5AC and MUC5B levels in the supernatant. Statistical analysis was 
conducted using a one-way ANOVA test. The data are representative of three independent experiments (n=6) 
(see table 5-1). Bars represent mean ± S.E.M values of each group.   
 
 
  Lithocholic acid  
Concentration 
μmol/L 
1 5 10 15 20 
MUC5AC ↑*** ↑*** ↑* _______ _______ 
MUC5B   ↑**** ↑*** ↑** ↑** _______ 
Table 5-1: The effect of different levels of Lithocholic acid on the NCL-H292 cell line following stimulation for 
48 hours, ↑ Increase demonstrated.  * Significant stimulation of MUC5AC and MUC5B release. (* = p<0.05, ** 
= p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Figure 5-6 and Table 5-2 illustrate that exposure of NCI-H292 cells to DCA at concentrations 
of 15, 30, 50, 75 and 100 µmol/L caused MUC5AC mucin levels to increase significantly. 
From the table, it is clear that MUC5AC mucin levels increased significantly at all 
concentrations. The highest level of MUC5AC mucin production was with 15 µmol/L DCA 
and the level of MUC5AC mucin production then fell off due to cell death (see Figure 3-14B) 
but remained significantly higher than the control. 
Furthermore, Figure 5-6 and Table 5-2  reveal that exposure of NCI-H292 cells to DCA at 
concentrations of 15 and 30 µmol/L caused MUC5B mucin levels to increase significantly. 
The highest level of MUC5B mucin release occurred with 15 µmol/L DCA. The MUC5B 
mucin levels reduced at 30µmol/L DCA but remained significantly above the control. There 
was no increase in MUC5B mucin due to cell viability being significantly affected by DCA at 
50, 75 and 100 μmol/L (see Figure 3-14B) . 
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Figure 5-6: MUC5AC and MUC5B mucin release by NCI-H292 cells following exposure to DCA for 48 hours. 
Indirect ELISA was used to measure MUC5AC and MUC5B levels in the supernatant. Statistical analysis was 
conducted using a one-way ANOVA test. The data are representative of three independent experiments (n=6) 
(see table 5-2). Bars represent mean ± S.E.M values of each group. 
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  Deoxycholic acid  
Concentration 
μmol/L 
15 30 50 75 100 
MUC5AC ↑*** ↑*** ↑* ↑* ↑* 
MUC5B ↑*** ↑** _______ _______ _______ 
Table 5-2: The effect of different levels of Deoxycholic acid on the NCL-H292 cell line following stimulation 
for 48 hours, ↑ Increase demonstrated.  * Significant stimulation of MUC5AC and MUC5B release. (* = p<0.05, 
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
  
182 
 
Figure 5-7 and Table 5-3 reveal a significant increase in MUC5AC mucin levels with CA at 
concentrations of 15, 30 and 50 μmol/L. The highest level of MUC5AC mucin secretion was 
obtained with 15µmol/L of CA. The MUC5AC mucin levels reduced at 50 µmol/L CA but 
remained significantly above the control. The highest concentrations of CA (75 and 100 
µmol/L) did not increase MUC5AC production significantly. 
Figure 5-7 and Table 5-3 illustrates that exposure of NCI-H292 cells to CA at concentrations 
of 15, 30, 50, 75 and100 µmol/L caused MUC5B mucin levels to increase significantly. The 
highest level of MUC5B mucin production was with 15 µmol/L CA and there was an inverse 
dose-response to CA. 
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Figure 5-7: MUC5AC and MUC5B mucin release by NCI-H292 cells following exposure to CA for 48 hours. 
Indirect ELISA was used to measure MUC5AC and MUC5B levels in the supernatant. Statistical analysis was 
conducted using a one-way ANOVA test.  The data are representative of three independent experiments (n=6) 
(see table 5-3). Bars represent mean ± S.E.M values of each group. 
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  Cholic acid  
Concentration 
μmol/L 
15 30 50 75 100 
MUC5AC ↑*** ↑*** ↑** _______ _______ 
MUC5B ↑*** ↑*** ↑*** ↑** ↑* 
Table 5-3: The effect of different levels of Cholic acid on the NCL-H292 cell line following stimulation for 48 
hours, ↑ Increase demonstrated.  * Significant stimulation of MUC5AC and MUC5B release. (* = p<0.05, ** = p 
< 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Figure 5-8 and Table 5-4 demonstrate a significant increase in MUC5AC mucin levels, with 
CDCA at concentrations of 50, 75 and 100 μmol/L, but not at 15 and 30 µmol/L. The highest 
level of MUC5AC mucin production was at 50 µmol/L CDCA then declines as the 
concentration of CDCA increases up to 100 µmol/L.  
Moreover, Figure 5-8 and Table 5-4 show that exposure of NCI-H292 cells to CDCA at 
concentrations of 30, 50, 75 and 100 µmol/L caused MUC5B mucin levels to increase 
significantly, but this was not observed at concentrations of 15 µmol/L CDCA. MUC5B 
mucin levels increased significantly at 30 µmol/L CDCA and increased further to the 
maximum level of 75 µmol/L CDCA. The level of MUC5B mucin production then fell off at 
100 µmol/L CDCA but remained significantly higher than the control. 
 
C 1
5
3
0
5
0
7
5
1
0
0
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
3 .0
C h e n o d e o x y c h o lic  a c id  ( m o l/L )
(
g
/L
) M U C 5 A C
M U C 5 B
N C I -H 2 9 2  c e lls
 
Figure 5-8: MUC5AC and MUC5B mucin release by NCI-H292 cells following exposure to CDCA for 48 
hours. Indirect ELISA was used to measure MUC5AC and MUC5B levels in the supernatant. Statistical analysis 
was conducted using a one-way ANOVA test. The data are representative of three independent experiments 
(n=6) (see table 5-4). Bars represent mean ± S.E.M values of each group. 
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  Chenodeoxycholic acid  
Concentration 
μmol/L 
15 30 50 75 100 
MUC5AC _______ _______ ↑*** ↑** ↑* 
MUC5B _______ ↑** ↑***   ↑***   ↑** 
Table 5-4: The effect of different levels of Chenodeoxycholic acid on the NCL-H292 cell line following 
stimulation for 48 hours, ↑ Increase demonstrated.  * Significant stimulation of MUC5AC and MUC5B release.  
(* = p<0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA).  
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Levels of MUC5AC secreted by NCI-H292 cells into the culture medium were measured 
using indirect ELISA. It is obvious from the results presented in Figure 5-5 to Figure 5-8 that 
there was an inverse dose-response to LCA, DCA and CA, but not with CDCA. Low 
concentrations of LCA, DCA and CA give the highest response. By contrast, the MUC5AC 
levels significantly increased following stimulation by 50 μmol/L or above of CDCA. The 
CDCA showed no effect on cell viability, however it is possible that the assay was saturated 
and the signal out of the range of the absorbance measurement obscuring a change in cell 
number and that cell death accounted for the reduced MUC5AC levels, further experiments 
are necessary to clarify if this is the case Figure 3-15 A).   
Looking at MUC5B mucin production by NCI-H292 cells that were measured by indirect 
ELISA, it can be observed that primary BA (CA and CDCA) with 15 µmol/L of CA and 75 
µmol/L of CDCA caused the highest level of MUC5B mucin released. The second highest 
level of MUC5B mucin production occurred with 15 µmol/L of DCA; moreover, there was an 
inverse dose-response to DCA. Conversely, the LCA caused the lowest level of MUC5B 
mucin secretion due to cell death (see Figure 3-14A). Nevertheless, mucin production by LCA 
remains significantly higher than the control. 
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5.4.3 Effect of BA stimulation on the regulation of MUC5B and MUC5AC genes in 
NCI-H292 cells 
NCI-H292 cells were exposed to BAs for 48 hours to determine the effect on MUC5AC and 
MUC5B gene expression. Based on the ELISA results, BA concentrations that caused the 
highest levels of mucin were as follows: 1 and 5 µmol/L LCA; 15 and 30 µmol/L DCA; 15 
and 30 µmol/L CA; and 50 and 75 µmol/L CDCA. 
Figure 5-9  illustrates the MUC5AC mRNA levels determined using RT-PCR. All BA 
concentrations yielded increased MUC5AC expression. CA at 30µmol/L and 15 µmol/L of 
DCA caused the highest level of upregulation with six-fold increase, and the lowest level of 
upregulation was with 75 µmol/L CDCA, a five-fold increase. 
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Figure 5-9: MUC5AC mRNA expression following BA exposure. Confluent NCI-H292 cells were cultured for 
48 hours under the following conditions: no BA; 1 and 5 µmol/L LCA; 15 and 30 µmol/L DCA; 15 and 30 
µmol/L CA and 50 and 75 µmol/L CDCA. MUC5AC mRNA levels were normalised using HPRT1 mRNA and 
are presented as mean ±SEM (n=3). All treatment groups exhibited significant upregulation of MUC5AC 
mRNA. (*** = p < 0.001 compared with control, ANOVA). 
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Figure 5-10 illustrates MUC5B mRNA levels determined using RT-PCR. All BA 
concentrations yielded increased MUC5B expression. The lowest level of upregulation was 
with DCA, 30 µmol/L a three-fold increase and the highest was with CA, 30 µmol/L, a seven-
fold increase over control. 
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Figure 5-10: MUC5B mRNA expression following BA exposure. Confluent NCI-H292 cells were cultured for 
48 hours under the following conditions: no BA; 1 and 5 µmol/L l LCA; 15 and 30 µmol/L DCA; 15 and 30 
µmol/L CA and 50 and 75 µmol/L CDCA. MUC5B mRNA levels were normalised using HPRT1 mRNA and 
are presented as mean ±SEM (n=3). All treatment groups exhibited significant upregulation of MUC5B mRNA. 
(** = p < 0.01, *** = p < 0.001 compared with control, ANOVA). 
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5.4.4 Effect of BA stimulation on mucin production in Calu-3 cells, quantified using 
the PAS method 
Mucin secretion by Calu-3 cells was evaluated using the PAS assay, which enables a simple, 
direct assay in supernatants. Calu-3 cells were stimulated for 48 hours with BAs at 
concentrations between 15 and 100µmol/L.  
Figure 5-11 illustrates a significant increase in mucin production by Calu-3 cells challenged 
with 15 and 30 µmol/L LCA in comparison with unchallenged cells. However, 50, 75 and 100 
µmol/L LCA did not significantly induce mucin production. 
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Figure 5-11: Mucin released by Calu-3 cells following 48h LCA stimulation. PAS was used to measure mucin 
in cell supernatants, and this was statistically analysed using a one-way ANOVA test. P values of ≤ 0.05 were 
regarded as significant. These results are mean ± S.E.M values from (n=6) experiments. (*** = p < 0.001 
compared with control, ANOVA). 
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Figure 5-12 highlights a significant increase in mucin production by Calu-3 cells challenged 
with 15, 30, 50, 75 and 100 µmol/L DCA in comparison with unchallenged cells. Mucin 
production increased from 15 to 30µmol/L with the largest output produced by 30 µmol/L. 
There was a slow decline for 30 to 100 µmol/L DCA. 
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Figure 5-12: Mucin released by Calu-3 cells following 48h DCA stimulation. PAS was used to measure mucin 
in cell supernatants and this was statistically analysed using a one-way ANOVA test. P values of ≤ 0.05 were 
regarded as significant. These results are mean ± S.E.M values from (n=6) experiments. (* = p<0.05, ** = p < 
0.01, *** = p < 0.001 compared with control, ANOVA). 
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Figure 5-13 illustrates a significant increase in mucin production by Calu-3 cells challenged 
with 15, 30, 50, 75 and 100 µmol/L CA in comparison with unchallenged cells. The levels of 
mucin production were the same for all concentrations of CA. 
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Figure 5-13: Mucin released by Calu-3 cells following 48h CA stimulation. PAS was used to measure mucin in 
cell supernatants, and this was statistically analysed using a one-way ANOVA test. P values of ≤ 0.05 were 
regarded as significant. These results are mean ± S.E.M values from (n=6) experiments. (** = p < 0.01 compared 
with control, ANOVA). 
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Figure 5-14 reveals a significant increase in mucin production by Calu-3 cells challenged with 
15, 30, 50, 75 and 100 µmol/L CDCA in comparison with unchallenged cells. The highest 
effect occured at 15 µmol/L CDCA. The mucin level was then reduced at 50 and 75 µmol/L 
CDCA, with 100 µmol/L CDCA giving a similar response to 50 µmol/L CDCA. 
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Figure 5-14: Mucin released by Calu-3 cells following 48h CDCA stimulation. PAS was used to measure mucin 
in cell supernatants, and this was statistically analysed using a one-way ANOVA test. P values of ≤ 0.05 were 
regarded as significant. These results are mean ± S.E.M values from (n=6) experiments. (* = p<0.05 and *** = p 
< 0.001 compared with control, ANOVA). 
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In general, looking at mucin production by Calu-3 cells measured by PAS assay, it can be 
observed that 15 and 30 µmol/L of LCA had the highest level of mucin released; however, the 
higher concentrations did not cause mucin secretion due to cell death (see Figure 3-20A) . The 
second highest level of mucin production occurred with 15 µmol/L of CDCA. Moreover, it is 
clear there was an inverse dose-response to CDCA. In contrast, CA caused the lowest level of 
mucin secretion with no difference in the level of mucin production by the Calu-3 cells 
between any of the CA concentrations (Figure 5-11 to Figure 5-14). 
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5.4.5 Measurement of MUC5AC and MUC5B mucin in Calu-3 cells 
MUC5AC and MUC5B secretion by Calu-3 cells is also affected by BA exposure. Levels of 
MUC5AC secreted by cells into the culture medium were measured using indirect ELISA. 
Figure 5-15 and Table 5-5 illustrate that Calu-3 cell exposure to LCA at concentrations of 15, 
30 and 50 µmol/L caused MUC5AC levels to increase significantly compared with the 
control. MUC5AC mucin levels increased significantly at 15 µmol/L LCA and rose further to 
the maximum level at 30 µmol/L. The level of MUC5AC mucin production then fell off at 50 
µmol/L due to cell death with 51±3% but remained significantly higher than the control. 
However, there was no increase in MUC5AC mucin due to cell viability being greatly 
affected by LCA at 75μmol/L with 78±3% cell death and 100μmol/L with 98±3% cell death 
(see Figure 3-20A) 
Calu-3 cells also produce MUC5B mucin. These cells were exposed to BAs for 48 hours at 
concentrations ranging from 15 to 100μmol/L, revealing that exposure of Calu-3 cells to LCA 
at concentrations of 15, 30, 50 and 75 µmol/L caused MUC5B mucin levels to increase 
significantly (Figure 5-15 and Table 5-5). The highest level of MUC5B mucin release 
occurred with 15 µmol/L LCA. The levels reduced at 75µmol/L LCA but remained 
significantly above the control. There was no increase in MUC5B mucin due to cell viability 
being greatly affected by LCA at 100 μmol/L with 95±3% cell death (see Figure 3-20A)  
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Figure 5-15: MUC5AC and MUC5B mucin release by Calu 3 cells following exposure to LCA for 48 hours. 
Indirect ELISA was used to measure MUC5AC and MUC5B levels in the supernatant. Statistical analysis was 
conducted using a one-way ANOVA test.  The data are representative of three independent experiments (n=6) 
(see table 5-5). Bars represent mean ± S.E.M values of each group. 
 
  Lithocholic acid  
Concentration 
μmol/L 
15 30 50 75 100 
MUC5AC ↑*** ↑***   ↑*** _______ _______ 
MUC5B ↑*** ↑*** ↑** ↑* _______ 
Table 5-5: The effect of different levels of Lithocholic acid on the Calu 3 cells line following stimulation for 48 
hours, ↑ Increase demonstrated.  * Significant stimulation of MUC5AC and MUC5B release. (* = p<0.05, ** = p 
< 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Figure 5-16 and Table 5-6 reveal that Calu-3 cell exposure to DCA at concentrations of 15, 
30, 50, 75 and 100 µmol/L caused MUC5AC mucin levels to increase significantly compared 
with the control. The MUC5AC mucin levels increased significantly at 15 µmol/L DCA and 
rose further to the highest level at 50 µmol/L DCA. The level of MUC5AC mucin production 
then decreased at 75 and 100 µmol/L DCA due to cell death  (see Figure 3-21 B) while 
remaining significantly higher than the control.  
Moreover, Figure 5-16 and Table 5-6 illustrate that exposure of Calu-3 cells to DCA at 
concentrations of 15, 30, 50, 75 and 100 µmol/L caused MUC5B mucin levels to increase 
significantly though to a lesser extent than MUC5AC.  MUC5B mucin levels increased 
significantly at 15 µmol/L DCA and rose further to the maximum level at 50 µmol/L DCA. 
The level of MUC5B mucin production then fell off at 75 and 100 µmol/L DCA due to cell 
death  (see Figure 3-21 B) while remaining significantly higher than the control. 
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Figure 5-16: MUC5AC and MUC5B mucin release by Calu 3 cells following exposure to DCA for 48 hours. 
Indirect ELISA was used to measure MUC5AC and MUC5B and MUC5B levels in the supernatant. Statistical 
analysis was conducted using a one-way ANOVA test. The data are representative of three independent 
experiments (n=6) (see table 5-6). Bars represent mean ± S.E.M values of each group. 
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  Deoxycholic  acid  
Concentration 
μmol/L 
15 30 50 75 100 
MUC5AC   ↑*** ↑***  ↑****     ↑***     ↑*** 
MUC5B ↑** ↑*** ↑*** ↑* ↑* 
Table 5-6: The effect of different levels of Deoxycholic acid on the Calu-3 cells line following stimulation for 
48 hours, ↑ Increase demonstrated.  * Significant stimulation of MUC5AC and MUC5B release. (* = p<0.05, ** 
= p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Figure 5-17 and Table 5-7 highlight that Calu-3 cell exposure to CA at concentrations of 15, 
30, 50, 75 and 100 µmol/L caused MUC5AC mucin levels to increase significantly compared 
with the control. The highest level of MUC5AC mucin secretion was with 15 µmol/L of CA 
and the mucin level then reduced to 50 µmol/L CA. This decreased further to the lowest level 
at 75, 100 µmol/L CA but no difference was found in the level of mucin production between 
75 and 100 µmol/L CA. 
Figure 5-17 and Table 5-7 highlight that exposure of Calu-3 cells to CA at concentrations of 
15, 30 and 50 µmol/L caused MUC5B mucin levels to increase significantly, again to a much 
lesser extent than seen with MUC5AC. The highest level of MUC5B mucin release occurred 
with 15 µmol/L CA. The levels reduced to 50µmol/L CA but remained significantly above the 
control. There was no increase in MUC5B mucin due to cell viability being significantly 
affected by CA at 75 and 100 μmol/L (see Figure 3-21A). 
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Figure 5-17:  MUC5AC and MUC5B mucin release by Calu 3 cells following exposure to CA for 48 hours. 
Indirect ELISA was used to measure MUC5AC and MUC5B levels in the supernatant. Statistical analysis was 
conducted using a one-way ANOVA test. The data are representative of three independent experiments (n=6) 
(see table 5-7). Bars represent mean ± S.E.M values of each group. 
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  Cholic acid  
Concentration 
μmol/L 
15 30 50 75 100 
MUC5AC ↑*** ↑***     ↑*** ↑** ↑** 
MUC5B ↑*** ↑*** ↑* _______ _______ 
Table 5-7: The effect of different levels of Cholic acid on the Calu-3 cells line following stimulation for 48 
hours, ↑ Increase demonstrated.  * Significant stimulation of MUC5AC and MUC5B release. (* = p<0.05, ** = p 
< 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Figure 5-18 and Table 5-8 illustrate that Calu-3 cell exposure to CDCA at concentrations of 
15, 30, 50, 75 and 100 µmol/L caused MUC5AC mucin levels to increase significantly 
compared with the control. The highest effect occurred at 15 µmol/L CDCA. The MUC5AC 
mucin level then reduced to 30 µmol/L CDCA, followed by a slow decline for 30 to 100 
µmol/L CDCA. 
Figure 5-18 and Table 5-8 demonstrate that exposure of Calu-3 cells to CDCA at 
concentrations of 15, 30, 50 and 75 µmol/L caused MUC5B mucin levels to increase 
significantly. The highest level of MUC5B mucin release occurred with 15 µmol/L CDCA. 
The levels MUC5B mucin reduced to 75µmol/L CDCA but remained significantly above the 
control. However, no significant increase was observed using concentrations of 100 µmol/L 
CDCA due to cytotoxicity (see Figure 3-21 B). 
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Figure 5-18: MUC5AC and MUC5B mucin release by Calu 3 cells following exposure to CA for 48 hours. 
Indirect ELISA was used to measure MUC5AC and MUC5B levels in the supernatant. Statistical analysis was 
conducted using a one-way ANOVA test. The data are representative of three independent experiments (n=6) 
(see table 5-8). Bars represent mean ± S.E.M values of each group. 
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  Chenodeoxycholic acid  
Concentration 
μmol/L 
15 30 50 75 100 
MUC5AC ↑**** ↑*** ↑*** ↑*** ↑*** 
MUC5B ↑* ↑* ↑* ↑* _______ 
Table 5-8: The effect of different levels of Chenodeoxycholic acid on the Calu-3 cells line following stimulation 
for 48 hours, ↑ Increase demonstrated.  * Significant stimulation of MUC5AC and MUC5B release. (* = p<0.05, 
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001 compared with control, ANOVA). 
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Levels of MUC5AC secreted by Calu-3 cells into the culture medium were measured using 
indirect ELISA. It is evident from results outlined in Figure 5-15 to Figure 5-18 that 15 and 
30 µmol/L (low concentration) of LCA, CA and CDCA had the highest level of mucin 
released. Conversely, 50 µmol/L of DCA produced the highest response. 
Looking at MUC5B mucin production by Calu-3 cells measured by indirect ELISA, we can 
observe that it was much lower than MUC5AC. The highest level of MUC5B mucin 
production occurred with 15 µmol/L of LCA with 7 mg/L, while the highest level of 
MUC5AC mucin production at 15 µmol/L of LCA was 25 mg/L. The 50 µmol/L of DCA had 
the highest effect on MUC5B and MUC5AC mucin production between all DCA 
concentrations. Moreover, there was an inverse dose-response to LCA, CA and CDCA. 
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5.4.6 Effect of BAs on regulation of MUC5B and MUC5AC Genes in Calu-3 cells 
Hypersecretion of mucus can also be detected through changes in gene expression, in 
particular, an increased expression of the genes for MUC5AC and MUC5B. Under 
investigation, Calu-3 cells were exposed to BAs for 48 hours to determine the effect on 
MUC5AC and MUC5B gene expression. Based on the previous ELISA results, BA 
concentrations that caused the highest levels of mucin production were used, as follows: 15 
and 30 µmol/L LCA; 30 and 50 µmol/L DCA; 15 and 30 µmol/L CA; and 15 and 30 µmol/L 
CDCA. 
Figure 5-19 illustrates the MUC5AC mRNA levels determined using RT-PCR. All BA 
concentrations yielded increased MUC5AC expression. LCA at concentration 30µmol/L and 
50 µmol/L of DCA caused the highest level of upregulation with eight-fold increase, and the 
lowest level of upregulation was with DCA 30 µmol/L and LCA 15, a six-fold increase. 
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Figure 5-19: MUC5AC RNA expression following BA exposure. Confluent Calu-3 cells were cultured for 48 
hours under the following conditions: no BA; 15 and 30 µmol/L LCA; 30- and 50 µmol/L DCA; 30 and 75 
µmol/L CA and 15 and 30 µmol/L CDCA. MUC5AC mRNA levels were normalised using HPRT1mRNA and 
are presented as mean ±SEM (n=3). All treatment groups exhibited significant upregulation of MUC5AC 
mRNA. (*** = p < 0.001 compared with control, ANOVA). 
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Figure 5-20 reveals the MUC5B mRNA levels determined using RT-PCR. All BA 
concentrations yielded increased MUC5B expression. LCA and DCA at concentration 30 
µmol/L induced nine-fold increases, and the lowest level of upregulation was with DCA 50 
µmol/L, a six-fold increase. 
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Figure 5-20: MUC5B RNA expression following BA exposure. Confluent Calu-3 cells were cultured for 48 
hours under the following conditions: no BA; 15 and 30 µmol/L LCA; 30 and 50 µmol/L DCA; 30 and 75 
µmol/L CA and 15 and 30 µmol/L CDCA. MUC5B mRNA levels were normalised using HPRT1 mRNA and 
are presented as mean ±SEM (n=3). All treatment groups exhibited significant upregulation of MUC5B mRNA. 
(*** = p < 0.001 compared with control, ANOVA). 
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5.5 Discussion 
Mucus is a critical factor in protecting the lungs and the rest of the airway system against 
foreign objects, toxins and pathogenic agents. Mucus hypersecretion is associated with 
various airway disorders, including COPD, CF and asthma (Lange and Vestbo, 2016; 
Theilmann et al., 2016). When gastric contents, including BAs, make their way into the 
airway, the mucosa may incur damage, resulting in symptoms that include overproduction of 
mucous (Fox and Forgacs, 2006). Such pathologies are often caused by aspiration of gastric 
reflux contents (Brownlee et al., 2016). Previous research, for example, has found a positive 
correlation between the presence of pepsin in the airway and mucus production. 
Stovold et al. noted that exposure of goblet cells (cell line HT29-MTX) to pepsin caused 
MUC5AC mucin levels to increase significantly. In this study, HT29-MTX cell lines were 
stimulated with 50 µg/ml pepsin at pH 7.4 and 50 µg/ml pepsin at pH 7.0. The level of 
MUC5AC production was measured by indirect ELISA. This study found that pepsin at pH 
7.0 significantly increased HT29-MTX cell mucin production from a baseline of 18µg/ml to 
26µg/ml at 72h (Stovold et al., 2008). 
The present study seeks to explore the production of MUC5AC mucin and MUC5B mucin in 
NCI-H292 and Calu-3 cells exposed to BAs at a range of concentrations. The toxic effect of 
BAs on the colonic mucosa (Turjman and Nair, 1981; Owen et al., 1984), and gastric mucosa 
(Gadacz and Zuidema, 1978; Gillen et al., 1988) is well researched, but less is known about 
the effect of BAs on oesophageal mucosa (Nasr et al., 2013). This study builds on the strong 
literature base linking oesophageal acid exposure to both mucosal damage and Barrett’s 
oesophagus, with its attendant complications (Legrand et al., 1990; Iftikhar et al., 1993; 
Takahashi et al., 2011). 
It is not yet known exactly how bile acids damage mucosal cells. The most likely mechanisms 
are either a) by detergent action or b) as free acids. BAs are capable of intracellular 
accumulation, causing mitochondrial toxicity and intramucosal damage. The BAs are able to 
breach the mucosal barrier in the stomach. Moreover, their detergent action may be far more 
damaging in the lungs, by disturbing the mucus layer and disrupting the surfactant-based 
lipids (Iftikhar et al., 1993; Jolly et al., 2004). 
BA concentrations greater than 1mmol/l are toxic to oesophageal mucosa in vivo (Gotley et 
al., 1991). Furthermore, the damaging effect of some BAs is significantly increased by the 
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presence of H⁺ ions, which renders them more hydrophobic (Hopwood et al., 1981; Gotley et 
al., 1991; Kauer et al., 1997). Levels of BA hydrophobicity are correlated with, for example, 
oxygen free radical production, which in turn influences their disruptive detergent effect 
(Toohill and Kuhn, 1997). The induction of apoptosis (Iftikhar et al., 1993) the induction of 
mucosal ornithine decarboxylase activity followed by stimulation of proliferation, and 
mitochondrial membrane disruption. Intracellular ionisation may be partially responsible for 
the accumulation of BAs in the oesophageal mucosa, which can reach up to seven times that 
of luminal BA concentrations. It is also thought that intracellular BA accumulation might be 
related to their ability to induce pathophysiological alteration in mucosal permeability and 
disrupt the mucosal barrier to diffusion (Schweitzer et al., 1986; Kauer et al., 1997). 
Due to the lack of reliable assay techniques there is considerable variability in the levels of 
detection of bile acids in healthy people and patients with respiratory disease which makes 
comparisons difficult. Indeed, BAL analysis has been the most popular form of study so far. 
This method has inherent problems, as it involves perfusion of the airways with 100-200 ml 
of fluid (180ml common), resulting in BAL appearing more dilute in terms of BAs (Perng et 
al., 2008; Zecca et al., 2008; Aseeri et al., 2012). BOS patients who have also received a lung 
transplant have been reported to exhibit greatly increased BA levels in BAL fluid, up to 32 
µmol/L compared to normal level which is from 0 to 16 µmol/L (D’Ovidio et al., 2005). 
Oesophageal bile acid levels which are considered normal – even in Barrett’s oesophagus – 
are between 0 and 200μmol/L and very rarely exceed 1000μmol/L. No bile acids are detected 
at all in about 25% of patients with reflux (Gotley et al., 1991). Patients with respiratory 
disease had higher level of bile acids in sputum. For example, the concentration of BAs found 
in sputum of patients with CF was 3.3μmol/l and with chronic cough patients 0.72μmol/l. A 
study of 38 patients was performed and only 16 who had DF508 (Delta-F508) homozygote 
genotype proved to have bile acids in sputum. DF508 (Delta-F508) is a common mutation 
within the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. 
This mutation is the most common cause of cystic fibrosis (CF) (Stanke, Ballmann et al. 
2008). On the other hand, bile acids were found in sputum of 4/10 chronic unexplained cough 
patients. No bile acids were found in healthy controls (Blondeau et al., 2008b). The effect of 
combinations of bile acids on the cell lines used in this study would be something for future 
research to address. Our own research group investigated the effect of combinations of bile 
acids on PBECs. Cells were stimulated with a bile acid mixture. The results showed that there 
was no significant changes in the levels of IL-8, IL-6 and GMCSF from PBECs after 
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stimulation with bile acid mixture (Aseeri, 2012). It is possible that the lack of stimulating 
effect of the mixture is because the conjugated bile acids are having an inhibitory effect 
(Pearson et al., 2011).  
Understanding the mechanisms inherent to chronic airway diseases relies on in vitro models, 
using primary epithelial cells and cell lines (Stewart et al., 2012). Primary cells are frequently 
considered the ‘gold standard’ for such research, but they do carry some disadvantages; for 
example, limited lifespan, variability between donors, passage number and cost. 
Consequently, further experiments using cell lines are required for validation. 
Calu-3 and NCI H292 cells are used commonly in vitro for gene regulation studies. These 
epithelial cell lines are derived from carcinomas and have the significant advantage of 
allowing the study of both MUC5 mRNA and MUC5 glycoprotein in the same model (Berger 
et al., 1999; Rose et al., 2000). 
This study found primarily that stimulation by BAs caused NCI-H292 and Calu-3 cells to 
secrete MUC5AC mucin and MUC5B mucin. It is, to the best of my knowledge, the only 
study that determines the effects of BA exposure on mucin expression and mucus 
overproduction by airway epithelial cells. MUC5B and MUC5AC are predominant in airway 
secretion and were, therefore, chosen as markers for screening. 
Berger et al. identified three carcinoma cell lines of respiratory tract tissue origin. Of these, 
Calu-3 and NCI-H292 both expressed MUC1, MUC4, MUC5AC, and MUC5B genes in 
varying combinations. Currently, it is held that MUC1, MUC4, MUC5AC and MUC5B are 
well expressed in both a healthy respiratory tract and lung cancer tumour tissues. MUC2 is 
less well expressed, suggesting that both normal and tumour respiratory epithelium Calu-3 
and NCI-H292 cell lines present similar mucin gene profiles (Berger et al., 1999). 
In this study, the supernatant was analysed for mucin, using a PAS assay which showed that the 
glycoprotein (mucin) content of NCI-H292 and Calu-3 cells secretions increased significantly. PAS 
assay is used routinely to detect mucin production by cells. The results of this study indicate that LCA, 
DCA, CA and DCA caused a significant increase in mucin production from NCI-H292 cells at all 
concentration, except 100µmol/l of CDCA and 15µmol/l of DCA. Moreover, this experiment 
detected the significant level of mucin after stimulating Calu-3 cells with DCA, CA and 
CDCA at all concentrations. LCA caused a significant increase at concentrations 15 and 30 
µmol/l, but the results did not reveal any increase at concentrations 50, 75 and 100 µmol/l due 
possibly to cell death. 
208 
 
 However, this technique was not sensitive enough to identify mucin, so an indirect ELISA 
was therefore used for additional analysis. These findings revealed that NCI-H292 cells 
produced maximal levels of MUC5AC and MUC5B following stimulation with the 
subsequent BA for 48 hours at concentrations: 1 and 5 µmol/L LCA; 15 and 30 µmol/L DCA; 
15 and 30 µmol/L CA; and 50 and 75 µmol/L CDCA. Similarly, Calu-3 cells produced 
maximal levels of MUC5AC and MUC5B following stimulation with the following BA for 
48 hours at concentrations: 15 and 30 µmol/L LCA; 30 and 50 µmol/L DCA; 15 and 30 
µmol/L CA; and 15 and 30 µmol/L CDCA, returning to basal levels. 
The results in this chapter demonstrated that low concentrations of bile acids stimulate 
significant MUC5AC and MUC5B production in NCI-H292 and Calu-3 cells, although higher 
bile acid concentrations yielded no significant increase in production. High concentrations of 
LCA affect cell viability (see Figure 3-14A and Figure 3-20A), and this was associated with 
no increase in MUC5AC and MUC5B mucins (see Figures 5-21 and 5-22). It was found 
however, that CA in high concentrations downregulated production of MUC5AC and 
MUC5B (see Figures 5-23and 5-24), whilst having no effect on cell viability (see Figure 
3-14A and Figure 3-20A). It can be inferred from these findings that the negative correlation 
between BA concentration and mucin production must be caused by factors other than cell 
viability. These factors are as yet unknown, but the following explanations are possible. First, 
downregulation of mucin production may be caused by extracellular matrix (ECM). Iwashita 
et al. (2010) found that type-IV collagen, found in ECM, inhibits MUC5AC production via 
integrin-signalling pathways. Integrins are the primary receptors involved in cell-cell and cell-
ECM adhesion. These heterodimers comprise of α2- and β-subunits, which bind cells to 
collagen, activating integrin signalling pathways, which in turn, can activate multiple types of 
gene expression. The researchers suggest that this process is involved in a previously 
unknown type of MUC5AC regulation involving integrins and ECM components. My study 
found that BA exposure stimulated ECM (Pro-collagen and fibronectin) expression (see 
chapter 4), further confirming the findings by Iwashita et al. (2010).   
Secondly, in vitro studies reveal that MUC5AC and MUC5B expression are stimulated by IL-
8 and IL-6 (Smirnova et al., 2002; Smirnova et al., 2003). On the other hand it has also been 
found that mucin genes and mucin secretion can be downregulated by certain inflammatory 
mediators, including IL-4 and IL-13 (Jayawickreme et al., 1999; Kim et al., 2002a). NHTBE 
cell cultures, when exposed to IL-4 exhibited a reduction in mucin secretion, and MUC5AC 
and MUC5B gene expression (Jayawickreme et al., 1999). Further to this, Kim et al. 
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confirmed the link between inflammatory mediators and mucin production by studying mucin 
gene expression and mucin secretion in human nasal epithelial cells when exposed to IL-13. 
Using an immunoblotting assay, they found that total mucin secretion and MUC5AC gene 
expression substantially decreased after exposure to IL-13 (Kim et al., 2002a). Consequently, 
it could be the case that high enough concentrations of bile acids can lead to an inflammatory 
release involving IL-4 and IL-13, thereby significantly affecting MUC5 regulation. Third, as 
bile acids accumulate they inhibit intracellular function which does not kill the cell but 
reduces the rate of all cellular processes such as protein synthesis (Tabas, 2002).  
In one study, Gosalia et al. demonstrated that mucus was produced by Calu-3 cells. The 
purpose of this study was to identify the regulatory mechanisms that control the expression of 
the genes within the gel-forming mucin gene cluster located at chromosome 11p15.5. In order 
to compare the individual mucin genes within a cell type, absolute quantification was used to 
measure mucin gene expression. Standard curves generated on cloned cDNAs for each gene 
were used to calculate the gene expression for the four gel-forming mucin genes (MUC2, 
MUC6, MUC5B and MUC5AC). In picomolar amounts, absolute expression was calculated 
in LS180 cDNA. It was demonstrated by these results that the lung carcinoma cell lines Calu-
3 and A549 both express MUC5AC mRNA, but that MUC5B mRNA is only expressed by 
A549 cells. Moreover, the significance of the CCCTC-binding factor (CTCF) sites to mucin 
gene expression was also demonstrated by this study when Calu-3 lung carcinoma cells were 
exposed to lipopolysaccharide (LPS). In this experiment, it was found that the LPS up-
regulation of MUC5AC and MUC2, and the repression of MUC5B transcription is 
accompanied by a depletion in the binding of CTCF at specific sites. Further, the treatment 
with LPS significantly reduced the expression of MUC5B, which would suggest a 
coordinated regulatory mechanism for the gene cluster, whereby the up-regulation of one or 
several gel-forming mucins is followed by the down-regulation of others. The mechanism 
whereby the expression of MUC5B is reduced may result in repressive histone modifications 
being established, which is consistent with previous observations on MUC5B regulation 
(Gosalia et al., 2013).  
Both surface epithelial cells and submucosal glands produce MUC5AC (Audie et al., 1993), 
but MUC5B tends only to be detected in submucosal glands (Berger et al., 1999). 
Consequently, it was expected that this study would find higher MUC5B levels in Calu-3 
cells, which are derived from submucosal glands (Kreda et al., 2007), where MUC5B is 
relatively greater than MUC5AC (Grainger et al., 2009).The ELISA assay in this study found 
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that both NCI-H292 and Calu-3 cells expressed MUC5AC and MUC5B. Kreda et al. (2007) 
used gel electrophoresis to quantify MUC5AC and MUC5B levels in Calu-3 cells, finding 
relatively low MUC5B levels in comparison with MUC5AC. The present study’s findings, 
therefore, concur with the literature (Kreda et al., 2007). 
Moreover, the lack of MUC5B induction by agonists of mucin synthesis and secretion 
suggests that its resulting mucin may be constitutively expressed. Ordinarily, basal mucin 
synthesis and secretion levels are maintained by MUC5B levels in airways. However, in cases 
of chronic airway diseases, enlargement of the submucosal glands may cause increased mucin 
secretion due to more cells being involved in MUC5B synthesis. In such situations, there is an 
advantage in having an alternative inducible mucin, MUC5AC, which can respond rapidly to 
irritants. Furthermore, such diseases often cause biochemical changes in airway mucus 
(Davies et al., 1996; Berger et al., 1999). This may be caused in part by differential regulation 
of airway mucins, both inducible and non-inducible. 
In this study, the total mucin was measured using a PAS assay. PAS assay is used routinely to 
detect mucin production by cells. However, this technique was not sensitive enough to 
identify mucin (Mantle and Allen, 1978). The differences between specific ELISA methods 
and the PAS method may be accounted for by the fact that the PAS assay is not solely specific 
to mucin. The PAS assay measures all carbohydrate containing molecules and is interfered 
with by protein and lipid to some extent.   
The most physiologically relevant cell type to evaluate airways damage was arguably primary 
human bronchial epithelial cells (PHBECs). However, these are costly and not easy to culture 
(Stewart et al., 2012). Moreover my results showed that it was possible to maintain primary 
epithelial cells for 2-3 passages on a plastic surface, but the populations are heterogeneous, 
and the mucin expressing phenotype has not been observed.  
Conversely, Berger et al. (1999) have found that carcinoma cell lines can be grown, 
maintained and passaged from epithelial samples. Our understanding of diseases such as 
COPD, CF, asthma and other inflammatory processes have benefited from such investigative 
models. Early models used submerged monolayer cell cultures on a plastic substrate. 
However, Sachs et al. (2003) found that using a defined medium and an air-liquid interface 
(ALI) to culture primary human bronchial epithelial cells (HBECs), enabled a more 
physiological model, thereby driving a differentiated phenotype. Studies using this model 
have observed a pseudostratified polarised phenotype, which incorporates both ciliated and 
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goblet cells, and exhibits high transepithelial electrical resistance (TEER) (Jiang et al., 2001; 
Chan et al., 2010). 
The formation of tight junctions can be measured indirectly via TEER, which can indicate 
epithelial layer disruption (Pedemonte, 1995), although it must be noted that ALI models 
exhibit limited capacity for cell differentiation. Calu-3 cells, for example, are similar to 
primary cells in terms of features (Stewart et al., 2012), but are also able to express apical 
MUC5, although they cannot form cilia (Grainger et al., 2006). 
Several studies have been carried out to investigate MUC gene regulation in NCI-H292 cells 
in vitro. Factors implicated in the upregulation of MUC5AC expression include: Cigarette 
smoke (Baginski et al., 2006), Interleukin-1β (Kim et al., 2002b), IL-4 (Dabbagh et al., 1999) 
and IL-17 (Chen et al., 2003). Borchers et al. (1999) studied the effects of TNF-α on 
MUC5AC and MUC5B steady-state mRNA levels in NCI-H292 cells, finding that TNF-α 
regulates MUC5AC but not MUC5B. They concluded that the pathogenesis of obstructive 
airway disease is caused partly by direct exposure to irritants, as well as inflammatory 
mediators, which increase the synthesis of mucin mRNA in airway epithelial cells (Borchers 
et al., 1999). NCI-H292 cells also produce mucus glycoconjugates. IL-6 expression in NCI-
H292 cells has also been investigated and found to increase mucin gene expression as well as 
mucin production (Louahed et al., 2000). 
Mucin upregulation is believed to be caused by the binding of these factors to specific surface 
cell receptors, such as P2Y2 and toll-like receptors (Voynow et al., 2006). Furthermore, 
mucin gene regulation is influenced by stimulation of the epidermal growth factor receptor 
(Takeyama et al., 1999). Once these receptors are bound (through a variety of stimulants), 
mitogen-activated protein kinase (MAPK) pathways are activated, triggering the activation of 
nuclear factor kappa B (NFKB), a transcription factor that also regulates mucin gene 
expression (Rose and Voynow, 2006). To elucidate the role of MUC5AC as a treatment target 
in bile duct inflammation, recent research has focused on the effect of lipopolysaccharide 
(LPS) stimulation on MUC5AC mRNA and protein expression. They further explored the 
role of p38 MAPK regulating MUC5AC in bile duct inflammation. Their results 
demonstrated that p38 MAPK can affect airway inflammation and gastric epithelial cell 
apoptosis by the influence of LPS induced bile duct inflammation by regulating MUC5AC 
expression (Xiong et al., 2016). 
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In vitro studies reveal that MUC5AC and MUC5B expression are also stimulated by IL-8 (a 
mucin secretagogue), IL-6 and GM-CSF (Smirnova et al., 2002; Smirnova et al., 2003). The 
connection between BAs and mucus secretion is, therefore, further elucidated by findings 
around the effects of BA exposure on IL-8, IL-6 and GM-CSF production, as described in 
chapter three. The epithelium produced IL-8 to combat toxins or pathogens that have made 
their way into the lung. The present study found that BA stimulation significantly increased 
IL-8 production in both NCI-H292 and Calu-3 cell lines. 
Stimulation of PHBECs by BAs was also found to stimulate GM-CSF production. GM-CSF is 
a growth factor involved in the regulation and control of neutrophils. The findings from this 
study (see Chapter 3) showed that aspiration of BAs can lead to neutrophilic inflammation, 
tissue remodelling (Walters et al., 2008) and mucus hypersecretion (Smirnova et al., 2002; 
Smirnova et al., 2003), causing potential lung injury. 
Other cytokines may also influence mucin production and secretion. Chen et al. (2003) 
exposed differentiated human primary tracheobronchial epithelial cells to various cytokines, 
including interleukins-1α&β, 13 and TNF-a, in an air-liquid interface culture. The study found 
that IL-6 and IL-17 stimulation resulted in elevated MUC5AC. Further investigation explored 
IL-17 stimulation of IL-6 production in bronchial epithelial cells, to determine if mucin 
expression might be mediated through an IL-6 paracrine/autocrine loop. MUC5 expression 
mediated by IL-17 was shown to decrease significantly when a neutralising IL-6 antibody was 
introduced (Chen et al., 2003). Airway epithelial cells also produce IL-6, so it is possible that 
BA stimulation of NCI-H292 and Calu-3 cells may, therefore, promote increased mucin 
production via a cytokine induction mechanism, resulting in further obstruction of previously 
injured airways (see Chapter 3). 
BA aspiration can also damage the pulmonary system (el-Serag and Sonnenberg, 1997; 
Wilshire et al., 2013) and cell membranes are especially vulnerable to bile damage, as shown 
by studies on Type II pneumocytes in vitro (D’Ovidio et al., 2005; D'Ovidio and Keshavjee, 
2006). Type II pneumocytes in the lungs are responsible for surfactant protein and 
phospholipid production and are therefore especially vulnerable to lipid disruption as a result 
of mucus barrier damage. 
In conclusion, patients with advanced lung disease, particularly CF (Blondeau et al., 2008a; 
Pauwels et al., 2012),COPD (Rascon-Aguilar et al., 2006), and ventilator-associated 
pneumonia (Wu et al., 2009), often also present with gastroesophageal reflux (GERD) 
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(Legendre et al., 2014). Many of these diseases also display mucin hypersecretion. The 
current study’s findings make a strong contribution to the argument that claims exposure to 
BAs strongly influences mucus production, potentially leading to – or furthering – airway 
injury. The present study focussed on Calu-3 and NCI H292 cells, exposing these to varying 
BA concentrations. The findings established Calu-3 and NCI H292 cells as good models for 
gene regulation studies in vitro. The broader study also found that NCI-H292 and Calu-3 
production of IL-8, IL6 and GM-CSF is heavily influenced by BA stimulation (see Chapter 
3). A potential connection, therefore, exists between increased mucus secretion and IL-8, IL6 
and GM-CSF production. 
 
Figure 5-25: diagram showing proposed influences of BAs in mucus production (Adapted from Varielle., 2011 
(Vareille et al., 2011)) 
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CHAPTER 6: GENERAL DISCUSSION AND CONCLUSION 
Lung disease is one of the world’s greatest causes of mortality and morbidity, and these cases 
are on the rise. As an example, COPD is the fifth largest cause of death worldwide, while 
interstitial lung disease (ILD) and cystic fibrosis (CF) are also prevalent with negative 
consequences such as a low life-quality and death. All these diseases are to some extent 
influenced by either chronic or acute inflammation, (Rincon and Irvin, 2012). For some 
considerable time, the connection between GOR and lung disease has come under suspicion 
(Pearson and Wilson, 1971; Belsey, 1979; D’Ovidio et al., 2005).  
In patients suffering from lung disease of varying types, the prevalence of GOR has in fact 
been recorded: for example abnormal levels of GOR have been identified in patients with 
idiopathic pulmonary fibrosis, cystic fibrosis (CF) and asthma (Feigelson et al., 1987; Tobin 
et al., 1998; Prather et al., 2014). Additionally, the development of pneumonia and 
bronchiolitis obliterans has also been linked to GOR (Liu et al., 2015). 
For chronic respiratory diseases such as the chronic cough (Sifrim et al., 2005; Houghton et 
al., 2016), cystic fibrosis (Blondeau et al., 2008a; Brodlie et al., 2015), and asthma (Harding, 
2001; Rosztóczy et al., 2008; Houghton et al., 2016), it has been identified by 
pathophysiological studies that gastroesophageal reflux (GOR) could be a common instigator. 
Moreover, an increased GOR following a lung transplantation (LTx) can also lead to 
bronchiolitis obliterans syndrome (BOS) or chronic rejection (Palmer et al., 2000; Young et 
al., 2003; D’Ovidio and Keshavjee, 2006; Blondeau et al., 2008a).  Exposure to gastric 
contents can also damage both nonciliated and ciliated epithelial cells within the airway 
(Wynne et al., 1981; Ohrui et al., 1997; Harding, 2001; Blondeau et al., 2008b).  
Furthermore, gastric contents that are aspirated impair mucociliary transport and facilitate the 
growth of bacteria within the airway tract (Zeiher and Hornick, 1996; D’Ovidio and 
Keshavjee, 2006). It is increasingly accepted that rather than being sterile as once taught that 
even in normal subjects there is a microbiome associated with the human respiratory system. 
Research into respiratory biomes is often concerned with detecting signature indicators of 
Cystic Fibrosis (CF) (Surette, 2014), Chronic Obstructive Pulmonary Disease (COPD) (Han 
et al., 2012) and, more recently, asthma and non-CF bronchiectasis (Boyton et al., 2013; 
Huang and Boushey, 2015). In particular, the pathogen Pseudomonas aeruginosa is being 
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increasingly associated with COPD and is strongly linked with intense airway inflammation 
and worse outcomes for COPD patients (Lin et al., 2007; Murphy et al., 2008).  
Bacterial enzyme action aids primary BA deconjugation into free bile acids. More 
specifically, the hydroxyl (OH) group is detached from the seventh carbon atom by the 
enzyme 7 alpha-dehydroxylase. Gastro-oesophageal reflux disease (GORD) patients 
undergoing therapy which targets acid suppression can exhibit overgrowth of bacteria in the 
intestine. In turn, this causes BAs to deconjugate, resulting in a greater number of 
unconjugated BAs in circulation that are more toxic (Solaas et al., 2000).  
For patients with such respiratory diseases, BA aspiration into the lungs has been found to be 
a significant co-morbidity factor (Aseeri et al., 2012; Reen et al., 2014). For patients with CF, 
there is a correlation between BA aspiration and both reduced biodiversity as well as 
increased levels of dominant Proteobacterial pathogens (Reen et al., 2012; Reen et al., 2014). 
In general, the presence of BAs in the respiratory tract is associated with increased 
inflammation (D’Ovidio et al., 2005).  
Among other findings, our own research group demonstrated that BA concentrations similar 
to those found in the stomach could have a negative impact on P. aeruginosa growth. 
Furthermore, P. aeruginosa behaviour was also altered when exposed to different BAs in 
different concentrations. The study found that P. aeruginosa exposure to BAs resulted in a 
tendency to form a biofilm, and the different BAs at different concentrations affected the type 
of biofilm formed. Moreover, this study confirms the ability of bacteria to survive in the 
stomach, constituting a potential reservoir of viable pathogens relevant to CF disease (Al-
Momani et al., 2016).  
Reen et al. (2016) carried out a systems-based analysis on P. aeruginosa – which is primarily 
associated with morbidity and mortality in CF patients – and other pathogens, to gain an 
understanding of their chronic response and the response of host cells to BA aspiration. An 
integrated approach was taken, drawing on transcriptomics, functional genomics and 
immunochemistry, which found that the bile response in both pathogen and host cells was 
underpinned by a network of genes linked to virulence, adaptive metabolism, and antibiotic 
tolerance. A chronic response could be elicited by individual BAs and chenodeoxycholic acid 
(CDCA) was found to signal across both pathogen and host cell interfaces. Distinct profiles 
were found for BA aspiration and non-aspiration through longitudinal analysis of the 
paediatric CF microbiome. Isolates from these patients underwent phenotypic analysis, which 
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found responses mostly conserved to physiologically relevant BA concentrations, although 
the study did find evidence of phenotypic heterogeneity (Reen et al., 2016). This study 
potentially significantly increases the understanding around the molecular mechanisms by 
which respiratory pathogens are stimulated by BAs to convert from an acute virulent lifestyle 
to a chronic infection phase, in particular P. aeruginosa. Antibiotic challenge has little effect 
on such chronic biofilm infections, which is noteworthy in the context of increased tolerance 
to the polymyxin and macrolide classes of antibiotics observed in the presence of bile. 
My overall hypothesis would be that the presence of BAs in the lungs of patients with 
respiratory disease – usually through aspiration – plays a significant role in the deterioration 
of lung function leading to increased morbidity and that the interaction of BAs with the 
respiratory microbiome could be a significant factor in this. 
A recent study has also shown that aspiration of non-sterile gastric juice may be a source of 
microbiological challenge in patients with CF. Aside from injuring the lung directly, aspirated 
acid also leads to release of the inflammatory cytokine IL-8, as measured in alveolar and 
bronchoalveolar lavage fluid (Zeiher and Hornick, 1996). 
Additionally, unusually high reflux levels are also experienced by children and adults 
suffering from CF (Ledson et al., 1998; Blondeau et al., 2008b; Aseeri et al., 2012; Brodlie et 
al., 2015). Furthermore, there is a growing consensus that non-acidic and clinically hidden, 
aspiration and reflux may be a substantial cause of lung injury (Blondeau et al., 2008b) and 
include a microbiological challenge to the lung (Al-Momani et al., 2016). Because of the 
neutralising effects present in duodenal contents, a duodeno-gastro-oesophageal refluxate has 
a higher tendency to be non-acidic, and also has the potential of containing bile acids which 
have associated biological effects.  Levels of BA up to the millimolar level have been found 
in refluxate obtained from GORD patients (Lefebvre et al., 2009). Moreover, BAs with a 
broad range of biological implications may be present in duodeno-gastro-oesophageal 
refluxate (Lefebvre et al., 2009). Blondeau et al, as well as a range of other studies from the 
Leuven group found that bile acids were identified in 60% of BAL samples from individuals 
with CF who had a lung transplant procedure. This indicates a potential role for the aspiration 
of bile acid in the pathophysiology of BOS (Blondeau et al., 2008a). Moreover, Brodlie et al, 
have recently demonstrated that, when measured by tandem mass spectrometry, bile acids can 
be detected in advanced CF lung disease within the lower airway, and that this possible cause 
of injury persists even after the lung has been transplanted (Brodlie et al., 2015).  
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Though the role BAs play in inflammation and respiratory infection is becoming subject to 
increasing and wider study, the underlying mechanisms of BA mediated injuries relevant to 
lung diseases are still poorly understood. In humans, the majority of BAs exist in their 
conjugated forms (Hofmann, 1999b).  In this project, the first aim was to explore the possible 
association between damage to the epithelium - which may enable inflammatory airway 
disease to develop - and the presence of bile acids in the airway.  I investigated the impact of 
CDCA, CD, LCA and DCA on cell viability and the expression of inflammatory markers (IL-
6, IL-8 and GMC-SF) present in inflammatory lung disease that play a significant role. 
An influx of inflammatory cells into the lung, which is chronic and fails to resolve is a 
primary characteristic of airway disease (Boehler et al. 1998) and chemokines such as (IL- 6) 
interleukin 6, and (IL-8) interleukin 8 and the colony-stimulating factor of granulocyte-
macrophage (GM-CSF) have all been demonstrated as key in inflammatory cell recruitment.  
In addition to being a neutrophilic chemoattractant, IL-8 is also an angiogenic factor. In order 
to identify the localisation of IL-8 within peribronchial lesions, immunostaining has been 
used (Zheng et al., 2000). The functions of IL-6 are to differentiate T-cells, to mature B-cells 
and to activate monocytes. Furthermore, when an infection is present, fever is also induced by 
the  pyrogenic effect (Rincon and Irvin, 2012). On the other hand, the role of GM-CSF is in 
the activation of macrophages and for neutrophils it is both a powerful chemoattractant and 
also increases neutrophil life span. As a result, this stimulates phagocytotic and microbicidal 
activity as well as oxidative metabolism, and also enhances the cytotoxicity of both 
neutrophils (Katano et al., 2010) and macrophages (Sorgi et al., 2012). 
For inflammatory mediator expression to be compared, both inducible and basal, before and 
after bile acid stimulation, four cell types were investigated in this study. The cell type that 
was the most physiologically relevant to assess damage in the airways were arguably primary 
human bronchial epithelial cells (PHBECs). However, these are difficult and expensive to 
culture (Stewart et al., 2012). As a consequence, the ability to provide a useful model to 
complement the use of PHBECs was a prime, important reason for the use of cell lines in my 
work. The human bronchial epithelial cell line, BEAS-2B was identified as able to secrete 
other cytokines in addition to IL-8 and IL-6 while maintaining the morphology of the 
epithelial cell in vitro. Due to these qualities, BEAS-2B is a popular cell line for functional 
studies which rely on the airway epithelial structure (Swanson et al., 2009). The 
mucoepidermoid NCI-H292, derived from the cell line carcinoma, reacts to the presence of 
cigarette smoke in a similar way to  PHBECs  and presents a useful model for studies on the 
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production of mucus (Binker et al., 2009). Furthermore, 16HBE14o-, the virally transformed 
bronchial epithelial line, is used often in research on barrier function and transportation of 
ions (Gruenert et al., 1988; Cozens et al., 1994).  Lastly, the Calu-3 cell line derived from 
human bronchial submucosal glands presents a model for studying liquids on the airway’s 
surface, mucins as well as substances that are similarly immunologically active (Shen et al., 
1994), alongside pro-inflammatory cytokines that are involved in epithelial damage and 
inflammation of the airway tract (Hamid et al., 1999).  
It has been previously reported that the conjugation of BAs results in the loss of their 
damaging effects (Debruyne et al., 2002; Blau et al., 2007). However, it should be mentioned 
that most BAs that reside in humans are found in conjugated forms (Hofmann, 1999b). 
Following treatment using proton pump inhibitors and acid suppression therapies, commonly 
used in the treatment of GORD, BAs can deconjugate (Theisen et al., 2000), which means 
that there may be an increased ratio of deconjugated to conjugated BAs for patients 
undertaking GORD treatment procedures (Theisen et al., 2000). One possible explanation for 
this could be that an overgrowth of bacteria within the patient’s stomach may arise as a result 
of suppression therapies, and this increased number of microbes deconjugate more of the 
patient’s bile acids (Dettmar et al., 2011). CDCA, DCA, and LCA have all been identified in 
their unconjugated forms within secretions of the airway (Wu et al., 2009); implying that, for 
patients with GORD, the effect of these may be of a particular relevance.  
As per the current view in this area of research, the understanding of the impact bile acids 
have in the airways is currently limited by a lack of reports that identify and quantify specific 
bile acid quantities within the lungs using accurate methodology. This is mainly because of 
difficulties with the sampling procedure and the low reliability of the bile acid assays. Until 
now, studies on BAL have been the primary subject of research.  The highest bile acid 
concentration in BAL was reported to be 100 μmol/L (D’Ovidio et al., 2005; Parikh et al., 
2013); as BAL samples are diluted at an estimated 100 to 200 fold in practice this implies that 
bile acid concentrations may be substantially more dilute in the BAL than those that the real-
life airways of the patient are actually exposed to. Because of this, the bile acid concentrations 
used in the current study ranged from 1 to 100 µmol/L, which more closely emulated the 
physiological bile acid content in gastric refluxate estimated to reach a patient in a real-life 
scenario. 
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Increased levels of GM-CSF, IL-6 and IL-8 following bile acid challenge have been 
demonstrated by my research, and these are frequently found in airways in lung disease where 
the injury had been impacted by reflux and aspiration. My findings reveal that BEAS-2B, 
NCI-H292, 16HBE14O and Calu-3 cell lines are useful and sensitively efficient models for 
studying respiratory processes in humans and for studying diseases related to lung injury 
induced by the aspiration of BAs. These cell lines provide data that are complimentary to the 
rarer and harder to obtain PHBECs. Overall my data in cell lines and PHBECs indicate that 
bile acid aspiration could be linked to airway inflammation via the production of 
inflammatory cytokines. 
This study’s second primary aim was to explore the link between the epithelial–mesenchymal 
transition (EMT), that may be causing airway fibrosis; and the presence of bile acids that may 
be injuring epithelial cells within the airway that enables this to occur. In embryonic 
development EMT is known to play a role in organogenesis, and also plays a vital role in the 
body’s wound healing process (Hay, 2005). However, when EMT becomes unregulated, it 
can also facilitate the progression of metastasis and cancer. EMT may also  play a role in 
chronic degenerative fibrotic disorders in the lung as well as in other organs within the body 
(Thiery, 2002; Wilson and Wynn, 2009). These effects have been implicated in a number of 
airway and lung pathophysiologies, including pulmonary fibrosis, COPD and the rejection of 
lung allografts. Despite the growing evidence that shows an association between fibrotic 
remodelling within organs and the lungs, and the presence of EMT, its role in fibrosis and 
airway remodelling has not been definitively demonstrated and there is little evidence to 
suggest this has any impact on bronchial epithelial cells (Doerner and Zuraw, 2009). 
E-cadherin has been demonstrated by various studies as a marker of differentiated epithelial 
phenotype (Arias, 2001; Zeisberg et al., 2003). Also, it is critical in maintaining epithelial 
polarity and  tight junction development (Tunggal et al., 2005). EMT comprises a number of 
stages, the first of these is E-cadherin downregulation. An increase in mesenchymal markers 
defines the acquisition of the mesenchymal phenotype, this includes fibronectin production, a 
protein that holds a function of reparing tissue and is involved in the adhesion and migration 
of cells (Miettinen et al., 1994). The production of matrix metalloproteinase (MMP) 9 by 
epithelial cells also characterises epithelial damage and EMT. The true reticular basement 
membrane, on which the epithelial cells are layered, contains Collagen type IV and MMP-9 is 
a type IV collagenase. By disrupting the airway epithelium’s basement membrane, MMPs can 
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cause inflammation, translocation, further EMT and other damage (Kalluri and Neilson, 
2003). 
Consisting of over 30 different types and all with significant biological roles, the transforming 
Growth Factor (TGF)-β1 family of growth factors is a well-known and especially effective 
inducer of EMT in either pathological or normal conditions. TGF- β1 is a pleiotropic growth 
factor and regulates both proliferation and epithelial cell plasticity, which on one hand inhibits 
the usual proliferation of epithelial cells (which thereby opposes the development of cancer), 
but on the other hand stimulates fibroblast characteristics.  
I have demonstrated in this study that the development of airway fibrosis may be associated 
with the presence of BAs, which may involve EMT. My study showed that BA’s triggered the 
production of excessive levels of growth factor and cytokines, as well as leading to the 
migration and proliferation of fibroblasts. It has been demonstrated by experiments in lung 
fibrosis that the growth factors and cytokines produced following BA stimulation result in the 
formation of myofibroblasts (Kim et al., 2006; Kim et al., 2009). The myofibroblast is 
defined as possessing a phenotype between that of a fibroblast and a smooth muscle cell, 
(Gabbiani, 1992). They can be found in all tissues in the body and play a vital role in 
remodelling after inflammation or injury (Powell et al., 1999). Collagenous and 
noncollagenous matrix molecules are produced by myofibroblasts, which may cause 
thickening and stiffening of the basement membrane. Consequently the myofibroblasts may 
be involved in the development of airway diseases (Singh and Hall, 2008).  
This study has provided evidence of EMT markers in primary epithelial cell cultures from 
lung allograft, tracheal epithelial cells (upper airway cells) from the subglottic area, BEAS-2B 
cell lines and 16HBE14o- cell lines. The process of EMT may provide an incentive for a 
pathway following injury in common diseases that is characterised by fibrosis and airway 
remodelling 
One interesting point to note is that these results confirm that, through exposure to BAs, EMT 
was induced in 16HBE14o- and BEAS-2B cells, which indicates that this effect is not 
constrained to the primary bronchial epithelial cells found in humans. This indicates that 
16HBE14O- and BEAS-2B cell lines are a useful and efficient model to study the processes 
of human diseases linked to the aspiration of BAs and the possible links with EMT.  These 
findings may have translational significance and may present new opportunities in therapy. 
My results indicate that modification of GORD could have a positive impact on the airways in 
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patients with existing lung disease. The process of EMT may represent a final common 
pathway following airway injury in diseases that leads to the characteristic fibrosis and airway 
remodelling.  
The final goal of the study was to investigate the impact BAs have on the expression of 
MUC5B and MUC5AC from Calu-3 and NCI-H292 cells. The production of mucus is an 
important part of the body’s immune response to pathogens within the respiratory tract. 
Mucus hyper-secretion is also an important contribution to the pathophysiology of common 
airways diseases such as COPD and asthma.  Within the human airway, cells that produce 
mucin comprise of secretory (serous and mucous) cells present in the submucosal glands and 
the goblet cells that are found on the surface of the airway epithelium. Neither mucous cells 
nor goblet cells have proven easy to isolate, nor have terminally differentiated cells from 
healthy epithelia been maintained as cell lines or established as a culture (Rose et al., 2000).  
When grown on plastic, primary epithelial cells that are isolated from tissues in the airway or 
the lungs can be conserved for two to three passages, but do not possess the phenotype 
associated with mucin-expressing cells. Additional problems are that culture conditions are 
rigorous, the populations of the cells are heterogeneous and the components required for the 
process are expensive. Conversely, carcinoma-derived cell lines of epithelial origin grow 
quickly, are passaged with ease and so these cell lines have been used for the study of 
epithelial-specific diseases such as asthma, COPD, CF and processes of inflammation (Berger 
et al., 1999). NCI H292 and Calu-3 cells are both epithelial carcinoma-derived cell lines. As 
an in vitro model system, they have been used frequently for research into regulation and 
present major advantages as the regulation of both the glycoprotein MUC5AC and MUC5B 
can be studied under this same framework (Berger et al., 1999; Rose et al., 2000).  
Within the process of mucus secretion, mucins are one of the primary components. Mucins 
themselves belong to a group of large glycoproteins and possess a molecular mass of several 
thousand kilodaltons. In mucus secretions, the mucin composition is the a major determinant 
of viscoelasticity (Corfield, 2015). MUC5B and MUC5AC appear to be the genes most 
prevalently expressed, and their glycoprotein products  are the most abundantly identified in 
secretions of mucus (Thornton et al., 1997; Voynow, 2002). Furthermore, MUC5AC appears 
to be mostly  manufactured by goblet cells within the airway epithelium (Suzaki et al., 2016), 
while MUC5B is mostly manufactured within the submucosal glands that lie underneath 
(Zanin et al., 2016). 
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For the colonic mucosa and gastric mucosa (Gadacz and Zuidema, 1978; Gillen et al., 1988), 
bile acids have a toxic impact (Turjman and Nair, 1981; Owen et al., 1984). Their toxic 
impact on the oesophageal mucosa however has undergone less significant research (Nasr et 
al., 2013). A much stronger link has been suggested between the exposure to oesophageal 
acid (OAE) and the presence of mucosal damage e.g. Barrett’s oesophagus, along with the 
complications that come with it (Legrand et al., 1990; Iftikhar et al., 1993; Takahashi et al., 
2011)  
In the case of many common, important airway diseases such as asthma and COPD, mucin is 
hyper secreted and reflux and aspiration has been implicated in the overall pathophysiology. 
In my project, the production of mucus was significantly increased over the course of this 
study by the NCI H292 and Calu-3, when the cells were exposed to varying levels of BAs. As 
a whole, the data from this study therefore strongly supports the hypothesis that exposure to 
BAs may have a substantial effect on mucus upregulation. This may therefore lead to injury in 
the airway and airflow limitation. My results also confirmed that within in vitro model 
system, NCI H292 and Calu-3 cells can be used for further research into the processes of 
mucin gene regulation. 
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6.1 Summary 
It has long been suspected that there is a significant association between lung disease 
and GOR. A high prevalence of GOR has been found amongst patients with cystic 
fibrosis, idiopathic pulmonary fibrosis and asthma (Feigelson et al., 1987; Tobin et al., 
1998). GORD patients’ refluxate can contain bile acids in concentrations up to 
millimolar levels.  
To conclude the work done in this project has extended this research area by showing:  
- Cell death was encountered after stimulation of Calu-3, BEAS-2B and 16HBE14O-cell 
lines with primary BAs (CA - CDCA) and secondary BAs (LCA- DCA). In contrast NCI-
H292 cell viability was affected by secondary BAs (LCA- DCA) only.   This suggests 
aspiration may be an important cause of injury to airway epithelium cells and the 
secondary BAs are more cytotoxic than primary BAs. 
- The cells used in this study increased the levels of IL-8, IL-6 and GMCSF released 
after challenge by primary and secondary bile acids. IL-8, IL-6 and GM-CSF are 
commonly implicated in airways and lung disease where reflux and aspiration have 
been implicated as a possible injury. 
- This study confirmed that NCI-H292, Calu-3, BEAS-2B and 16HBE14O-cell lines 
are a useful model to study human respiratory processes and diseases related to BAs 
aspiration-induced lung injury. 
- E-cadherin (an epithelial marker) expression was downregulated and Fibronectin (a 
mesenchymal marker) was upregulated by BA treatment in primary human 
bronchial epithelial cell cultures from lung allografts (PHBEC). These findings were 
also confirmed in tracheal epithelial cells (upper airway cells) from the subglottic 
area, BEAS-2B and 16HBE14O-cell lines 
- The level of TGF-β1, MMP9 and pro-collagen were increased from primary human 
bronchial epithelial cell cultures from lung allografts (PHBEC), tracheal epithelial 
cells from the subglottic area, BEAS-2B and 16HBE14O-cell lines after challenge 
with BAs.  
- Primary human bronchial epithelial cell cultures from lung allografts (PHBEC), 
tracheal epithelial cells from the subglottic area, BEAS-2B and 16HBE14O-cell 
lines underwent EMT after stimulation with BAs.  
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- The EMT process may represent a pathway following airway injury in diseases 
characterised by airway remodelling and fibrosis where GOR and aspiration are also 
implicated. 
- MUC5AC and MUC5B levels were induced in response to stimulation of Calu-3 
and NCI H292 cells with BAs. This suggests that aspiration may lead to mucus 
hypersecretion as seen in the disease.  
- The Calu-3 and NCI H292 cells can be used as an in vitro model system to study 
MUC gene regulation. 
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Figure 6-1: A proposed sequence of events following epithelial cells injury after exposure to bile acids 
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Future directions 
- In this study, submerged culture systems were used to study the association between 
airways diseases and BAs. Future work could include establishing an air-liquid interface 
of the primary bronchial epithelial cells. The cells will differentiate into ciliated epithelial 
cells. The BAs stimulation would then be repeated and a number of cytokine and mucins 
could be measured.  
- There is evidence that bile acids may be taken up by lung epithelia cells. It may therefore 
be of interest to stain biopsies and epithelial cells taken from lung transplant recipients for 
BAs, in an attempt to further understand what happens to the bile acids once they have 
been aspirated into the lungs. 
- Bile acids can be taken up by laryngeal epithelial cells (extra-oesophageal reflux disease);  
for this reason the impact of bile acids on a pharyngeal cell line should be investigated. 
- In this study cells were stimulated with BAs for 48 hours, future studies could evaluate 
the effect of longer term stimulation with bile acids.  
- My results showed that PHBEC, tracheal epithelial cells from the subglottic area, BEAS-
2B and 16HBE14O-cell lines underwent EMT after stimulation with BAs. These results 
should be confirmed by immunohistochemistry. 
- A study should be set up to investigate sensitive methods that can be used to measure bile 
acids in the airways. 
-  Mucus gel removed from the lungs of patient undergoing bronchoscopy with airway 
disease should be studied. Mucus gels consist of mucin IgA, protein, lipid, and nucleic 
acid. Studying the rheological properties of mucus gels is fundamental to understand the 
role of these non-mucin components.  
- The airway cancer cell line models could be used to provide additional insight into the 
differential regulation of EMT-associated phenotypes. For example, flow cytometry could 
be used to count epithelial and mesenchymal cell types within cultured cell samples. Flow 
cytometers separate different cell types suspended within a fluid stream through 
hydrodynamic focussing. One or more lasers are then pointed at the fluid stream and 
photomultipliers detect the resultant fluorescent and scattered light. Fluorophores on or 
within the cells are detected using optical filters and their emission spectra peaks can be 
used to establish a reliable cell-type count (O'Neill et al., 2013). Flow cytometry remains 
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the preferred method for sorting viable cells by focussing on multiple cell surface proteins 
and their quantitative, simultaneous analysis (Strauss et al., 2013). Flow based methods 
have been used for the quantification of EMT in the setting of lung transplantation. Flow 
cytometry may have several advantages including the fact that several markers can be 
detected at once and large numbers of cells can be counted. This could be a useful future 
development of EMT research in my future studies. 
Mesenchymal marker expression, specifically αSMA, S100A4 and ED-A FN and HLA-
DR, has been assessed using flow cytometry, whilst TGFβ1 and HGF expression has been 
measured in Bronchoalveolar Lavage (BAL). Patients with Bronchiolitis Obliterans 
Syndrome (BOS) exhibited increased expression of all three mesenchymal markers as 
well as HLA-DR. BAL HGF was also seen to increase, but TGFβ1 was not. Analysing 
bronchial brushing samples using flow cytometry has been shown to be safe, fast, simple 
and quantitative (Hodge et al., 2009). On this basis, the method is proposed as an 
important additional means for EMT development studies. 
- Discovery and quantification of transcripts can be carried out in a single experiment using 
the high-throughput assay RNA-Seq, or ‘whole transcriptome sequencing’ (Cloonan et 
al., 2008; Guttman et al., 2010). For experiments that involve a broader dynamic range of 
gene expression, it has been shown that RNA-Seq provides more accuracy than 
expression microarrays (Marioni et al., 2008; Fu et al., 2009). Such approaches may be 
useful for future studies of EMT. 
RNA-Seq is now a standard tool in many large-scale genomic analyses, which seek to 
establish connections between genetic variation and epigenetic state, and transcriptional 
and post-transcriptional regulation. A number of these studies have indicated that cell 
type and specificity are determined by alternative splicing and isoform selection (Pan et 
al., 2008; Graveley et al., 2011). Furthermore, a large number of genes are characterised 
by having a large genomic ‘footprint’, containing a range of splice variants, promoters 
and proteins. Measuring changes in the way individual transcripts are expressed allows 
investigation into the regulation of isoform selection and diversity. In airway diseases, 
RNA-Seq may be employed to identify airway transcriptome and gene expression 
alterations that are linked with exposure to BAs and inflammatory diseases. This assay is 
likely to enable better understandings of the molecular mechanisms involved in EMT 
therefore and could represent a future direction for this area of work. 
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APPENDICES 
APPENDIX 1 
Influence of individual bile acid on 16HBE14o- cell viability and inflammatory cytokine 
(IL-8, IL-6 and GM-CSF) release 
 
Measurement of IL-8, IL-6 and GM-CSF production from 16HBE14o- cells treated with LCA. ELISA was used 
to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS-not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from 16HBE14o- cells treated with DCA. ELISA was used 
to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from 16HBE14o- cells treated with CA. ELISA was used 
to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from 16HBE14o- cells treated with CDCA. ELISA was 
used to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: 
p<0.001. (NS- not significant). 
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APPENDIX 2 
Influence of individual bile acid on BEAS-2B cell viability and inflammatory cytokine 
(IL-8, IL-6 and GM-CSF) release 
 
Measurement of IL-8, IL-6 and GM-CSF production from BEAS-2B cells treated with LCA. ELISA was used 
to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from BEAS-2B cells treated with DCA. ELISA was used 
to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from BEAS-2B cells treated with CA. ELISA was used to 
measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from BEAS-2B cells treated with CDCA. ELISA was used 
to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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APPENDIX 3 
Influence of individual bile acid on NCI-H292 cell viability and inflammatory cytokine 
(IL-8, IL-6 and GM-CSF) release 
 
Measurement of IL-8, IL-6 and GM-CSF production from NCI-H292 cells treated with LCA. ELISA was used 
measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from NCI-H292 cells treated with DCA. ELISA was used 
to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from NCI-H292 cells treated with CA. ELISA was used to 
measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from NCI-H292 cells treated with CDCA. ELISA was 
used to measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-
way ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: 
p<0.001. (NS- not significant). 
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APPENDIX 4 
Influence of individual bile acid on Calu-3 cell viability and inflammatory cytokine (IL-
8, IL-6 and GM-CSF) release 
 
Measurement of IL-8, IL-6 and GM-CSF production from Calu-3 cells treated with LCA. ELISA was used to 
measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001.  
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from Calu-3 cells treated with DCA. ELISA was used 
measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from Calu-3 cells treated with CA. ELISA was used to 
measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: p<0.001. 
(NS- not significant). 
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Measurement of IL-8, IL-6 and GM-CSF production from Calu-3 cells treated with CDCA. ELISA was used to 
measured cytokine secretion. Statistical analysis was conducted using repeated-measures-paired-one-way 
ANOVA (n=6). Bars represent mean ± S.E.M values of each group, *: p<0.05, **: p<0.01and, ***: 
p<0.001.(NS- not significant). 
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APPENDIX 6 
- RPMI Medium 
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